Compounds and methods for treatment of viral infections
Patent Information
- Application Number
- HK62026124552
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-28
- Filing Date
- 2026-06-09
- Publication Date
- 2026-09-11
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480062110.2 (22) Application Date 2024.09.27 (30) Priority Data 63 / 586,024 2023.09.28 US (85) PCT International Application Entering National Phase Date 2026.03.26 (86) PCT International Application Application Data PCT / US2024 / 048813 2024.09.27 (87) PCT International Application Publication Data WO2025 / 072641 EN 2025.04.03 (71) Applicant Gilead Sciences, Inc. Address California, USA (72) Inventors R.L. Markman and D.S. Siegel (74) Patent Agency King & Wood Mallesons, Beijing 11256 Patent Attorney Ma Hui Zhang Ruirui (51) Int.Cl. C07F 9 / 6561 (2006.01) C07H 11 / 04 (2006.01) (54) Invention Title Compound and Method for Treating Viral Infections (57) Abstract Discloses a compound of formula (I) for treating viral infections and a method of using said compound alone or in combination with an adjuvant agent, as well as a salt of said compound or a pharmaceutical composition. Claims 7 pages Description 58 pages CN 121925423 A 2026.04.24 CN 1 21 92 54 23 A 1. A compound or a pharmaceutically acceptable salt thereof, wherein said compound has the following formula: ; wherein R is H, , , , or; R1 is C1-C8 alkyl; R2 is C1-C6 alkyl; and R3 is C1-C6 alkyl. 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is H, , or . 3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is H. 4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is . 5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is . 6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is . 7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is or . 8. The compound of claim 1 or any one of claim 7 or a pharmaceutically acceptable salt thereof, wherein R is . 9. The compound of claim 1, 7, and 8 or a pharmaceutically acceptable salt thereof, wherein R is . 10. The compound of claim 1 and any one of claims 7 to 9 or a pharmaceutically acceptable salt thereof, wherein R1 is methyl, ethyl11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R1 is a C3-C6 alkyl group. 12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R1 is methyl, ethyl, propyl, or butyl. 13. The compound of any one of claims 1 or 7, or a pharmaceutically acceptable salt thereof, wherein R is methyl. 14. The compound of any one of claims 1, 7, and 13, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl, ethyl, propyl, or butyl. 15. The compound of any one of claims 1, 7, 13, and 14, or a pharmaceutically acceptable salt thereof, wherein R3 is methyl, ethyl, propyl, or butyl. 16. The compound of any one of claims 1, 7, and 13 to 15, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl, ethyl, propyl, or butyl, and R3 is methyl, ethyl, propyl, or butyl. 17. The compound of any one of claims 1, 7, and 13 to 16, or a pharmaceutically acceptable salt thereof, wherein R2 is butyl and R3 is butyl. 18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: (Claims 2 / 7, page 3, CN 121925423 A, ...). 19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: . 20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: . 21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: . 22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: (Claims 3 / 7, page 4, CN 121925423 A). 23. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: . 24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. 25. A pharmaceutical composition according to claim 23, further comprising an additional therapeutic agent. 26. A pharmaceutical composition according to claim 23 or 24, wherein the pharmaceutical formulation is for subcutaneous, intramuscular, intravenous, oral, or inhalation administration. 27. A pharmaceutical composition according to any one of claims 23 to 25, wherein the pharmaceutical formulation is for oral administration. 28. A method of treating or preventing a viral infection in a person in need, wherein the method comprises administering to the person...29. The method of claim 27, wherein the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof, is administered to the person via oral, intramuscular, intravenous, subcutaneous, or inhalation administration. 30. The method of claim 27 or 28, wherein the method comprises administering at least one additional therapeutic or prophylactic agent to the person. 31. The method of claim 29, wherein the additional therapeutic or prophylactic agent is monoupivir, oseltamivir, nematvir, or ritonavir. 32. The method of any one of claims 27 to 30, wherein the viral infection is a coronavirus infection. 33. The method of any one of claims 27 to 31, wherein the viral infection is a zoonotic coronavirus infection. 34. The method of any one of claims 27 to 32, wherein the viral infection is caused by a virus having at least 70% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 35. The method according to any one of claims 27 to 33, wherein the viral infection is caused by a virus having at least 80% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. (Claims 4 / 7, page 5, CN 121925423 A) 36. The method according to any one of claims 27 to 34, wherein the viral infection is caused by a virus having at least 90% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 37. The method according to any one of claims 27 to 35, wherein the viral infection is caused by a virus having at least 95% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 38. The method according to any one of claims 27 to 32, wherein the viral infection is selected from the group consisting of: 229E virus infection, NL63 virus infection, OC43 virus infection, and HKU1 virus infection. 39. The method of any one of claims 27 to 32, wherein the viral infection is SARS-CoV-2 infection (COVID-19). 40. The method of any one of claims 27 to 32, wherein the viral infection is SARS-CoV virus infection. 41. The method of any one of claims 27 to 32, wherein the viral infection is MERS-CoV virus infection.42. The method of any one of claims 27 to 29, wherein the viral infection is a pulmonaviridae virus infection. 43. The method of any one of claims 27 to 29 and 41, wherein the pulmonaviridae virus infection is a respiratory syncytial virus infection. 44. The method of any one of claims 27 to 29 and 41, wherein the pulmonaviridae virus infection is a human metapneumovirus infection. 45. The method of any one of claims 27 to 29, wherein the viral infection is a microviridae virus infection. 46. The method of any one of claims 27 to 29, wherein the viral infection is an enterovirus infection. 47. The method of any one of claims 27 to 29 and 45, wherein the viral infection is selected from the group consisting of: Coxsackie A virus infection, Coxsackie A virus infection, enterovirus D68 infection, enterovirus B69 infection, enterovirus D70 infection, enterovirus A71 infection, and poliovirus infection. 48. The method of any one of claims 27 to 29 and 44, wherein the microviridae virus infection is a human rhinovirus infection (HRV). 49. The method according to any one of claims 27 to 29 and 44, wherein the microribonucleoviridae virus infection is HRV-A infection, HRV-B infection, or HRV-C infection. 50. The method according to any one of claims 27 to 29, wherein the viral infection is a flaviviridae virus infection. 51. The method according to any one of claims 27 to 29 and 49, wherein the flaviviridae virus infection is dengue virus infection, yellow fever virus infection, West Nile virus infection, tick-borne encephalitis, Kunzin Japanese encephalitis, St. Louis encephalitis, Murray Valley encephalitis, Omsk hemorrhagic fever, bovine viral diarrhea, Zika virus infection, Alkulma hemorrhagic fever (AHF) virus, or HCV infection. 52. The method according to any one of claims 27 to 29, wherein the viral infection is a filoviridae virus infection. 53. The method according to any one of claims 27 to 29 and 51, wherein the viral infection is Ebola virus infection or Marburg virus infection. 54. The method of any one of claims 27 to 29, wherein the viral infection is an orthomyxovirus infection. 55. The method of any one of claims 27 to 29 and 53, wherein the viral infection is an influenza virus infection. 56. The method of any one of claims 27 to 29, 53, and 54, wherein the viral infection is an influenza A virus infection or an influenza B virus infection. 57. The method of any one of claims 27 to 29, wherein the viral infection is an arenaviridae virus infection.58. The method of any one of claims 27 to 29 and 57, wherein the viral infection is Lassa virus infection or Junin virus infection. 59. The method of any one of claims 28 to 30, wherein the viral infection is a paramyxoviridae virus infection. 60. The method of any one of claims 28 to 30 and 59, wherein the viral infection is Langya virus infection. 61. The method of any one of claims 28 to 30 and 59, wherein the viral infection is Hennipa virus infection. 62. The method of any one of claims 28 to 30, 57 and 58, wherein the viral infection is human parainfluenza virus infection, Nipah virus infection, Hendra virus infection, measles infection or mumps infection. 63. The method of any one of claims 27 to 29, wherein the viral infection is Bunyavirales infection. 64. The method of any one of claims 27 to 29 and 63, wherein the viral infection is a Leukoviridae virus infection, Nairoviridae virus infection, Arenaviridae virus infection or Hantaviridae virus infection. 65. The method according to any one of claims 27 to 29, 63, and 64, wherein the viral infection is Crimean-Congo hemorrhagic fever virus infection, Rift Valley fever virus infection, or Hantavirus infection. 66. The method according to any one of claims 27 to 30, wherein the viral infection is poxvirus infection. 67. The method according to any one of claims 28 to 30 and 66, wherein the viral infection is monkeypoxvirus infection. 68. The method according to any one of claims 28 to 30, wherein the viral infection is peccarivirus infection. 69. The method according to any one of claims 28 to 30 and 68, wherein the viral infection is eastern equine encephalitis virus infection, western equine encephalitis virus infection, Venezuelan equine encephalitis virus infection, or chikungunya virus infection. 70. A method for preparing a medicament for treating or preventing viral infections in persons in need, characterized by the compound according to any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof. 71. Use of the compound according to any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing viral infections in persons in need. 72. The use according to claim 61, wherein the medicament is used in conjunction with at least one additional therapeutic or preventative agent. 73. The use according to claim 63, wherein the additional therapeutic or preventative agent is monoupivir, oseltamivir, nematvir, or ritonavir. 74. A composition comprising any one of the compounds according to claims 1 to 22 or a pharmaceutically acceptable salt thereof, said composition for treating or preventing viral infections in persons in need.75. The composition of claim 64, wherein the composition comprises at least one additional therapeutic agent or prophylactic agent. 76. The composition of claim 65, wherein the additional therapeutic agent or the prophylactic agent is monoupivir, oseltamivir, nematvir, or ritonavir. Claims 7 / 7 Page 8 CN 121925423 A Compounds and methods for treating viral infections Cross-Reference to Related Applications
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 586,024, filed September 28, 2023, which is incorporated herein by reference in its entirety. Background Art
[0002] There is a need for compounds and methods for treating viral infections such as those of the Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, Arenaviridae, Orthomyxovirus, and Coronaviridae families. This disclosure addresses the above and other needs. Summary of the Invention
[0003] This disclosure provides compounds of Formula I: Formula I or a pharmaceutically acceptable salt thereof, wherein R is defined herein.
[0004] This document also provides a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
[0005] This document also provides a method for treating or preventing viral infections in a person in need, wherein the method comprises administering to the person a compound disclosed herein (e.g., a compound of formula I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein.
[0006] This document also provides the use of a compound disclosed herein (e.g., a compound of formula I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing viral infections in a person in need.
[0007] This document also provides a composition comprising a compound described herein (e.g., a compound of formula I) or a pharmaceutically acceptable salt thereof, the composition being used for treating or preventing viral infections in a person in need. Detailed Description
[0008] I. Overview The present invention relates throughout to methods and compounds for treating or preventing viral infections such as paramyxoviridae, pulmonaviridae, microribonucleoviridae, flaviviridae, filoviridae, arenaviridae, orthomyxoviridae, and coronavirusidae infections.
[0009] II. Definitions Specification 1 / 58 pages 9 CN 121925423 AUnless otherwise indicated, the following terms and phrases as used herein are intended to have the following meanings: “alkyl” refers to a saturated hydrocarbon chain that is unbranched or branched. For example, an alkyl group may have 1 to 8 carbon atoms (i.e., C1-C8 alkyl), 1 to 6 carbon atoms (i.e., C1-C6 alkyl), or 1 to 3 carbon atoms (i.e., C1-C3 alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, isopropyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, isobutyl, -CH2CH(CH3)2), 2-butyl (s-Bu, sec-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, tert-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3) CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH (CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3) (CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)) CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), and 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2) and 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3).
[0010] Unless otherwise specified, the carbon atoms of compounds of Formula I are intended to have a tetravalent oxidation state. If, in some chemical structural representation, the carbon atom is not connected to a sufficient number of variables to produce a tetravalent oxidation state, it should be assumed that the remaining carbon substituent required to provide a tetravalent oxidation state is hydrogen.
[0011] Unless otherwise specified, as used herein, the term “treatment” means reversing, alleviating, or inhibiting the progression of one or more symptoms of a disease or condition to which the term applies. As used herein, the term “treatment” refers toThe act of treatment, as "treatment" is defined above.
[0012] "Prevention" means any treatment of a disease or condition that prevents the development of clinical symptoms of the disease or condition. In some embodiments, the compounds and compositions disclosed herein may be administered to subjects (including humans) at risk of having a disease or condition. As used herein, the term "prevention" covers the administration of a compound, composition, or pharmaceutically acceptable salt according to the embodiments disclosed herein before or after an individual's exposure to a virus but before the onset of symptoms of viral infection and / or before the virus is detected in the blood. The term also refers to the prevention of the onset of disease symptoms and / or the prevention of the virus from reaching detectable levels in the blood. The term includes pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) and event-driven or "on-demand" prophylaxis. The term also refers to the prevention of perinatal transmission of the virus from mother to infant by administration to the mother before delivery and to the infant in the first few days of life. The term also refers to the prevention of transmission of the virus via blood transfusion.
[0013] As used herein, the term “therapeutic effective amount” is the amount of the compound described herein (e.g., a compound of formula I) present in the composition described herein that is required to deliver a desired level of the drug in the secretions and tissues of the airways and lungs, or alternatively, that is required to produce a desired physiological response or desired biological effect in the bloodstream of the subject to be treated when such a composition is administered via a chosen route of administration. The precise amount will depend on many factors, such as the specific compound described herein (e.g., a compound of formula I), the specific activity of the composition, the delivery device used, the physical properties of the composition, its intended use, and patient considerations such as the severity of the disease state, patient cooperation, etc., and this precise amount can be readily determined by those skilled in the art based on the information provided herein.
[0014] III. Any reference to the compounds of the invention described herein also includes a reference to their pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts of the compounds of this invention include salts derived from suitable bases such as alkali metals or alkaline earth metals (e.g., Na+, Li+, K+, Ca+2 and Mg+2), ammonium, and NR4+ (where R is defined herein). Pharmaceutically acceptable salts of nitrogen atoms or amino groups include: (a) acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, nitric acid, etc.); and (b) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, hydroxyethanesulfonic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic acid, and sulfosalicylic acid.Acids, glycolic acid, 2-hydroxy-3-naphthyl ester, dihydroxynaphthyl salt, salicylic acid, stearic acid, phthalic acid, mandelic acid, lactic acid, ethanesulfonic acid, lysine, arginine, glutamic acid, glycine, serine, threonine, alanine, isoleucine, leucine, etc.; and (c) salts formed from elemental anions such as chlorine, bromine, and iodine. Pharmaceutically acceptable salts of hydroxy compounds include combinations of the anions of said compounds with suitable cations such as Na+ and NR4+.
[0015] For therapeutic uses, salts of the active ingredients of the compounds of the present invention will be pharmaceutically acceptable, i.e., they will be salts derived from pharmaceutically acceptable acids or bases. However, salts of pharmaceutically unacceptable acids or bases may also be used, for example, for the preparation or purification of pharmaceutically acceptable compounds. All salts, whether or not derived from pharmaceutically acceptable acids or bases, are within the scope of the present invention.
[0016] It should also be understood that the compositions herein comprise the non-ionic and zwitterionic forms of the compounds of the present invention and combinations with a stoichiometric amount of water in a hydrate.
[0017] It should be noted that the present invention covers all enantiomers, diastereomers, racemic mixtures, tautomers, polymorphs, and pseudopolymorphs of the compounds described herein (e.g., compounds within the scope of Formula I) and their pharmaceutically acceptable salts. All such mixtures of enantiomers and diastereomers are within the scope of the present invention.
[0018] The compounds of the present invention, exemplified by Formula I, may have a chiral center, such as a chiral carbon atom or phosphorus atom. Thus, the compounds of the present invention comprise racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and transisomers. Furthermore, the compounds of the present invention comprise optical isomers enriched or resolved at any or all asymmetric, chiral atoms. In other words, the chiral center, as apparent from the description, is provided as a chiral isomer or racemic mixture. Both racemic mixtures and diastereomer mixtures, as well as isolated or synthesized individual optical isomers (which are substantially free of their enantiomers or diastereomer conjugates), are within the scope of the present invention. Racemic mixtures are separated into their individual, substantially optically pure isomers using suitable techniques, such as separating diastereomeric salts formed with optically active auxiliaries (e.g., acids or bases) and then converting the diastereomeric salts back into the optically active substance. In most cases, the desired optical isomers are synthesized via stereospecific reactions, starting with appropriate stereoisomers of the desired starting material.
[0019] The stereochemical definitions and conventions used herein generally follow those of S. P. Parker, ed., “McGraw-Hill Dictionary of Chemical Terms” (1984), McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of OrganicCompounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in an optically active form, that is, they have the ability to rotate the plane of polarization of light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule around its chiral center. The prefixes d and l, D and L or (+) and (-) are used to indicate the plane polarization rotation symbol of the compound, where S, (-) or 1 indicates that the compound is levorotatory, while compounds prefixed with R, (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be called enantiomers, and mixtures of such isomers are generally called enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur in the absence of stereoselectivity or stereospecificity in a chemical reaction or process. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomers that lacks optical activity.
[0020] In some cases, the compounds of the present invention may also exist as tautomers. Although only one delocalized resonance structure can be described on page 3 / 58 of the specification, CN 121925423 A, all such forms are considered within the scope of the present invention. For example, for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazolium systems, olefin-amine tautomers may exist, and all their possible tautomer forms are within the scope of the present invention.
[0021] Any formula or structure given herein, including compounds of formula I, is also intended to represent the unlabeled form of the compound as well as the isotopically labeled form. Isotopically labeled compounds have the structure described by the formula given herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Examples of isotopes that may be incorporated into the compounds of this disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to, 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I. Various isotopically labeled compounds of this disclosure, such as those incorporating radioactive isotopes such as 3H, 13C, and 14C. Such isotopically labeled compounds can be used in metabolic studies, reaction kinetic studies, detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), including the determination of tissue distribution of drugs or substrates, or for use in the radiotherapy of patients.
[0022] This disclosure also includes compounds (e.g., compounds of formula I) in which one to x hydrogen atoms attached to a carbon atom are replaced by deuterium, where x is the number of hydrogen atoms in the molecule. Such compounds exhibit increased resistance to metabolism and are therefore suitable for use in…When administered to mammals, especially humans, the half-life of any of the compounds described herein (e.g., compounds of Formula I) is prolonged. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). In view of this disclosure, such compounds are synthesized by methods known in the art, for example by using starting materials in which one or more hydrogen atoms have been replaced by deuterium.
[0023] The deuterium-labeled or substituted therapeutic compounds of this disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, which involve distribution, metabolism, and excretion (ADME). Substitution with a heavier isotope (such as deuterium) may provide certain therapeutic advantages resulting from greater metabolic stability, such as increased half-life in vivo, reduced dose requirements, and / or improved therapeutic index. 18F-labeled compounds may be used in PET or SPECT studies. The isotopically labeled compounds and their prodrugs disclosed herein can generally be prepared by replacing non-isotopically labeled reagents with readily available isotopically labeled reagents in the schemes or the procedures disclosed in the examples and formulations described below. It should be understood that deuterium in this context is considered a substituent in the compounds of Formula I.
[0024] In some embodiments, the carbon bonded at the 5-position to the tetrahydrofuran ring of Formula I is replaced by one or two deuterium atoms. In some embodiments, the compound of Formula I is. In some embodiments, the compound of Formula I is. In some embodiments, the compound of Formula I is, , , or. In some embodiments, the compound of Formula I is, or.
[0025] The concentration of such heavier isotopes (especially deuterium) can be defined by an isotope enrichment factor. In the compounds of this disclosure, any atom not specifically designated as a particular isotope means any stable isotope representing that atom. Unless otherwise stated, when a position is specifically designated as “H” or “hydrogen”, that position is understood to be hydrogen having its natural abundance isotopic composition. Therefore, in the compounds of this disclosure, any atom specifically designated as deuterium (D) means to represent deuterium.
[0026] Whenever a compound described herein is substituted with more than one of the same designated groups (e.g., “R” or “R,”), it should be understood that these groups may be the same or different, i.e., each group is independently chosen.
[0027] The wavy line, , indicates the position of a covalent bond attached to an adjacent substructure, group, portion, or atom.
[0028] In some embodiments, compounds of formula I are provided herein: Formula I; wherein R is H, , , , , or; R1 is a C1-C8 alkyl; R2 is a C1-C6 alkyl; andR3 is a C1-C6 alkyl group.
[0029] In some embodiments of the compound of formula I or a pharmaceutically acceptable salt thereof, R is H, , or. In some embodiments, R is H. In some embodiments, R is, or. In some embodiments, R is or. In some embodiments, R is or. In some embodiments, R is or. In some embodiments, R is or. In some embodiments, R is. In some embodiments, R is. In some embodiments, R is.
[0030] In some embodiments of the compound of formula I, R is or.
[0031] In some embodiments of the compound of formula I, R is or.
[0032] In some embodiments of the compound of formula I, R is. In some embodiments, R is.
[0033] In some embodiments of the compound of formula I, R is, wherein R1 is methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some embodiments, R is, wherein R1 is a C3-C6 alkyl. In some embodiments, R is, wherein R1 is.
[0034] In some embodiments of the compound of formula I, R is, wherein R1 is methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some embodiments, R is, wherein R1 is a C3-C6 alkyl. In some embodiments, R is, wherein R1 is.
[0035] In some embodiments of the compound of formula I, R is.
[0036] In some embodiments of the compound of formula I, R is, wherein R2 is methyl, ethyl, propyl, or butyl, and R3 is a C1-C6 alkyl. In some embodiments, R is, wherein R3 is methyl, ethyl, propyl, or butyl, and R2 is a C1-C6 alkyl. In some embodiments, R is, wherein R2 is methyl, ethyl, propyl, or butyl, and R3 is methyl, ethyl, propyl, or butyl. In some embodiments, R is, wherein R2 is butyl, and R3 is butyl.
[0037] In some embodiments, the compound of formula I is selected from the group consisting of, , , , and.
[0038] In some embodiments, the compound of formula I is selected from the group consisting of and. Specification 8 / 58 pages 16 CN 121925423 A
[0039] In some embodiments, the compound of formula I is selected from the group consisting of, , and.
[0040] In some embodiments, the compound of formula I is.
[0041] In some embodiments, the compound of formula I is.
[0042] In some embodiments, the compound of formula I is.
[0043] In some embodiments, the compound of formula I is.
[0044] In some embodiments, the compound of formula I is.
[0045] IV. Pharmaceutical formulation instructions 9 / 58 pages 17 CN 121925423 A Although the compounds of this disclosure (“active ingredients”) can be administered alone, they are preferably provided as pharmaceutical formulations. The veterinary and human formulations of the present invention comprise at least one active ingredient as defined above, together with one or more of its acceptable carriers and optional other therapeutic ingredients, especially those additional therapeutic ingredients discussed herein. The carrier must be “acceptable”, i.e., compatible with the other components of the formulation and physiologically harmless to its recipient.
[0046] These formulations include those suitable for the foregoing routes of administration. The formulations are readily available in unit dosage forms and can be prepared by any suitable method known in the pharmaceutical field. Techniques and formulations are generally found in “Remington’s Pharmaceutical Sciences” (Mack Publishing Co., Easton, PA). Such methods include the step of associating the active ingredient with a carrier constituting one or more auxiliary ingredients. Generally, formulations are prepared by uniformly and tightly associating the active ingredient with a liquid carrier or a finely divided solid carrier or both, and then, if desired, shaping the product.
[0047] In some embodiments, the pharmaceutical formulation is intended for subcutaneous, intramuscular, intravenous, oral, or inhalation administration.
[0048] In some embodiments, the compounds described herein (e.g., compounds of Formula I) or their pharmaceutically acceptable salts described herein have optimized / improved pharmacokinetic properties and are suitable for oral administration. For example, compounds of Formula I have improved bioavailability and are therefore applicable by oral administration.
[0049] In some embodiments, formulations of the present invention suitable for oral administration may be provided as discrete units such as capsules, granules, or tablets, each containing a predetermined amount of the active ingredient; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil liquid emulsions. The active ingredient may also be administered as pills, granules, or pastes.
[0050] In some embodiments, tablets are prepared by compression or molding, optionally with one or more excipients. Compressed tablets can be prepared by compressing an active ingredient in a free-flowing form (such as powder or granules) in a suitable machine, optionally mixed with a binder, lubricant, inert diluent, preservative, surfactant, or dispersant. Molded tabletsTablets can be prepared by molding a mixture of powdered active ingredients moistened with an inert liquid diluent in a suitable machine. Tablets may optionally be coated or scored, and may optionally be formulated to provide a slow or controlled release of the active ingredient therefrom.
[0051] For infections of the eyes or other external tissues (e.g., the mouth and skin), the formulation is applied as a topical ointment or cream containing active ingredients in amounts, for example, from 0.075% w / w to 20% w / w (including active ingredients in increments of 0.1% w / w, such as 0.6% w / w, 0.7% w / w, etc.), preferably from 0.2% w / w to 15% w / w, and most preferably from 0.5% w / w to 10% w / w. When formulated as an ointment, the active ingredient may be used with a paraffin base or a water-miscible ointment base. Alternatively, the active ingredient may be formulated as a cream with an oil-in-water emulsion base.
[0052] If desired, the aqueous phase of the cream matrix may contain, for example, at least 30% w / w of polyols, i.e., alcohols having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerin, and polyethylene glycol (including PEG 400), and mixtures thereof. Topical formulations may ideally include compounds that enhance the absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogues.
[0053] The oil phase of the emulsion of the present invention may be composed of known ingredients in a known manner. While this phase may consist only of emulsifiers (or emulsifiers), it ideally includes at least one emulsifier with fats or oils, or with a mixture of both fats and oils. Preferably, hydrophilic emulsifiers are included together with lipophilic emulsifiers that act as stabilizers. It is also preferably to include both oils and fats. Emulsifiers, with or without stabilizers, together constitute so-called emulsified waxes, and the waxes, together with oils and fats, constitute so-called emulsified ointment matrices, which form the oily dispersed phase of the cream formulation.
[0054] Emulsifiers and emulsion stabilizers suitable for formulations of the present invention include Tween® 60, Span® 80, cetearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate. Additional emulsifiers and emulsion stabilizers suitable for formulations of the present invention include Tween® 80.
[0055] Suitable oils or fats are selected for the formulation based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining, and washable product with a suitable consistency to avoid leakage from tubes or other containers. Straight-chain or branched monoalkyl or dialkyl esters, such as diisohexadiate, isohexadecanyl stearate, and propyl coconut fatty acid esters, can be used.A mixture of diol diesters, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate, or branched esters known as Crodamol CAP, the last three being preferred esters. These esters may be used alone or in combination, depending on the desired properties. Alternatively, high-melting-point lipids, such as white soft paraffin and / or liquid paraffin or other mineral oils, may be used.
[0056] Pharmaceutical formulations according to the invention comprise compounds according to the invention, as well as one or more pharmaceutically acceptable carriers or excipients and optional other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. For example, when intended for oral use, tablets, lozenges, tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known in the art for manufacturing pharmaceutical compositions, and such compositions may contain one or more pharmaceutical agents, including sweeteners, flavoring agents, coloring agents, and preservatives, to provide a palatable formulation. Tablets containing an active ingredient mixed with a non-toxic, pharmaceutically acceptable excipient suitable for tablet manufacturing are acceptable. These excipients may be, for example, inert diluents such as calcium carbonate or sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated using known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract, thereby providing sustained action over a longer period. For example, delaying materials such as glyceryl monostearate or glyceryl distearate may be used alone or in combination with waxes.
[0057] Formulations for oral use may also be provided as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., calcium phosphate or kaolin), or as soft gelatin capsules in which the active ingredient is mixed with an aqueous or oily medium (e.g., peanut oil, liquid paraffin, or olive oil).
[0058] The aqueous suspension of the present invention contains an active substance mixed with excipients suitable for manufacturing aqueous suspensions. Such excipients include suspending agents, such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, and gum arabic; and dispersants or wetting agents, such as naturally occurring phospholipids (e.g., lecithin), condensation products of olefinic oxygen and fatty acids (e.g., polyoxyethylene stearate), condensation products of ethylene oxide and long-chain fatty alcohols (e.g., heptadecanethoxycetyl alcohol), and condensation products of ethylene oxide and esters derived from fatty acids and hexyl anhydrides (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives, such as ethylparaben or n-propylparaben, one or more colorants, one or more flavoring agents, and one or more other preservatives.Various sweeteners such as sucrose or saccharin. Other non-limiting examples of suspending agents include cyclodextrins. In some examples, the suspending agent is sulfobutyl ether β-cyclodextrin (SEB-β-CD), such as Captisol®.
[0059] Oily suspensions can be formulated by suspending the active ingredient in vegetable oils (such as peanut oil, olive oil, sesame oil, or coconut oil) or mineral oils (such as liquid paraffin). Oral suspensions may contain thickeners such as beeswax, hard paraffin, or cetyl alcohol. Sweeteners (such as those described above) and flavoring agents may be added to provide palatable oral formulations. These compositions may be preserved by adding antioxidants (such as ascorbic acid).
[0060] The dispersible powders and granules of the present invention, suitable for preparing aqueous suspensions by adding water, provide an active ingredient mixed with a dispersant or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are exemplified above as disclosed on page 11 / 58 of the specification, CN 121925423 A. Additional excipients, such as sweeteners, flavoring agents, and coloring agents, may also be present.
[0061] The pharmaceutical compositions of the present invention may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil (such as olive oil or peanut oil), a mineral oil (such as liquid paraffin), or a mixture thereof. Suitable emulsifiers include naturally occurring gums, such as gum arabic and tragacanth; naturally occurring phospholipids, such as soybean lecithin; esters or metaesters derived from fatty acids and hexitan anhydrides, such as sorbitan monooleate; and condensation products of these metaesters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweeteners and flavoring agents. Syrups and elixirs may be formulated with sweeteners such as glycerin, sorbitol, or sucrose. Such formulations may also contain modifiers, preservatives, flavoring agents, or coloring agents.
[0062] The pharmaceutical compositions of the present invention may be in the form of sterile injectable formulations, such as sterile injectable aqueous or oily suspensions. The suspension may be formulated using suitable dispersants or wetting agents and suspending agents mentioned above, according to known techniques. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic, parenteral-acceptable diluent or solvent (such as a solution in 1,3-butanediol), or prepared as a lyophilized powder. Acceptable solvents and media are water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile non-volatile oils are generally used as solvents or suspension media. For this purpose, any mild non-volatile oil may be used, including synthetic monoglycerides or diglycerides. Additionally, fatty acids such as oleic acid may also be used in the preparation of injections. Acceptable solvents and media are water, Ringer's solution, isotonic sodium chloride solution, and hypertonic sodium chloride solution.
[0063] The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will depend on the host being treated and the specificThe method of administration varies. For example, a sustained-release formulation intended for oral administration to humans may contain about 1 mg to 1000 mg of active material, which is compounded with a suitable and convenient amount of carrier material, which may vary between about 5% to about 95% (weight:weight) of the total composition. Pharmaceutical compositions can be prepared to provide an easily measurable dosage. For example, an aqueous solution intended for intravenous infusion may contain about 3 mg to 500 mg of active ingredient per milliliter of solution to allow for infusion of a suitable volume at a rate of about 30 mL / hr.
[0064] Formulations suitable for topical application to the eyes also include eye drops, wherein the active ingredient is dissolved or suspended in a suitable carrier, particularly in an aqueous solvent of the active ingredient. The active ingredient is preferably present in such formulations at a concentration of 0.5% to 20%, advantageously 0.5% to 10%, and particularly about 1.5% w / w.
[0065] Formulations suitable for topical application in the oral cavity include lozenges containing a flavoring active ingredient, typically sucrose and gum arabic or tragacanth; tablets containing an inert active ingredient, such as gelatin and glycerin, or sucrose and gum arabic; and mouthwashes containing the active ingredient in a suitable liquid carrier.
[0066] Formulations for rectal application may be provided as suppositories having a suitable matrix, such as cocoa butter or salicylates.
[0067] In some embodiments, the compounds disclosed herein are administered by inhalation. In some embodiments, formulations suitable for intrapulmonary or intranasal application have a particle size, for example, in the range of 0.1 micrometers to 500 micrometers, such as 0.5 micrometers, 1 micrometer, 30 micrometers, 35 micrometers, etc., and are administered by rapid inhalation through the nasal passage or by oral inhalation to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder application may be prepared according to conventional methods and may be delivered together with other therapeutic agents. In some embodiments, the compounds used herein are formulated and administered as dry powders. In some embodiments, the compounds used herein are formulated and administered as nebulized formulations. In some embodiments, the compounds used herein are formulated for delivery via a face mask. In some embodiments, the compounds used herein are formulated for delivery via a face mask inhaler.
[0068] Formulations suitable for vaginal administration may be provided in the form of pessaries, tampons, creams, gels, pastes, foams, or spray formulations, containing, in addition to the active ingredient, a suitable carrier known in the art. Specification 12 / 58 pages 20 CN 121925423 A
[0069] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions that may contain antioxidants, buffers, antibacterial agents, and solutes to make the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents and thickeners.
[0070] The formulations are present in single-dose or multi-dose containers, such as sealed ampoules and vials, and can be stored under lyophilized (freeze-dried) conditions, requiring only the addition of a sterile liquid carrier, such as water for injection, immediately before use. Temporary injection solutions and suspensions are prepared from sterile powders, granules, and tablets of the aforementioned types. Preferred single-dose formulations are those containing a daily dose or a sub-daily dose or a suitable portion thereof of the active ingredient as described above.
[0071] It should be understood that, in addition to the ingredients specifically mentioned above, the formulations of the present invention may include other agents conventional in the art associated with the types of formulations discussed, such as those suitable for oral administration, which may include flavoring agents.
[0072] The present invention further provides veterinary drug compositions comprising at least one active ingredient as defined above and its veterinary drug carrier.
[0073] The veterinary drug carrier is a material that can be used to administer the composition and may be a solid, liquid, or gaseous material that is otherwise inert or acceptable in the veterinary field and compatible with the active ingredient. These veterinary drug compositions may be administered orally, parenterally, or by any other desired route.
[0074] The compounds of the present invention are used to provide controlled-release pharmaceutical formulations (“controlled-release formulations”) containing one or more of the compounds of the present invention as active ingredients, wherein the release of the active ingredient is controlled and regulated to allow administration at a lower frequency or to improve the pharmacokinetic or toxicological characteristics of a given active ingredient. Kits are also provided herein that comprise the compounds disclosed herein, pharmaceutically acceptable salts thereof, stereoisomers, mixtures of stereoisomers, or tautomers. In some embodiments, the kit described herein may contain a label and / or instructions for use to treat a disease or condition of a subject (e.g., a human) in need of the compound. In some embodiments, the disease or condition is a viral infection.
[0075] In some embodiments, the kit may also contain one or more additional therapeutic agents and / or instructions for use to treat a disease or condition of a subject (e.g., a human) in need of the compound in combination with another therapeutic agent.
[0076] In some embodiments, the kits provided herein contain a single dose unit of the compound as described herein, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate, or solvation thereof. Examples of single dose units may include pills, tablets, capsules, pre-filled syringes or syringes, IV bags, inhalers, nebulizers, etc., each comprising a therapeutically effective amount of the compound in question, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate, or solvation thereof. In some embodiments, the kit may contain a single dose unit, and in other embodiments, multiple dose units are present, e.g., the number of dose units required for a specified regimen or cycle.
[0077] Articles of manufacture are also provided, comprising: a compound of formula I or a pharmaceutically acceptable salt thereof, a stereoisomer, a mixture of stereoisomers or tautomers thereof, and a container. In some embodiments, the container of the article is a vial, can, ampoule, pre-filled syringe, blister pack, can, canister, bottle, box, intravenous bag, inhaler or nebulizer.
[0078] VI. Administration One or more compounds of the present invention are administered by any route suitable for the condition to be treated. Suitable routes include oral, rectal, inhalation, pulmonary, local (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural). In some embodiments, the compounds disclosed herein are administered by inhalation or intravenous administration. In some embodiments, the compounds disclosed herein are administered orally. It should be understood that preferred routes may vary depending on the conditions of, for example, the recipient of the specification 13 / 58 pages 21 CN 121925423 A.
[0079] In the method of treating viral infection of the present invention, the compounds of the present invention can be administered at any time to a person who may be exposed to a virus or who already has a viral infection. In some embodiments, the compounds of the present invention can be administered prophylactically to a person who has been in contact with a person with a viral infection or is at risk of being in contact with a person with a viral infection, such as a healthcare provider. In some embodiments, the administration of the compounds of the present invention can be to a person who has tested positive for a viral infection but has not yet shown symptoms of a viral infection. In some embodiments, the compounds of the present invention can be administered to a person at the onset of symptoms of a viral infection.
[0080] In some embodiments, the methods disclosed herein include event-driven administration to a subject of the compounds described herein (e.g., compounds of Formula I) or pharmaceutically acceptable salts thereof.
[0081] As used herein, the terms “event-driven” or “event-driven administration” mean that the compound described herein (e.g., the compound of formula I) or a pharmaceutically acceptable salt thereof is administered (1) prior to an event that will expose an individual to a virus (or otherwise increase the individual’s risk of acquiring a viral infection) (e.g., 2 hours, 1 day, 2 days, 5 days, or 7 days or more prior to the event); and / or (2) during an event that will expose an individual to a virus (or otherwise increase the individual’s risk of acquiring a viral infection) (or more than one repeated event); and / or (3) after an event that will expose an individual to a virus (or otherwise increase the individual’s risk of acquiring a viral infection) (or after the final event in a series of repeated events). In some embodiments, event-driven administration is performed before the subject is exposed to a virus. In some embodiments, event-driven administration is performed after the subject is exposed to a virus. In some embodiments, event-driven administration is performed both before and after the subject is exposed to a virus.
[0082] In some embodiments, the methods disclosed herein involve administration before and / or after an event that will expose an individual to a virus or otherwise increase the individual's risk of acquiring a viral infection, such as as pre-exposure prophylaxis (PrEP) and / or as post-exposure prophylaxis (PEP). In some embodiments, the methods disclosed herein include pre-exposure prophylaxis (PrEP). In some embodiments, the methods disclosed herein include post-exposure prophylaxis (PEP).
[0083] In some embodiments, a compound of formula I or a pharmaceutically acceptable salt thereof is administered before the subject is exposed to a virus.
[0084] In some embodiments, a compound of formula I or a pharmaceutically acceptable salt thereof is administered before and after the subject is exposed to a virus.
[0085] In some embodiments, a compound of formula I or a pharmaceutically acceptable salt thereof is administered after the subject is exposed to a virus.
[0086] Examples of event-driven dosing regimens include administering a compound of Formula I or a pharmaceutically acceptable salt thereof 24 to 2 hours prior to viral exposure, followed by administering a compound of Formula I or a pharmaceutically acceptable salt thereof every 24 hours during exposure, followed by further administration of a compound of Formula I or a pharmaceutically acceptable salt thereof after the last exposure, and a final administration of a compound of Formula I or a pharmaceutically acceptable salt thereof 24 hours later.
[0087] Another example of an event-driven dosing regimen includes administering a compound of Formula I or a pharmaceutically acceptable salt thereof 24 hours prior to viral exposure, followed by daily administration during exposure, and a final administration approximately 24 hours after the last exposure (which may be an increased dose, such as a double dose).
[0088] The specific dose level of the compounds of this disclosure for any particular subject will depend on a variety of factors, including the activity of the specific compound used, the age, weight, general health condition, sex, diet, time of administration, route of administration and excretion rate, drug combination, and severity of the specific disease. For example, the dose may be expressed as milligrams (mg / kg) of the compound described herein per kilogram of subject body weight. Doses between about 0.1 mg / kg and 150 mg / kg may be appropriate, as per the product manual (page 14 / 58, CN 121925423 A). In some embodiments, doses between about 0.1 mg / kg and 100 mg / kg may be appropriate. In other embodiments, doses between 0.5 mg / kg and 60 mg / kg may be appropriate. Normalization based on the subject's weight is particularly useful when adjusting doses between subjects with large size differences (such as when using the drug in children and adults, or when converting an effective dose for a non-human subject, such as a dog, to a dose suitable for a human subject).
[0089] The daily dose may also be described as the total amount of the compounds described herein administered per dose or per day. The compounds of Formula IThe daily dose of the compound or its pharmaceutically acceptable salt may be between about 1 mg and 4,000 mg, between about 2,000 mg / day and 4,000 mg / day, between about 1 mg / day and 2,000 mg / day, between about 1 mg / day and 1,000 mg / day, between about 10 mg / day and 500 mg / day, between about 20 mg / day and 500 mg / day, between about 50 mg / day and 300 mg / day, between about 75 mg / day and 200 mg / day, or between about 15 mg / day and 150 mg / day.
[0090] The dosage or frequency of administration of the compounds disclosed herein may be adjusted during treatment at the discretion of the administering physician.
[0091] The compounds disclosed herein may be administered to an individual (e.g., a human) in a therapeutically effective amount. In some embodiments, the compound is administered once daily.
[0092] The compounds provided herein may be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration. Therapeutic amounts of the compounds may include from about 0.00001 mg / kg body weight / day to about 10 mg / kg body weight / day, such as from about 0.0001 mg / kg body weight / day to about 10 mg / kg body weight / day, or such as from about 0.001 mg / kg body weight / day to about 1 mg / kg body weight / day, or such as from about 0.01 mg / kg body weight / day to about 1 mg / kg body weight / day, or such as from about 0.05 mg / kg body weight / day to about 0.5 mg / kg body weight / day. In some embodiments, therapeutic amounts of the compounds provided herein include from about 0.3 mg / day to about 30 mg / day, or from about 30 mg / day to about 300 mg / day, or from about 0.3 mg / day to about 30 mg / day, or from about 30 mg / day to about 300 mg / day.
[0093] The compounds of this disclosure may be combined with one or more additional therapeutic agents at any dose of the compounds of this disclosure (e.g., 1 mg to 1000 mg of the compound). Therapeutic amounts may include about 0.1 mg / dose to about 1000 mg / dose, such as about 50 mg / dose to about 500 mg / dose, or such as about 100 mg / dose to about 400 mg / dose, or such as about 150 mg / dose to about 350 mg / dose, or such as about 200 mg / dose to about 300 mg / dose, or such as about 0.01 mg / dose to about 100 mg / dose, or such as about 0.01 mg / dose to about 100 mg / dose, or such as about 0.1 mg / dose to about 100 mg / dose, or such as about 1 mg / dose to about 100 mg / dose, or such as about 1 mg / dose to about 100 mg / dose, or such as about 1 mg / dose to about 1000 mg / dose. Other therapeutically effective amounts of the compounds of Formula I are about 1 mg / dose.Dosage, or approximately 2mg / dose, 3mg / dose, 4mg / dose, 5mg / dose, 6mg / dose, 7mg / dose, 8mg / dose, 9mg / dose, 10mg / dose, 15mg / dose, 20mg / dose, 25mg / dose, 30mg / dose, 35mg / dose, 40mg / dose, 45mg / dose, 50mg / dose, 55mg / dose, 60mg / dose, 65mg / dose, 70mg / dose, 75mg / dose, 80mg / dose, 85mg / dose, 90mg / dose, 95mg / dose, or approximately 100mg / dose. Other therapeutically effective doses of the compounds disclosed herein are approximately 100 mg / dose, 125 mg / dose, 150 mg / dose, 175 mg / dose, 200 mg / dose, 225 mg / dose, 250 mg / dose, 275 mg / dose, 300 mg / dose, 325 mg / dose, 350 mg / dose, 375 mg / dose, 400 mg / dose, 425 mg / dose, 450 mg / dose, 475 mg / dose, 500 mg / dose, 525 mg / dose, 550 mg / dose, 575 mg / dose, 600 mg / dose, 625 mg / dose, 650 mg / dose, 675 mg / dose, 700 mg / dose, 725 mg / dose, 750 mg / dose, 775 mg / dose, 800 mg / dose, 825 mg / dose. 850 mg / dose, 875 mg / dose, 900 mg / dose, 925 mg / dose, 950 mg / dose, 975 mg / dose, or about 1000 mg / dose.
[0094] In some embodiments, the method described herein comprises administering to a subject an initial daily dose of about 1 mg to 500 mg of the compound provided herein, and gradually increasing the dose until clinical efficacy is achieved. Increments of about 5 mg, 10 mg, 25 mg, 50 mg, or 100 mg may be used to increase the dose. The dose may be increased daily, every other day, twice a week, once a week, once every two weeks, once every three weeks, or once a month.
[0095] When administered orally, the total daily dose for human subjects may be between about 1 mg / day and 4,000 mg / day, between about 1 mg / day and 3,000 mg / day, between 1 mg / day and 2,000 mg / day, between about 1 mg / day and 1,000 mg / day, between about 10 mg / day and 500 mg / day, between about 50 mg / day and 300 mg / day, between about 75 mg / day and 200 mg / day, or between about 100 mg / day and 150 mg / day. In some embodiments, the total daily dose for human subjects may be about 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, 500 mg / day, 600 mg / day, 700 mg / day, or 800 mg / day when administered as a single dose.The daily dose for human subjects may be approximately 200 mg / day, 300 mg / day, 1000 mg / day, 1100 mg / day, 1200 mg / day, 1300 mg / day, 1400 mg / day, 1500 mg / day, 1600 mg / day, 1700 mg / day, 1800 mg / day, 1900 mg / day, 2000 mg / day, 2100 mg / day, 2200 mg / day, 2300 mg / day, 2400 mg / day, 2500 mg / day, 2600 mg / day, 2700 mg / day, 2800 mg / day, 2900 mg / day, or 3000 mg / day, administered as a single dose. In some embodiments, the total daily dose for human subjects may be approximately 200 mg / day, 300 mg / day, 400 mg / day, 500 mg / day, 600 mg / day, 700 mg / day, or 800 mg / day, administered as a single dose. In some implementations, the total daily dose for human subjects may be approximately 300 mg / day, 400 mg / day, 500 mg / day, or 600 mg / day, administered as a single dose. In some implementation schemes, the total daily dose for human subjects may be approximately 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, 500 mg / day, 600 mg / day, 700 mg / day, 800 mg / day, 900 mg / day, 1000 mg / day, 1100 mg / day, 1200 mg / day, 1300 mg / day, 1400 mg / day, 1500 mg / day, 1600 mg / day, 1700 mg / day, 1800 mg / day, 1900 mg / day, 2000 mg / day, 2100 mg / day, 2200 mg / day, 2300 mg / day, 2400 mg / day, 2500 mg / day, 2600 mg / day, 2700 mg / day, or 2800 mg / day. 2900mg / day, 3000mg / day, 3100mg / day, 3200mg / day, 3300mg / day, 3400mg / day, 3500mg / day, 3600mg / day, 3700mg / day, 3800mg / day, 3900mg / day, or 4000mg / day. In some implementations, the total daily dose for human subjects may be approximately 100 mg / day–200 mg / day, 100 mg / day–300 mg / day, 100 mg / day–400 mg / day, 100 mg / day–500 mg / day, 100 mg / day–600 mg / day, 100 mg / day–700 mg / day, 100 mg / day–800 mg / day, 100 mg / day–900 mg / day, 100 mg / day–1000 mg / day, 500 mg / day–1100 mg / day, 500 mg / day–1200 mg / day, 500 mg / day–1300mg / day, 500mg / day-1400mg / day, 500mg / day-1500mg / day, 500mg / day-1600mg / day, 500mg / day-1700mg / day, 500mg / day-1800mg / day, 500mg / day-1900mg / day, 500mg / day-2000mg / day, 1500mg / day-2100mg / day, 1500mg / day-2200mg / day, 1500mg / day-2300mg / day, 1500mg / day-2400mg / day, 1500mg / day-2500mg / day, 2000mg / day-2600mg / day, 2000mg / day-2700mg / day, 2000mg / day-2800mg / day 2000mg / day–2900mg / day, 2000mg / day–3000mg / day, 2500mg / day–3100mg / day, 2500mg / day–3200mg / day, 2500mg / day–3300mg / day, 2500mg / day–3400mg / day, 2500mg / day–3500mg / day, 3000mg / day–3600mg / day, 3000mg / day–3700mg / day, 3000mg / day–3800mg / day, 3000mg / day–3900mg / day, or 3000mg / day–4000mg / day.
[0096] In some embodiments, the total daily dose for human subjects may be approximately 100mg / day administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 150 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 200 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 250 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 300 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 350 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 400 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 450 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 500 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 550 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 600 mg / day, administered as a single dose. In some implementations, the total daily dose for human subjects may be approximately 650 mg / day, administered as a single dose. In some implementations, the total daily dose for human subjects may be...The total daily dose for a human subject may be approximately 700 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 750 mg / day, administered as a single dose (see page 16 / 58 of CN 121925423 A). In some embodiments, the total daily dose for a human subject may be approximately 800 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 850 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 900 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 950 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 1000 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 1500 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be approximately 2000 mg / day, administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 2500 mg / day administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 3000 mg / day administered as a single dose. In some embodiments, the total daily dose for a human subject may be about 4000 mg / day administered as a single dose.
[0097] The single dose may be administered hourly, daily, weekly, or monthly. For example, the single dose may be administered every 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, or every 24 hours. The single dose may also be administered every 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or every 7 days. The single dose may also be administered every 1 week, 2 weeks, 3 weeks, or every 4 weeks. In some embodiments, the single dose may be administered weekly. The single dose may also be administered monthly. In some embodiments, the compounds disclosed herein are administered once daily in the methods disclosed herein. In some embodiments, the compounds disclosed herein are administered twice daily in the methods disclosed herein. In some embodiments, the compounds disclosed herein are administered three times daily in the methods disclosed herein.
[0098] In some embodiments, the compounds disclosed herein are administered once daily at a total daily dose of 100 mg / day to 4000 mg / day. In some embodiments, the compounds disclosed herein are administered twice daily at a total daily dose of 100 mg / day to 4000 mg / day. In some embodiments, the compounds disclosed herein are administered three times daily at a total daily dose of 100 mg / day to 4000 mg / day.
[0099] The frequency of the dosage of the compounds disclosed herein will be determined by the needs of the individual patient and may be, for example, once daily or twice or more daily. Administration of the compounds continues as long as treatment of the viral infection is required. For example, it may be...The compound is administered to a person infected with a virus for a period of 20 to 180 days, or for example, 20 to 90 days, or for example, 30 to 60 days.
[0100] The administration may be intermittent, with the patient receiving a daily dose of the compound of this disclosure for a period of several days or more, followed by a period of several days or more without receiving a daily dose of the compound. For example, the patient may receive a dose of the compound every other day or three times a week. Again, by way of example, the patient may receive a daily dose of the compound for a period of 1 to 14 days, followed by a period of 7 to 21 days without receiving a dose of the compound, followed by a period of a daily dose of the compound again for a subsequent period (e.g., 1 to 14 days). The alternating periods of administration followed by non-administration of the compound may be repeated as needed to treat the patient's clinical needs.
[0101] The compounds of this disclosure or pharmaceutical compositions thereof may be administered once, twice, three times, or four times daily using any of the suitable patterns described above. Moreover, the application or treatment with the compound can continue for several days; for example, for a treatment cycle, treatment typically continues for at least 7, 14, or 28 days. Treatment cycles are well known in cancer chemotherapy and typically alternate with rest periods of about 1 to 28 days, typically about 7 or about 14 days, between cycles. In other embodiments, treatment cycles may also be continuous.
[0102] VII. Method of Use This disclosure also provides a method for treating or preventing a viral infection in a subject (e.g., a person) of need, the method comprising administering the compound described herein to the subject.
[0103] In some embodiments, this disclosure provides a method for treating a viral infection in a subject (e.g., a person) of need, the method comprising administering the compound described herein to the subject of need.
[0104] In some embodiments, the compound described herein is administered to a person via oral, intramuscular, intravenous, subcutaneous, or inhalation administration.
[0105] In some embodiments, this disclosure provides a method of treating or preventing a viral infection in a subject (e.g., a person) of need, the method comprising administering to the subject a compound disclosed herein and at least one additional active therapeutic or preventative agent.
[0106] In some embodiments, this disclosure provides a method of treating a viral infection in a subject (e.g., a person) of need, the method comprising administering to the subject a compound disclosed herein and at least one additional active therapeutic or preventative agent.
[0107] In one embodiment, this disclosure provides a method of inhibiting viral polymerase in cells, the method comprising contacting virus-infected cells with a compound disclosed herein, thereby inhibiting the viral polymerase.
[0108] In one embodiment, this disclosure provides a method of inhibiting viral polymerase in cells, the method comprising...This includes contacting virus-infected cells with the compounds disclosed herein and at least one additional active therapeutic agent, thereby inhibiting viral polymerase.
[0109] This document also provides the use of the compounds disclosed herein for treating or preventing viral infections in a subject in need. For example, this document provides the use of the compounds disclosed herein for treating viral infections in a subject in need.
[0110] In some embodiments, the viral infection is a paramyxoviridae virus infection. Therefore, in some embodiments, this disclosure provides a method for treating a paramyxoviridae infection in a subject in need (e.g., a person), the method comprising administering the compounds disclosed herein to the subject. Paramyxoviridae viruses include, but are not limited to, Nipah virus, Hendra virus, measles virus, mumps virus, and parainfluenza virus.
[0111] In some embodiments, the viral infection is a human parainfluenza virus infection, Nipah virus infection, Hendra virus infection, measles infection, or mumps infection.
[0112] In some embodiments, the viral infection is a pulmonaviridae virus infection. Therefore, in some embodiments, this disclosure provides a method for treating a pulmonaviridae virus infection in a person in need, the method comprising administering the compounds provided herein to the person. Pneumoviridae viruses include, but are not limited to, respiratory syncytial virus (RSV) and human metapneumovirus (HMV). In some embodiments, a Pneumoviridae virus infection is a respiratory syncytial virus infection. In some embodiments, a Pneumoviridae virus infection is a HMV infection.
[0113] In some embodiments, this disclosure provides compounds disclosed herein for treating a person in need of a Pneumoviridae virus infection. In some embodiments, a Pneumoviridae virus infection is a respiratory syncytial virus (RSV) infection. In some embodiments, a Pneumoviridae virus infection is a HMV infection.
[0114] In some embodiments, this disclosure provides a method for treating a person in need of an RSV infection, the method comprising administering the compounds provided herein to the person. In some embodiments, the person has a chronic respiratory syncytial virus infection. In some embodiments, the person has an acute RSV infection.
[0115] In some embodiments, a method for inhibiting RSV replication is provided, wherein the method comprises administering the compounds disclosed herein to a person in need, wherein the administration is by inhalation.
[0116] In some embodiments, this disclosure provides a method for reducing viral load associated with RSV infection, wherein the method comprises administering the compounds disclosed herein to a person infected with RSV.
[0117] In some embodiments, the viral infection is a picoriviridae virus infection. Therefore, in some embodiments, this disclosure provides a method for treating a picoriviridae virus infection in a person in need, the method comprising administering the compounds disclosed herein to that person. Picoriviridae viruses are those that cause conditions including herpetic pharyngitis, aseptic meningitis, etc. (Instructions for use 18 / 58, page 26 CN)121925423 A Enteroviruses causing heterogeneous infections, including poliomyelitis, common cold-like syndrome (human rhinovirus infection), nonparalytic poliomyelitis-like syndrome, epidemic pleuropneumonia (an acute, febrile, infectious disease that typically occurs during epidemics), hand-foot-mouth syndrome, pancreatitis in children and adults, and severe myocarditis. In some embodiments, the piconeviridae virus infection is a human rhinovirus infection (HRV). In some embodiments, the piconeviridae virus infection is an HRV-A, HRV-B, or HRV-C infection.
[0118] In some embodiments, the virus infection is selected from the group consisting of: Coxsackie A virus infection, Coxsackie A virus infection, enterovirus D68 infection, enterovirus B69 infection, enterovirus D70 infection, enterovirus A71 infection, and poliovirus infection.
[0119] In some embodiments, this disclosure provides compounds for treating piconeviridae virus infections in people in need. In some embodiments, the picornaviridae virus infection is a human rhinovirus infection.
[0120] In some embodiments, the viral infection is a flaviviridae virus infection. Therefore, in some embodiments, this disclosure provides a method of treating a person in need of a flaviviridae virus infection, the method comprising administering the compound described herein to the person. Representative flaviviridae viruses include, but are not limited to, dengue fever, yellow fever, West Nile virus, Zika virus, Japanese encephalitis virus, and hepatitis C virus (HCV). In some embodiments, the flaviviridae virus infection is a dengue virus infection. In some embodiments, the flaviviridae virus infection is a yellow fever virus infection. In some embodiments, the flaviviridae virus infection is a West Nile virus infection. In some embodiments, the flaviviridae virus infection is a Zika virus infection. In some embodiments, the flaviviridae virus infection is a Japanese encephalitis virus infection. In some embodiments, the flaviviridae virus infection is a hepatitis C virus infection.
[0121] In some embodiments, the flaviviridae virus infection is dengue virus infection, yellow fever virus infection, West Nile virus infection, tick-borne encephalitis, Kunzin Japanese encephalitis, St. Louis encephalitis, Murray Valley encephalitis, Omsk hemorrhagic fever, bovine viral diarrhea, Zika virus infection, or HCV infection.
[0122] In some embodiments, this disclosure provides the use of the compounds disclosed herein for the treatment of flaviviridae virus infection in persons of need. In some embodiments, the flaviviridae virus infection is dengue virus infection. In some embodiments, the flaviviridae virus infection is yellow fever virus infection. In some embodiments, the flaviviridae virus infection is West Nile virus infection. In some embodiments, the flaviviridae virus infection is Zika virus infection. In some embodiments, the flaviviridae virus infection is hepatitis C virus infection.
[0123] In some embodiments, the viral infection is a filoviridae virus infection. Therefore, in some embodiments, this document provides a method for treating a person in need of a filoviridae virus infection, the method comprising administering to that person a compound disclosed herein. Representative filoviridae viruses include, but are not limited to, Ebola virus (variants Zaire, Bundibugio, Sudan, Tai Forest, or Reston) and Marburg virus. In some embodiments, the filoviridae virus infection is an Ebola virus infection. In some embodiments, the filoviridae virus infection is a Marburg virus infection.
[0124] In some embodiments, this disclosure provides compounds for treating a person in need of a filoviridae virus infection. In some embodiments, the filoviridae virus infection is an Ebola virus infection. In some embodiments, the filoviridae virus infection is a Marburg virus infection.
[0125] In some embodiments, the viral infection is a coronavirus infection. Therefore, in some embodiments, this document provides a method for treating a person in need of a coronavirus infection, wherein the method comprises administering to that person a compound provided herein. In some embodiments, the coronavirus infection is severe acute respiratory syndrome (SARS-CoV) infection, Middle East respiratory syndrome (MERS) infection, SARS-CoV-2 infection, other human coronaviruses (229E, NL63, OC43, HKU1, or WIV1), or zoonotic coronaviruses (PEDV or HKU CoV isolates, such as HKU3, HKU5, or HKU9). In some embodiments, as described on page 19 / 58 of CN 121925423 A, the viral infection is severe acute respiratory syndrome (SARS) infection. In some embodiments, the viral infection is Middle East respiratory syndrome (MERS) infection. In some embodiments, the viral infection is SARS-CoV-2 infection. In some embodiments, the viral infection is a zoonotic coronavirus infection. In some embodiments, the viral infection is caused by a virus having at least 70% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. In some embodiments, viral infection is caused by a virus having at least 80% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. In some embodiments, viral infection is caused by a virus having at least 90% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. In some embodiments, viral infection is caused by a virus with...Viruses whose polymerases are selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2 have at least 95% sequence homology are caused by viruses.
[0126] In some embodiments, viral infection is caused by variants of SARS-CoV-2, such as variants B.1.1.7 (UK variant), B.1.351 (South Africa variant), P.1 (Brazil variant), B.1.1.7 and E484K variants, B.1.1.207 variant, B.1.1.317 variant, B.1.1.318 variant, B.1.429 variant, B.1.525 variant, or P.3 variant. In some embodiments, viral infection is caused by variant B.1.1.7 of SARS-CoV-2. In some embodiments, viral infection is caused by variant B.1.351 of SARS-CoV-2. In some embodiments, viral infection is caused by variant P.1 of SARS-CoV-2.
[0127] In some embodiments, this disclosure provides compounds for treating coronavirus infections in persons in need. In some embodiments, the coronavirus infection is severe acute respiratory syndrome (SARS) infection, Middle East respiratory syndrome (MERS) infection, SARS-CoV-2 infection, other human coronaviruses (229E, NL63, OC43, HKU1, or WIV1) infection, and zoonotic coronaviruses (PEDV or HKU CoV isolates, such as HKU3, HKU5, or HKU9) infection. In some embodiments, the viral infection is severe acute respiratory syndrome (SARS) infection. In some embodiments, the viral infection is Middle East respiratory syndrome (MERS) infection. In some embodiments, the viral infection is SARS-CoV-2 infection (COVID19).
[0128] In some embodiments, the viral infection is an isopiraviridae virus infection. Therefore, in some embodiments, this disclosure provides a method of treating an isopiraviridae virus infection in persons in need, the method comprising administering to the person the compounds disclosed herein. In some embodiments, the isopiraviridae virus infection is lassa virus infection or junin virus infection.
[0129] In some embodiments, this disclosure provides compounds for treating arenaviridae virus infections in persons in need. In some embodiments, the arenaviridae virus infection is lassa virus infection or Junin virus infection.
[0130] In some embodiments, the viral infection is an orthomyxovirus infection, such as an influenza virus infection. In some embodiments, the viral infection is influenza A virus infection, influenza B virus infection, or influenza C virus infection.
[0131] In some embodiments, the viral infection is Bunyavirales infection. Therefore, in some embodiments, this disclosure provides compounds for treating arenaviridae virus infections in persons in need.A method for treating Bunyavirales infection in a subject (e.g., a human) in need is disclosed, comprising administering to the subject the solid form disclosed herein. Bunyavirales infection includes, but is not limited to, infections of the Leukoviridae family (e.g., Rift Valley fever virus), the Arenaviridae family (e.g., Lassa virus and Junin virus as described above), the Nairoviridae family (e.g., Crimean-Congo hemorrhagic fever (CCHF) virus), and the Hantaviridae family (e.g., Hantavirus).
[0132] As more fully described herein, the compounds described herein may be administered to an individual (e.g., a human) infected with a virus in combination with one or more adjunctive therapeutic agents. The adjunctive therapeutic agents may be administered to the infected individual simultaneously with, before, or after administration of the compounds of this disclosure.
[0133] VIII. Combination Therapy The compounds described herein may also be used in combination with one or more adjunctive therapeutic agents. Therefore, this document also provides a method of treating a subject with a viral infection, as described on pages 20 / 58 of CN 121925423 A, wherein such method comprises administering to the subject one or more of the compounds disclosed herein and a therapeutically effective amount of one or more adjunctive therapeutic or prophylactic agents.
[0134] In some embodiments, the adjunctive therapeutic agent is an antiviral agent. Any suitable antiviral agent may be used in the methods described herein. In some embodiments, the antiviral agent is selected from: 5-substituted 2'-deoxyuridine analogs, nucleoside analogs, pyrophosphate analogs, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, entry inhibitors, acyclic guanosine analogs, acyclic nucleoside phosphonate analogs, HCV NS5A / NS5B inhibitors, influenza virus inhibitors, interferon, immunostimulants, oligonucleotides, antimitotic inhibitors, and combinations thereof.
[0135] In some embodiments, the adjunctive therapeutic agent is a 5-substituted 2'-deoxyuridine analog. For example, in some embodiments, the adjunctive therapeutic agent is selected from: iodouridine, trifluorouridine, brovudine [BVDU], and combinations thereof.
[0136] In some embodiments, the adjunctive therapeutic agent is a nucleoside analog. For example, in some embodiments, the adjunctive therapeutic agent is selected from: vidarabine, entecavir (ETV), telmivudine, lamivudine, adefovir dipivoxil, tenofovir disoproxil fumarate (TDF), and combinations thereof. In some embodiments, the adjunctive therapeutic agent is favipiravir, ribavirin, galidivir, β-D-N4-hydroxycytidine, or combinations thereof.
[0137] In some embodiments, the adjunctive therapeutic agent is a pyrophosphate analog. For example, in some embodiments, the adjunctive therapeutic agent is phosphonoformic acid or phosphonoacetic acid. In some embodiments, the adjunctive therapeutic agent is phosphonoformic acid.
[0138] In some embodiments, the adjunctive therapeutic agent is a nucleoside reverse transcriptase inhibitor. In some embodiments, the antiviral agent is zidovudine, didanoxin, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, and combinations thereof.
[0139] In some embodiments, the adjunctive therapeutic agent is a non-nucleoside reverse transcriptase inhibitor. In some embodiments, the antiviral agent is selected from: nevirapine, delavudine, efavirenz, etravirine, rilpivirine, and combinations thereof.
[0140] In some embodiments, the adjunctive therapeutic agent is a protease inhibitor. In some embodiments, the protease inhibitor is an HIV protease inhibitor. For example, in some embodiments, the antiviral agent is selected from: saquinavir, ritonavir, indinavir, nelfinavir, ampravir, lopinavir, atazanavir, fossavir, derreiravir, telanavir, cobistat, and combinations thereof. In some embodiments, the antiviral agent is selected from: saquinavir, ritonavir, indinavir, nelfinavir, ampravir, lopinavir, atazanavir, fossavir, drenellavir, telanavir, and combinations thereof. In some embodiments, the protease inhibitor is an HCV NS3 / 4A protease inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: voxiprevir, anavipiravir, boprevir, paliperevir, cimetidine, telaprevir, vaniprevir, gzopiclone, ribavirin, danoprevir, fadaprevir, vedoprevir, sovalpirevir, drenellavir, nalaprevir, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: voxiprevir, anavipiravir, boprevir, paliperevir, cimetidine, telaprevir, vaniprevir, gzopiclone, and combinations thereof.
[0141] In some embodiments, the adjunctive therapeutic agent is an integrase inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: retigvir, dulutegravir, erteiravir, abacavir, lamivudine, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: bicagvir, retigvir, dulutegravir, cabotevir, erteiravir, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: bicagvir, dulutegravir, cabotevir, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is bicagvir.
[0142] In some embodiments, the adjunctive therapeutic agent is an entry inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: docosanol, enfviride, maraviro, ibazizumab, fotexavir, lelimumab, ibazizumab, fotexavir, palizumab, intravenous respiratory syncytial virus immunoglobulin [RSV-IGIV], varicella-zoster immunoglobulin [VariZIG], varicella-zoster immunoglobulin [VZIG], and combinations thereof. Instruction manual, pages 21 / 58, 29 CN 121925423 A
[0143] In some embodiments, the adjunctive therapeutic agent is an acyclic guanosine analog. For example, in some embodiments, the adjunctive therapeutic agent is selected from: acyclovir, ganciclovir, valacyclovir (also known as valacyclovir), valganciclovir, penciclovir, famciclovir, and combinations thereof.
[0144] In some embodiments, the adjunctive therapeutic agent is an acyclic nucleoside phosphonate analog. For example, in some embodiments, the adjunctive therapeutic agent is selected from: cidofovir, adefovir, adefovir dipivoxil, tenofovir, TDF, emtricitabine, efavirenz, rilpivirine, erteiravir, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: cidofovir, adefovir, adefovir dipivoxil, tenofovir, TDF, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: cidofovir, adefovir dipivoxil, TDF, and combinations thereof.
[0145] In some embodiments, the adjunctive therapeutic agent is an HCV NS5A / NS5B inhibitor. In some embodiments, the adjunctive therapeutic agent is an NS3 / 4A protease inhibitor. In some embodiments, the adjunctive therapeutic agent is an NS5A protease inhibitor. In some embodiments, the adjunctive therapeutic agent is a nucleoside / nucleotide type NS5B polymerase inhibitor. In some embodiments, the adjunctive therapeutic agent is a non-nucleoside type NS5B polymerase inhibitor. In some embodiments, the adjunctive therapeutic agent is selected from: daclatasvir, ledipasvir, velpatasvir, obbitasvir, elbasvir, sofosbuvir, dasabuvir, ribavirin, anavipiravir, cimetidine, paliprevir, ritonavir, elbasvir, gzopivir, AT-527, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: daclatasvir, ledipasvir, velpatasvir, obbitasvir, elbasvir, sofosbuvir, dasabuvir, and combinations thereof.
[0146] In some embodiments, the adjunctive therapeutic agent is an influenza virus inhibitor. In some embodiments, the adjunctive therapeutic agent is a matrix 2 inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: amantadine, amantadine ethylamine, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is a neuraminidase inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: zanamivir, oseltamivir, peramivir, lanimivir caprylate, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is a polymerase inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: ribavirin, favipiravir, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: amantadine, amantadine ethylamine, arbidol (uminovir), baloxavir masboxylate, oseltamivir, peramivir, ingavirin, lanimivir caprylate, zanamivir, favipiravir, ribavirin, and combinations thereof. In some embodiments...In the treatment regimen, the adjunctive therapeutic agent is selected from: amantadine, amantadine ethylamine, zanamivir, oseltamivir, peramivir, lanimivir caprylate, ribavirin, favipiravir, and combinations thereof.
[0147] In some embodiments, the adjunctive therapeutic agent is interferon. In some embodiments, the adjunctive therapeutic agent is selected from: interferon alfacon 1, interferon α1b, interferon α2a, interferon α2b, pegylated interferon alfacon 1, pegylated interferon α1b, pegylated interferon α2a (PegIFNα-2a), and PegIFNα-2b. In some embodiments, the adjunctive therapeutic agent is selected from: interferon alfacon 1, interferon α1b, interferon α2a, interferon α2b, pegylated interferon α2a (PegIFNα-2a), and PegIFNα-2b. In some embodiments, the adjunctive therapeutic agent is selected from: interferon alfacon 1, pegylated interferon α2a (PegIFNα-2a), PegIFNα-2b, and ribavirin. In some embodiments, the adjunctive therapeutic agent is pegylated interferon α-2a, pegylated interferon α-2b, or a combination thereof.
[0148] In some embodiments, the adjunctive therapeutic agent is an immunostimulant. In some embodiments, the adjunctive therapeutic agent is an oligonucleotide. In some embodiments, the adjunctive therapeutic agent is an antimitotic inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: formimivir, prodafiloyl, imiquimod, phenrexate, and combinations thereof.
[0149] In some embodiments, the adjunctive therapeutic agent is selected from: bexifovir, nitrozonide, REGN2222, doravirine, sofosbuvir, velpatasvir, daclatasvir, anavipiravir, becabuvir, FV100, lemetmovir, and combinations thereof.
[0150] In some embodiments, the adjunctive therapeutic agent is a drug for treating RSV. For example, in some embodiments, the antiviral agent is ribavirin, ALS-8112, or pretovir. For example, in some embodiments, the antiviral agent is ALS-8112 or pretovir.
[0151] In some embodiments, the adjunctive therapeutic agent is a drug for treating picornavirus. In some embodiments, the adjunctive therapeutic agent is selected from: hydantoin, guanidine hydrochloride, L-butyrosine sulfoxide, Py-11, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is a picornavirus polymerase inhibitor. In some embodiments, the adjunctive therapeutic agent is rupinetrivir.
[0152] In some embodiments, the adjunctive therapeutic agent is a drug for treating malaria. In some embodiments, the adjunctive therapeutic agent is chloroquine.
[0153] In some embodiments, the adjunctive therapeutic agent is selected from: hydroxychloroquine, chloroquine, artemether, benzyl fluorene, atovaquinone, chloroguanidine, tafenoxanol, phenazine, artemisinin ester, dihydroartemisinin, piperaquine, artemisinin ester, amodiaquine, phenazine, artemisinin ester, halofantroline, quinine sulfate, mefloquine, sorimycin, pyrimethamine, MMV-390048, ferrocene chloroquine, artemisinin mesylate, ganaplacide, DSM-265, cipargamine, artemisininone, and combinations thereof.
[0154] In some embodiments, the adjunctive therapeutic agent is a pharmaceutical agent for treating coronaviruses. In some embodiments, the adjunctive therapeutic agent is selected from: IFX-1, FM-201, CYNK-001, DPP4-Fc, leopard frog enzyme, nabumostat, LB-2, AM-1, antiviral porin, and combinations thereof.
[0155] In some embodiments, the adjunctive therapeutic agent is an agent used to treat Ebola virus. For example, in some embodiments, the adjunctive therapeutic agent is selected from: ribavirin, palilizumab, murvizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444, MDT-637, BMS-433771, amiodarone, dronedarone, verapamil, Ebola convalescent plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino- 5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), favipiravir (also known as T-705 or Avigan), T-705 monophosphate, T-705 diphosphate, T-705 triphosphate, FGI-106 (1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinolone-1,7-diamine), JK-05, TKM-Ebola, ZMapp, rNAPc2, VRC-EBOADC076-00-VP, OS-2966, MVA-BN Filo, brincidofovir, Ebola vaccine based on Vaxart adenovirus vector 5, Ad26-ZEBOV, FiloVax vaccine, GOVX-E301, GOVX-E302, Ebola virus invasion inhibitor (NPC1 inhibitor), rVSV-EBOV, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is ZMapp, mAB114, REGEN-EB3, and combinations thereof.
[0156] In some embodiments, the adjunctive therapeutic agent is an agent for treating HCV. In some embodiments, the adjunctive therapeutic agent is an HCV polymerase inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: sofosbuvir, GS-6620, PSI-938, ribavirin, tegobvir, redabuvir, MK-0608, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is an HCV protease inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: such as GS-9256, veldovir, voxiprevir, and combinations thereof.
[0157] In some embodiments, the adjunctive therapeutic agent is an NS5A inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: ledipasvir, velpatasvir, and combinations thereof.
[0158] In some embodiments, the adjunctive therapeutic agent is an anti-HBV agent. For example, in some embodiments, the adjunctive therapeutic agent is tenofovir disoproxil fumarate and emtricitabine or combinations thereof. Examples of adjunctive anti-HBV agents include, but are not limited to, α-hydroxytophenone, amdoxovir, antroquinonol, β-hydroxycytosine nucleotide, ARB-199, CCC-0975, CCC-R08, elvucitabine, ezetimibe, cyclosporine A, gentiopicrin, HH-003, hepalatide, JNJ-56136379, nitrozonide, birinapant, NJK14047, NOV-205 (molixan, BAM-205), and the product information for Oridol (page 23 / 58, CN 121925423 A). (oligotide), mivotilate, feron, GST-HG-131, levamisole, Ka Shu Ning, alloferon, WS-007, Y-101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, oleanolic acid, HepB-nRNA, cTP-5 (rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106, Hepbarna, IPB-006IA, Hepuyinfen, DasKloster 0014-01, ISA-204, Jiangantai (Ganxikang), MIV-210, OB-AI-004, PF-06, picroside DasKloster-0039, hepulantai, IMB-2613, TCM-800B, reduced glutathione, RO-6864018, RG-7834, QL-007 Sofosbuvir, Leadipasvir, UB-551, and ZH-2N, as well as US20150210682 (Roche), US 2016 / 0122344 (Roche), WO2015173164, WO2016023877, US2015252057A (Roche), WO16128335A1 (Roche), WO16120186A1 (Roche), US2016237090A (Roche), WO16107833A1 (Roche), WO16107832A1 (Roche), US2016176899A (Roche), and WO16102438A1 The compounds disclosed in Roche, WO16012470A1 (Roche), US2016220586A (Roche), and US2015031687A (Roche). In some embodiments, the additional therapeutic agent is an HBV polymerase inhibitor. Examples of HBV DNA polymerase inhibitors include, but are not limited to, adefovir (HEPSERA®), emtricitabine (EMTRIVA®), tenofovir disoproxil fumarate (VIREAD®), tenofovir alafenamide, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide hemifumarate, tenofovir alafenamide diterpenoid, tenofovir alafenamide diterpenoid, tenofovir octadecyloxyethyl ester, CMX-157, tenofovir alafenamide exalidex, besifovir, entecavir (BARACLUDE®), entecavir maleate, telbivudine (TYZEKA®), feloxivir, pradefovir, clavudine, ribavirin, and lamivudine (EPIVIR-HBV®). ), azidophosphine, famciclovir, fusolin, metavivir, SNC-019754, FMCA, AGX-1009, AR-II-04-26, HIP-1302, tenofovir disoproxil fumarate aspartate, tenofovir disoproxil fumarate orotate, and HS-10234. In some embodiments, the adjunctive therapeutic agent is an HBV capsid inhibitor.
[0159] In some embodiments, the adjunctive therapeutic agent is a pharmaceutical agent for treating HIV. In some embodiments, the adjunctive therapeutic agent is selected from: HIV protease inhibitors, HIV integrase inhibitors, entry inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, acyclic nucleoside phosphonate analogs, and combinations thereof.
[0160] In some embodiments, the adjunctive therapeutic agent is selected from: HIV protease inhibitors, HIV non-nucleoside or non-nucleotide reverse transcriptase inhibitors, and combinations thereof.Transcriptionase inhibitors, HIV nucleoside or nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editing agents (such as CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALEN), and cell therapies (such as chimeric antigen receptor T cells, CAR-T cell receptors and engineered T cell receptors, TCR-T, autologous T cell therapy).
[0161] In some embodiments, the additional therapeutic agent is selected from: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversal agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies and bispecific antibodies and "antibody-like" therapeutic proteins, and combinations thereof.
[0162] In some embodiments, the additional treatment is an HIV combination drug. Examples of HIV combination therapies include, but are not limited to, ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); BIKTARVY® (bicagvir, emtricitabine, and tenofovir alafenamide); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (ertiravir, cobistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofovir alafenamide, emtricitabine, and rilpivirine); CN 121925423 A (Instructions for Use, page 24 / 58, 32). Tenofovir alafenamide, emtricitabine, cobistat, and ertirapvir; SYMTUZA® (direravir, tenofovir alafenamide hemifumarate, emtricitabine, and cobistat); (efavirenz, lamivudine, and tenofovir disoproxil fumarate); (lamivudine and tenofovir disoproxil fumarate); tenofovir and lamivudine; tenofovir alafenamide and emtricitabine; tenofovir alafenamide hemifumarate and emtricitabine; tenofovir alafenamide hemifumarate, emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate, emtricitabine, cobistat, and ertirapvir; COMBIVIR® (zidovudine and lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine);(ABC+3TC); KALETRA® (ALUVIA®; lopinavir and ritonavir); TRIUMEQ® (durutexvir, abacavir and lamivudine); TRIZIVIR® (Abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); Atazanavir and cobistat; Atazanavir sulfate and cobistat; Atazanavir sulfate and ritonavir; Dermiravir and cobistat; Dulutegravir and rilpivirine; Dulutegravir and rilpivirine hydrochloride; Dulutegravir, abacavir sulfate, and lamivudine; Lamivudine, nevirapine, and zidovudine; Rytegvir and lamivudine; Doravirine, lamivudine, and tenofovir disoproxil fumarate; Doravirine, lamivudine, and tenofovir disoproxil fumarate; Dapivirine + levonorgestrel, Dulutegravir + lamivudine; Durutvir + emtricitabine + tenofovir disoproxil fumarate, alfavirine + emtricitabine + tenofovir disoproxil fumarate, lamivudine + abacavir + zidovudine, lamivudine + abacavir, lamivudine + tenofovir disoproxil fumarate, lamivudine + zidovudine + nevirapine, lopinavir + ritonavir, lopinavir + ritonavir + abacavir + lamivudine, lopinavir + ritonavir + zidovudine + lamivudine, tenofovir + lamivudine, and tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir, ritonavir, zidovudine, and lamivudine.
[0163] In some embodiments, the additional therapeutic agent is an HIV protease inhibitor. For example, in some implementations, the adjunctive treatment agent is selected from: saquinavir, ritonavir, indinavir, nelfinavir, ampravir, lopinavir, atazanavir, fossavir, drenellavir, telanavir, cobicistat, ASC-09, AEBL-2, MK-8718, GS-9500, GS-1156, and combinations thereof. For example, in some implementations, the adjunctive treatment agent is selected from: saquinavir, ritonavir, indinavir, nelfinavir, ampravir, lopinavir, atazanavir, fossavir, drenellavir, telanavir, and cobicistat. In some embodiments, the adjunctive treatment agent is selected from: ampravir, atazanavir, becanavir, drenellavir, fossavir, fossavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, telanavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, TMC-310911, and combinations thereof.
[0164] In some embodiments, the adjunctive treatment agent is an HIV integrase inhibitor. For example, in some embodiments, the adjunctive treatment agent is selected from: retegvir, erteiravir, dulutegravir, abacavir, lamivudine, bicagvir, and combinations thereof.Combination. In some embodiments, the adjunctive treatment is bicagravir. In some embodiments, the adjunctive treatment is selected from the group consisting of: bicagravir, erteiravir, curcumin, curcumin derivatives, chicoric acid, chicoric acid derivatives, 3,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid derivatives, ginsenoside tricarboxylic acid, ginsenoside tricarboxylic acid derivatives, caffeic acid phenylethyl ester, caffeic acid phenylethyl ester derivatives, tyrphostin, tyrphostin derivatives, quercetin, quercetin derivatives, retegvir, dulutegravir, JTK-351, bicagravir, AVX-15567, BMS-986197, cabotevir (long-acting injectable), diketoquinoline-4-1 derivatives, integrase-LEDGF inhibitors, ledgins, M-522, M-532, NSC-310217. NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, stilbene disulfonic acid, T-169, VM-3500, cabotevir, and combinations thereof.
[0165] In some embodiments, the adjunctive therapeutic agent is an HIV entry inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: entviride, maraviro, and combinations thereof. Other examples of HIV entry inhibitors include, but are not limited to, cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 linker inhibitors, DS-003 (BMS - Specification 25 / 58 pages 33 CN 121925423 A 599793), gp120 inhibitors, and CXCR4 inhibitors. Examples of CCR5 inhibitors include apravirone, vevicvirone, maravirone, cinevirovirone, lelimumab (PRO-140), adatabvir (RAP-101), nifevirone (TD-0232), anti-GP120 / CD4 or CCR5 bispecific antibody, B-07, MB-66, peptide C25P, TD-0680, and vMIP (Haimipu). Examples of CXCR4 inhibitors include praxavir, ALT-1188, N15 peptide, and vMIP (Haimipu).
[0166] In some embodiments, the adjunctive therapeutic agent is an HIV nucleoside reverse transcriptase inhibitor. In some embodiments, the adjunctive therapeutic agent is an HIV non-nucleoside reverse transcriptase inhibitor. In some embodiments, the adjunctive therapeutic agent is an acyclic nucleoside phosphonate analog. In some embodiments, the adjunctive therapeutic agent is an HIV capsid inhibitor.
[0167] In some embodiments, the adjunctive therapeutic agent is an HIV nucleoside or nucleotide reverse transcriptase inhibitor. For example, adjunctive...Therapeutic agents are selected from: adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, VIDEX® and VIDEX EC® (didanovine, ddl), abacavir, abacavir sulfate, alovudine, aripipridine, sensavudine, doxostatin, evitabine, famciclovir, fosalvudine tidoxil, CMX-157, dapoxil, doravirin, etravirin, OCR-5753, orotic tenofovir disoproxil fumarate, fozivudine tidoxil. tidoxil), islatravir, lamivudine, phosphazid, stavudine, zalcitabine, zidovudine, rovafovir estarafenamide (GS-9131), GS-9148, MK-8504, MK-8591, MK-858, VM-2500, KP-1461, and combinations thereof.
[0168] In some embodiments, the additional therapeutic agent is an HIV non-nucleoside or non-nucleotide reverse transcriptase inhibitor. For example, the adjuvant agents are selected from: dapiril, delavudine, delavudine mesylate, doravirine, efavirenz, ectrevirine, lentinan, MK-8583, nevirapine, rilpivirine, TMC-278LA, ACC-007, AIC-292, KM-023, PC-1005, elfavirine rilp (VM-1500), and combinations thereof.
[0169] In some embodiments, the adjunctive treatment agent is selected from ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (erteiravir, cobistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (Tenofovir alafenamide, emtricitabine, cobistat, and ertirapvir); Adefovir; Adefovir dipivoxil; Cobistat; Emtricitabine; Tenofovir; Tenofovir disoproxil fumarate; Tenofovir alafenamide; Tenofovir disoproxil fumarate; Tenofovir alafenamide; Tenofovir disoproxil fumarate; TRIUMEQ® (durutexvir, abacavir, and lamivudine); Durutvir, abacavir sulfate, and lamivudineRipinavir; Ripinavir and Lamivudine; Maraviro; Enfuviride; ALUVIA® (KALETRA®; Lopinavir and Ritonavir); COMBIVIR® (Zidovudine and Lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; Abacavir Sulfate and Lamivudine; ABC+3TC); TRIZIVIR® (Abacavir Sulfate, Zidovudine and Lamivudine; ABC+AZT+3TC); Rilpivirine; Rilpivirine Hydrochloride; Atazanavir Sulfate and Cobistat; Atazanavir and Cobistat; Derreiravir and Cobistat; Atazanavir; Atazanavir Sulfate; Dulutegravir; Ertirapvir; Ritonavir; Atazanavir Sulfate and Ritonavir; Dermiravir; Lamivudine; Prandtine; Fosanavir; Fosanavir calcium Efavirone; Etravirine; Nefenavirvir; Nefenavirvir mesylate; Interferon; Doxorinosine; Stavudine; Indinavir; Indinavir sulfate; Tenofovir and Lamivudine; Zidovudine; Nevirapine; Saquinavir; Saquinavir mesylate; Aldehyde; Zacitabine; Telanavir; Ampravir; Deravudine; Deravudine mesylate; Radha-108 (receptor alcohol); Lamivudine and Tenofovir disoproxil fumarate; Efavirone, Lamivudine and Tenofovir disoproxil fumarate; Aziphosphonate; Lamivudine, Nevirapine and Zidovudine (Instructions for Use, 26 / 58 pages, 34 CN 121925423 A); Abacavir; and Abacavir sulfate.
[0170] In some embodiments, the adjunctive therapeutic agent is selected from: colistin, penrubocin, ictabin, betasine, epirubocin, iprostol, vaportide, aprepitant, caspofungin, perphenazine, atazanavir, efavirenz, ritonavir, acyclovir, ganciclovir, penciclovir, prulifloxacin, bicagvir, nelfinavir, tegobuvir, nelfinavir, praziquantel, pitavastatin, perampanel, eszopiclone, and zopiclone.
[0171] In some embodiments, the adjunctive therapeutic agent is an inhibitor of Bruton's tyrosine kinases (BTK, AGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLA; NCBI gene ID: 695). For example, in some embodiments, the adjunctive therapeutic agent is selected from: (S)-6-amino-9-(1-(but-2-ethynyl)pyrrolidine-3-yl)-7-(4-phenoxyphenyl)-7H-purine-8(9H)-one, acalabrutinib (ACP-196), BGB-3111, CB988, HM71224, ibrutinib, M-2951 (evobrutinib), M7583, tirabrutinib (ONO-4059), PRN-1008, septemide.Tinib (CC-292), TAK-020, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS-12, TAS-5315, AZD6738, acalatinib, danvastatin, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: teiralutinib, ibrutinib, acalatinib, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is selected from: teiralutinib, ibrutinib, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is a tyrosine kinase inhibitor A9 (A9).
[0172] In some embodiments, the adjunctive therapeutic agent is a KRAS inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from: AMG-510, COTI-219, MRTX-1257, ARS-3248, ARS-853, WDB-178, BI-3406, BI-1701963, ARS-1620 (G12C), SML-8-73-1 (G12C), compound 3144 (G12D), Kobe0065 / 2602 (Ras GTP), RT11, MRTX-849 (G12C), and K-Ras (G12D) selective inhibitory peptides, including KRpep-2 (Ac-RRRRCPLYISYDPVCRR-NH2), KRpep-2d (Ac-RRRRCPLYISYDPVCRRRR-NH2), and combinations thereof.
[0173] In some embodiments, the additional therapeutic agent is a proteasome inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from the group consisting of ixazomib, carfilzomib, marizomib, bortezomib, and combinations thereof. In some embodiments, the adjunctive therapeutic agent is carfilzomib.
[0174] In some embodiments, the adjunctive therapeutic agent is a vaccine. For example, in some embodiments, the adjunctive therapeutic agent is a DNA vaccine, an RNA vaccine, a live attenuated vaccine, a therapeutic vaccine, a prophylactic vaccine, a protein-based vaccine, or a combination thereof. In some embodiments, the adjunctive therapeutic agent is mRNA-1273. In some embodiments, the adjunctive therapeutic agent is INO-4800 or INO-4700. In some embodiments, the adjunctive therapeutic agent is the live attenuated RSV vaccine MEDI-559, the anti-RSV human monoclonal antibody REGN2222, palizumab, respiratory syncytial virus immunoglobulin, intravenous respiratory syncytial virus immunoglobulin [RSV-IGIV], and combinations thereof. In some implementations, the adjunctive treatment is an HBV vaccine, such as pediarix, engerix-B, and recombivax.HB. In some embodiments, the adjunctive therapeutic agent is a VZV vaccine, such as zostavax and varivax. In some embodiments, the adjunctive therapeutic agent is an HPV vaccine, such as cervarix, gardasil 9, and gardasil. In some embodiments, the adjunctive therapeutic agent is an influenza virus vaccine. For example, (i) a monovalent influenza A vaccine (e.g., a monovalent influenza A [H5N1] virus vaccine and a monovalent influenza A [H1N1] 2009 virus vaccine), (ii) a trivalent influenza A and B virus vaccine (e.g., Afluria, Agriflu, Fluad, Fluarix, Flublok, Flucelvax, FluLaval, Fluvirin, and Fluzone), and (iii) a quadrivalent influenza A and B virus vaccine (FluMist, Fluarix, Fluzone, and FluLaval). In some embodiments, the adjunctive therapeutic agent is a human adenovirus vaccine (e.g., adenovirus type 4 and 7 vaccines, live, orally). In some embodiments, the adjunctive therapeutic agent is a rotavirus vaccine (e.g., Rotarix for rotavirus serotypes G1, G3, G4, or G9 and RotaTeq for rotavirus serotypes G1, G2, G3, or G4). In some embodiments, the adjunctive therapeutic agent is a hepatitis A virus vaccine (e.g., Havrix and Vaqta). In some embodiments, the adjunctive therapeutic agent is a polio virus vaccine (e.g., Kinrix, Quadracel, and Ipol). In some embodiments, the adjunctive therapeutic agent is a yellow fever virus vaccine (e.g., YF-Vax). In some embodiments, the adjunctive therapeutic agent is a Japanese encephalitis virus vaccine (e.g., Ixiaro and JE-Vax). In some embodiments, the adjunctive therapeutic agent is a measles vaccine (e.g., M-M-R II and ProQuad). In some embodiments, the adjunctive therapeutic agent is a mumps vaccine (e.g., M-M-R II and ProQuad). In some embodiments, the adjunctive therapeutic agent is a rubella vaccine (e.g., M-M-R II and ProQuad). In some embodiments, the adjunctive therapeutic agent is a varicella vaccine (e.g., ProQuad). In some embodiments, the adjunctive therapeutic agent is a rabies vaccine (e.g., Imovax and RabAvert). In some embodiments, the adjunctive therapeutic agent is a smallpox virus (smallpox) vaccine (ACAM2000). In some embodiments, the adjunctive therapeutic agent is a hepatitis E virus (HEV) vaccine (e.g., HEV239). In some embodiments, the adjunctive therapeutic agent is a 2019-nCoV vaccine.
[0175] In some embodiments, the adjunctive therapeutic agent is an antibody, such as a monoclonal antibody. For example, the adjunctive therapeutic agent is an anti-2019-nCoV antibody selected from: Regeneron antibody, Wuxi antibody, Vir Biotechnology antibody, antibodies targeting the SARS-CoV-2 spike protein, antibodies that neutralize SARS-CoV-2 (SARS-CoV-2 neutralizing antibodies), and combinations thereof. In some embodiments, the adjunctive therapeutic agent is the anti-SARS-CoV antibody CR-3022. In some embodiments, the adjunctive therapeutic agent is an aPD-1 antibody.
[0176] In some embodiments, the adjunctive therapeutic agent is a recombinant cytokine gene-derived protein injection.
[0177] In some embodiments, the adjunctive therapeutic agent is a polymerase inhibitor. In some embodiments, the adjunctive therapeutic agent is a DNA polymerase inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is cidofovir. In some embodiments, the adjunctive therapeutic agent is an RNA polymerase inhibitor. For example, in some embodiments, the adjunctive therapeutic agent is selected from: ribavirin, favipiravir, lamivudine, pimodevir, and combinations thereof.
[0178] In some embodiments, the additional therapeutic agent is selected from: lopinavir, ritonavir, interferon α-2b, ritonavir, arbidol, hydroxychloroquine, direravir and cobicistat, arbidol hydrochloride, oseltamivir, litonavir, emtricitabine, tenofovir alafenamide fumarate, baloxavir macozide, ruxotetinib, and combinations thereof.
[0179] In some embodiments, the additional therapeutic agent is selected from: 6'-fluoromyomycin analog, acyclovir fleximer analog, disulfiram, thiopurine analog, ASC09F, GC376, GC813, phenyl isoserine derivative, neuraminidase inhibitor analog, pyrimethamine derivative, bananins and 5-hydroxytryptamine derivative, SSYA10-001, griffithsin, HR2P-M1, HR2P-M2, P21S10, dihydrotanshinone E-64-C and E-64-D, OC43-HR2P, MERS-5HB, 229E-HR1P, 229E-HR2P, resveratrol, 1-thia-4-azaspiro[4.5]dec-3-one derivatives, gemcitabine hydrochloride, loperamide, recombinant interferon, cyclosporine A, arapovir, imatinib mesylate, dasatinib, sumetinib, trametinib, rapamycin, sacatinib, chlorpromazine, trifluprozine, fluphenazine, thiotetrazine, promethazine, cyclophilic protein inhibitors, K11777, carmostat, K22, teicoplanin derivatives, benzo[a]heterocyclic amine derivative N30, mycophenolic acid, sevestrol, and combinations thereof.
[0180] In some embodiments, the adjunctive therapeutic agent is an antibody. In some embodiments, the adjunctive therapeutic agent is an antibody that binds to a coronavirus, such as an antibody that binds to SARS-CoV or MERS-CoV. In some embodiments, the adjunctive therapeutic agent is a 2019-nCoV virus antibody.
[0181] The compositions of the present invention are also used in combination with other active ingredients. For the treatment of 2019-nCoV virus infection, preferably, the other active therapeutic agents have activity against coronavirus infection, such as activity against 2019-nCoV virus infection. The compounds and compositions of the present invention are also intended for use in providing general care to patients suffering from 2019-nCoV virus infection, including parenteral fluids (including glucose saline and Ringer's lactate) and nutrients, antibiotics (including metronidazole and cephalosporins, such as ceftriaxone and cefuroxime) and / or antifungal prophylaxis, fever and pain medications, antiemetics (such as metoclopramide) and / or antidiarrheals, vitamin and mineral supplements (including vitamin K and zinc sulfate), anti-inflammatory agents (such as ibuprofen or steroids), corticosteroids such as methylprednisolone, immunomodulatory drugs (e.g., interferon), and 2019-nCoV-targeting drugs. Other small molecule or biological agents such as, but not limited to, lopinavir / ritonavir, EIDD-1931, favipiravir, ribavirin, neutralizing antibodies, etc., vaccines, pain medications, and medications for other common diseases in the patient population, such as antimalarial agents (including artemether and artemisinin-benfluridine combination therapy), typhoid vaccines (including quinolone antibiotics such as ciprofloxacin, macrolide antibiotics such as azithromycin, cephalosporin antibiotics such as ceftriaxone, or aminopenicillins such as ampicillin) or Shigella infection. In some embodiments, the adjunctive therapeutic agent is dihydroartemisinin / piperaquine. In some embodiments, the adjunctive therapeutic agent is EIDD-2801 (MH-4482, monoupivir).
[0182] In some embodiments, the adjunctive therapeutic agent is an immunomodulator. Examples of immunotherapy-based therapies include Toll-like receptor modulators such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13; programmed cell death protein 1 (Pd-1) modulators; programmed death ligand 1 (Pd-L1) modulators; IL-15 modulators; DermaVir; interleukin-7; hydroxychloroquine (hydroxylated chloroquine); prazolam (aldeleukin, IL-2); interferon α; interferon α-2b; interferon α-n3; pegylated interferon α; interferon γ; hydroxyurea; mycophenolate mofetil (MPA) and its derivatives.Ester derivative mycophenolate mofetil (MMF); ribavirin; polymeric polyethyleneimine (PEI); geopon; IL-12; WF-10; VGV-1; MOR-22; BMS-936559; CYT-107; interleukin-15 / Fc fusion protein; AM-0015; ALT-803; NIZ-985; NKTR-255; NKTR-262; NKTR-214; nifedipine; pegylated interferon α-2a; pegylated interferon α-2b; recombinant interleukin-15; Xmab-24306; RPI-MN; STING modulator; RIG-I modulator; NOD2 modulator; SB-9200; and IR-103. In some embodiments, the adjunctive therapeutic agent refers to fingolimod, leflunomide, or a combination thereof. In some embodiments, the adjunctive therapeutic agent is thalidomide.
[0183] In some embodiments, the adjunctive therapeutic agent is an IL-6 inhibitor, such as tocilizumab, thalidomide, or a combination thereof.
[0184] In some embodiments, the adjunctive therapeutic agent is an anti-TNF inhibitor. For example, the adjunctive therapeutic agent is adalimumab, etanercept, golimumab, infliximab, or a combination thereof.
[0185] In some embodiments, the adjunctive therapeutic agent is a JAK inhibitor, such as baricitinib, filgortinib, baricitinib, or a combination thereof.
[0186] In some embodiments, the adjunctive therapeutic agent is an anti-inflammatory agent, such as pirfenidone.
[0187] In some embodiments, the adjunctive therapeutic agent is an antibiotic for secondary bacterial pneumonia. For example, adjunctive treatment agents are macrolide antibiotics (e.g., azithromycin, clarithromycin, and mycoplasma pneumoniae), fluoroquinolones (e.g., ciprofloxacin and levofloxacin), tetracyclines (e.g., doxycycline and tetracycline), or combinations thereof.
[0188] In some embodiments, the compounds described herein are used in combination with standards of care for pneumonia (see, for example, Pediatric Community Pneumonia Guidelines, CID 2011:53 (October 1)). Treatment of pneumonia generally involves curing the infection and preventing complications. Specific treatment will depend on several factors, including the type and severity of pneumonia, the individual's age, and overall health. Options include: (i) antibiotics, (ii) cough medicines, and (iii) antipyretics / analgesics (e.g., aspirin, ibuprofen (Advil, Motrin IB, etc.), and acetaminophen (Tylenol, etc.)). In some embodiments, adjunctive treatment agents are bromhexine cough suppressants.
[0189] In some embodiments, the compounds described herein are combined with immunoglobulins from cured COVID-19 patients.Combination use. In some embodiments, the compounds described herein are used in combination with plasma infusion. In some embodiments, as described on pages 29 / 58 of CN 121925423 A, the compounds described herein are used in combination with stem cells.
[0190] In some embodiments, the additional therapeutic agent is a TLR agonist. Examples of TLR agonists include, but are not limited to, vesamimod (GS-9620), GS-986, IR-103, lefemod, tilsotolimod, rintatolimodod, DSP-0509, AL-034, G-100, cobitolimod, AST-008, motolimod, GSK-1795091, GSK-2245035, VTX-1463, GS-9688, LHC-165, BDB-001, RG-7854, teiramod, and RO-7020531.
[0191] In some embodiments, the adjunctive therapeutic agent is selected from: bortezomib, flurazepam, ponatinib, sorafenib, peramisone, clotropone, flucloxacillin, serindole, clovididipine, atorvastatin, sinusizine, clofazimine, fosapiram, and combinations thereof.
[0192] In some embodiments, the adjunctive therapeutic agent is azithromycin, suramin, triazolene, dipyridamole, bevacizumab, meperizumab, GD31 (Rhizobium spp.), NLRP inflammasome inhibitors, or α-ketoamines. In some embodiments, the adjunctive therapeutic agent is recombinant human angiotensin-converting enzyme 2 (rhACE2). In some embodiments, the adjunctive therapeutic agent is viral macrophage inflammatory protein (vMIP).
[0193] In some embodiments, the adjunctive therapeutic agent is an antiviral porin therapeutic agent. For example, the adjunctive therapeutic agent is BIT-314 or BIT-225. In some embodiments, the adjunctive therapeutic agent is a coronavirus E protein inhibitor. For example, the adjunctive therapeutic agent is BIT-009. Other examples of adjunctive therapeutic agents include those described in WO-2004112687, WO-2006135978, WO-2018145148, and WO-2009018609.
[0194] In some embodiments, the adjunctive therapeutic agent or prophylactic agent is monopivir, oseltamivir, nirmatrelvir, or ritonavir. In some embodiments, the adjunctive therapeutic agent or prophylactic agent is ritonavir or cobistat.
[0195] In some embodiments, the adjunctive therapeutic agent is a 2,5-oligoadenylate synthase stimulator, a 5-HT 2a receptor antagonist, a 5-lipoxygenase inhibitor, an ABL family tyrosine kinase inhibitor, an Abl tyrosine kinase inhibitor, or an aldehyde dehydrogenase inhibitor.Preparations, acetyl-CoA carboxylase inhibitors, actin antagonists, actin modulators, activity-dependent neuroprotective modulators, adenosine A3 receptor agonists, adrenergic receptor antagonists, adrenal medullary ligands, adrenal medullary ligand inhibitors, late glycosylation product receptor antagonists, late glycosylation product receptor modulators, AKT protein kinase inhibitors, alanine- and proline-rich secretory protein stimulators, aldose reductase inhibitors, alkaline phosphatase stimulators, α2-adrenergic receptor antagonists, α2B-adrenergic receptor agonists, AMP-activated protein kinase stimulators, AMPA receptor modulators, amyloid deposition inhibitors, androgen receptor antagonists, angiotensin II AT-1 receptor antagonists, angiotensin II AT-2 receptor agonists, angiotensin II receptor modulators, angiotensin-converting enzyme 2 inhibitors, angiotensin-converting enzyme 2 modulators, angiotensin-converting enzyme 2 stimulators, angiotensin receptor modulators, annexin A5 stimulators. Anoctamin 1 inhibitors, anticoagulants, antihistamines, antihypertensive agents, antithrombotic agents, AP1 transcription factor regulators, apralin receptor agonists, APOA1 gene stimulators, apolipoprotein A1 agonists, apolipoprotein B antagonists, apolipoprotein B regulators, apolipoprotein C3 antagonists, aryl hydrocarbon receptor agonists, aryl hydrocarbon receptor antagonists, ATP-binding cassette transporter B5 regulators, Axl tyrosine kinase receptor inhibitors, bactericidal permeability-increasing protein inhibitors, basigin inhibitors, basigin regulators, BCL2 gene inhibitors, BCL2L11 gene stimulators, Bcr protein inhibitors, β1-adrenergic receptor regulators, β2-adrenergic receptor agonists, β-adrenergic receptor agonists, β-inhibitory protein stimulators, coagulation regulators, BMP10 Gene inhibitors, BMP15 gene inhibitors, bone morphogenetic protein-10 ligand inhibitors, bone morphogenetic protein-15 ligand inhibitors, bradykinin B2 receptor antagonists, brain-derived neurotrophic factor ligands, bromine-domain-containing protein 2 inhibitors, bromine-domain-containing protein 4 inhibitors, Btk tyrosine kinase inhibitors, C-reactive protein modulators, Ca2+ release-activated Ca2+ channel 1 inhibitors, cadherin-5 modulators, calcium-activated chloride channel inhibitors, calcium channel modulators, calpain-I inhibitors, calpain-II inhibitors, calpain-IX inhibitors, cannabinoid CB2 receptor agonists, cannabinoid receptor modulators, casein kinase II inhibitors, CASP8-FADD-like regulatory factor inhibitors, caspase inhibitors, catalase stimulators, CCL26 gene inhibitors, CCR2 chemokine antagonists, CCR5 chemokine antagonists, CD11a agonists.CD122 agonists, CD3 antagonists, CD4 agonists, CD40 ligands, CD40 ligand modulators, CD40 ligand receptor agonists CD40 ligand receptor modulators, CD49d agonists, CD70 antigen modulators, CD73 agonists, CD73 antagonists, CD95 antagonists, CFTR inhibitors, CGRP receptor antagonists, chemokine receptor-like 1 agonists, chloride channel inhibitors, chloride channel modulators, cholera enterotoxin subunit B inhibitors, cholesterol ester transporter inhibitors, collagen modulators, complement C1s subfraction inhibitors, complement C3 inhibitors, complement C5 factor inhibitors, complement C5a factor inhibitors, complement factor H stimulators, complement cascade inhibitors, complement factor C2 inhibitors, complement factor D inhibitors, connective tissue growth factor ligand inhibitors, coronavirus nucleoprotein modulators, coronavirus small envelope protein modulators, coronavirus spike glycoprotein inhibitors, coronavirus spike glycoprotein modulators, COVID19 envelope small membrane protein modulators, COVID19 nonstructural protein 8 modulators, COVID19 nucleoprotein modulators, COVID19 protein 3a inhibitors, COVID19 replicase polyprotein 1a inhibitors, COVID19 replicase polyprotein 1a Modulators, COVID-19 replicase polyprotein 1ab inhibitors, COVID-19 replicase polyprotein 1ab modulators, COVID-19 spike glycoprotein inhibitors, COVID-19 spike glycoprotein modulators, COVID-19 structural glycoprotein modulators, CRF-2 receptor agonists CSF-1 agonists, CSF-1 antagonists, CX3CR1 chemokine antagonists, CXC10 chemokine ligand inhibitors, CXC5 chemokine ligand inhibitors, CXCL1 gene regulators, CXCL2 gene regulators, CXCL3 gene regulators, CXCR1 chemokine antagonists, CXCR2 chemokine antagonists, CXCR4 chemokine antagonists, cyclin D1 inhibitors, cyclin E inhibitors, cyclin-dependent kinase-1 inhibitors, cyclin-dependent kinase-2 inhibitors, cyclin-dependent kinase-5 inhibitors, cyclin-dependent kinase-7 inhibitors, cyclin-dependent kinase-9 inhibitors, cyclooxygenase 2 inhibitors, cyclooxygenase inhibitors, cyclophilic protein inhibitors, cysteine protease inhibitors, cytochrome P450. 3A4 inhibitors, cytokine receptor antagonists, cytotoxic T lymphocyte protein gene regulators, cytotoxic T lymphocyte protein-4 inhibitors, cytotoxic T lymphocyte protein-4 stimulators, DDX3 inhibitors, dehydrogenase inhibitors, dehydropeptidase-1 regulators, deoxyribonuclease I stimulators, deoxyribonuclease γ stimulators, deoxyribonuclease stimulators, dihydroceramide δ4 dehydrogenase inhibitors, dihydroorotate dehydrogenase inhibitors, dipeptidyl peptidaseI inhibitors, dipeptidyl peptidase III inhibitors, diuretics, DNA-binding protein inhibitors, DNA methyltransferase inhibitors, dopamine transporter inhibitors, E-selectin antagonists, Ecto-NOX disulfide thiol exchanger 2 inhibitors, EGFR gene inhibitors, elongation factor 1α2 regulators, endoplasmic reticulum regulators, endonuclease DICER regulators, endothelin ET-A receptor antagonists, epidermal growth factor receptor antagonists, E-selectin antagonists, estrogen receptor β agonists, estrogen receptor regulators, eukaryotic initiation factor 4A-I inhibitors, exo-α-sialic acid activator regulators, export protein 1 inhibitors, factor Ia regulators, factor Iia regulators, factor VII antagonists, factor Xa antagonists, factor Xia antagonists, FGF receptor antagonists, FGF-1 ligands, FGF-1 ligand inhibitors, FGF-2 ligand inhibitors, FGF1 receptor antagonists, FGF2 receptor antagonists, FGF3 receptor antagonists. Flt3 tyrosine kinase inhibitors, Fractalkine ligand inhibitors, free fatty acid receptor 2 agonists, free fatty acid receptor 3 agonists, furin protease inhibitors, Fyn tyrosine kinase inhibitors, FYVE (phosphoinositol kinase inhibitors), G protein-coupled bile acid receptor 1 agonists, GABA A receptor modulators, galactoglobin-3 inhibitors, γ-secretase inhibitors, GDF agonists, colloid stimulators, glial cell neurotrophic factor ligands, glucocorticoid receptor agonists, glutathione peroxidase stimulators, GM-CSF ligand inhibitors, GM-CSF receptor agonists, GM-CSF receptor modulators, Griffithsin modulators, growth regulator protein α ligand inhibitors, Grp78 calcium-binding protein inhibitors, heat shock protein HSP90α inhibitors, heat shock protein HSP90β inhibitors, heat shock protein inhibitors, heat shock protein stimulators, hemagglutinin (Instructions for Use, Page 31 / 58, 39 CN 121925423 A) Hemoglobin modulators, hemolysin α inhibitors, heparanase inhibitors, heparin agonists, hepatitis B structural protein inhibitors, hepatitis C virus NS5B polymerase inhibitors, HIF prolyl hydroxylase inhibitors, HIF prolyl hydroxylase-2 inhibitors, high-mobility group box B1 inhibitors, histamine H1 receptor antagonists, histamine H2 receptor antagonists, histone deacetylase-6 inhibitors, histone inhibitors, HIV protease inhibitors, HIV-1 gp120 protein inhibitors, HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HLA class I antigen modulators, HLA class II antigen modulators, host cytokine modulators, Hsp90 inhibitors, human papillomavirus E6 protein modulators, human papillomavirus E7 protein modulators, hypoxia-inducedFactor inhibitors, gene inhibitors, hypoxia-inducible factor-2α modulators, I-κB kinase inhibitors, I-κB kinase modulators, ICAM-1 stimulators, IgG receptor FcRn large subunit p51 modulators, IL-12 receptor antagonists, IL-15 receptor agonists, IL-15 receptor modulators, IL-17 antagonists, IL-18 receptor accessory protein antagonists, IL-2 receptor agonists, IL-22 agonists, IL-23 antagonists, IL-6 receptor agonists, IL-6 receptor antagonists, IL-6 receptor modulators, IL-7 receptor agonists, IL-8 receptor antagonists, IL-12 gene stimulators, IL-8 gene modulators, immunoglobulin G modulators, immunoglobulin G1 agonists, immunoglobulin G1 modulators, immunoglobulin agonists, immunoglobulin γ Fc receptor I modulators, immunoglobulin κ modulators. Inosine monophosphate dehydrogenase inhibitors, insulin sensitizers, integrin agonists, integrin α-4 / β-7 antagonists, integrin α-V / β-1 antagonists, integrin α-V / β-6 antagonists, interferon agonists, interferon α14 ligands, interferon α2 ligands, interferon α2 ligand modulators, interferon α ligands, interferon α ligand inhibitors, interferon α ligand modulators, interferon β ligands, interferon γ ligand inhibitors, interferon γ receptor agonists, interferon γ receptor antagonists, interferon receptor modulators, interferon type I receptor agonists, interleukin 17A ligand inhibitors, interleukin 17F ligand inhibitors, interleukin 18 ligand inhibitors, interleukin 22 ligands, interleukin-1β ligand inhibitors, interleukin-1β ligand modulators, interleukin-1 ligand inhibitors. Interleukin-2 ligand, interleukin-29 ligand, interleukin-6 ligand inhibitor, interleukin-7 ligand, interleukin-8 ligand inhibitor, IRAK-4 protein kinase inhibitor, JAK tyrosine kinase inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Jak3 tyrosine kinase inhibitor, Jun N-terminal kinase inhibitor, Jun N-terminal kinase modulators, kallikrein modulators, Kelch-like ECH-associated protein 1 modulators, Kit tyrosine kinase inhibitors, KLKB1 gene inhibitors, lactoferrin stimulants, lanosterol-14 demethylase inhibitors, Lck tyrosine kinase inhibitors, leukocyte Ig-like receptor A4 modulators, leukocyte elastase inhibitors, leukotriene BLT receptor antagonists, leukotriene D4 antagonists, leukotriene receptor antagonists, Listeria hemolysin stimulants, liver X receptor antagonists, low molecular weight heparin, lung surfactant-associated protein B stimulants, lung surfactant-associated protein D modulators, Lyn tyrosine kinase inhibitors, Lyn tyrosine kinase stimulants, lysine-specific histone demethylase 1 inhibitors, macrophage migration inhibitory factor inhibitors, mannan-binding lectin serineAnisotropic protease inhibitors, mannan-binding lectin serine protease-2 inhibitors, MAO B inhibitors, MAP kinase inhibitors, MAPK gene regulators, matrix metalloproteinase regulators, Maxi K potassium channel inhibitors, MCL1 gene inhibitors, MEK protein kinase inhibitors, MEK-1 protein kinase inhibitors, melanocortin MC1 receptor agonists, melanocortin MC3 receptor agonists, metalloproteinase-12 inhibitors, METTL3 gene inhibitors, membrane spike protein inhibitors, membrane spike protein regulators, monocyte chemotactic protein 1 ligand inhibitors, monocyte differentiation antigen CD14 inhibitors, mRNA guanine N7 methyltransferase regulators, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, mTOR inhibitors, mucolipin regulators, muscarinic receptor antagonists, myeloperoxidase inhibitors, NACHT LRR PYD domain protein 3 inhibitors, NAD synthase regulators, NADPH Oxidase inhibitors, neurocilia 2 modulators, neuroplasticity inhibitors, NFE2L2 gene stimulators, NK cell receptor agonists, NK1 receptor antagonists, NMDA receptor antagonists, NMDA receptor ε2 subunit inhibitors, non-receptor tyrosine kinase TYK2 antagonists, non-nucleoside reverse transcriptase inhibitors, nsp12 polymerase inhibitors, nucleoside erythroid 2-related factor 2 stimulators, nuclear factor κB inhibitors, nuclear factor κB modulators, nuclease stimulators, nucleolarine inhibitors, nucleoprotein inhibitors, nucleoprotein modulators, nucleoside reverse transcriptase inhibitors, opioid receptor agonists, opioid receptor antagonists, opioid receptor µ-modulators, opioid receptor σ-antagonists, ORF1ab polyprotein inhibitors, ornithine decarboxylase inhibitors, outer membrane protein inhibitors, OX40 ligands, p38 MAP kinase α inhibitors, p38 MAP kinase inhibitors, p38 MAP kinase modulators, p53 tumor suppressor protein stimulators, palmitoyl protein thioesterase 1 inhibitors, papain inhibitors, PARP inhibitors, PARP modulators, PDE 10 inhibitors, PDE 3 inhibitors, PDE 4 inhibitors, PDGF receptor α antagonists, PDGF receptor antagonists, PDGF receptor β antagonists, peptidyl-prolyl cis-trans isomerase A inhibitors, peroxidase 6 modulators, PGD2 antagonists, PGI2 agonists, P-glycoprotein inhibitors, phosphoinositol 3-kinase inhibitors, phosphoinositol-3-kinase δ inhibitors, phosphoinositol-3-kinase γ inhibitors, phospholipase A2 inhibitors, PIKfyve inhibitors, plasma kallikrein inhibitors, plasminogen activator inhibitor 1 inhibitors, platelet inhibitors, platelet glycoprotein VI inhibitors, Polo-like kinase 1 inhibitors, poly-ADP-ribose polymerase 1Inhibitors, including poly-ADP-ribose polymerase 2 inhibitors, polymerase cofactor VP35 inhibitors, PPARα agonists, progesterone receptor agonists, programmed cell death protein 1 modulators, prolyl hydroxylase inhibitors, prostaglandin E synthase-1 inhibitors, protease inhibitors, proteasome inhibitors, protein arginine deiminase IV inhibitors, protein tyrosine kinase inhibitors, protein tyrosine phosphatase β inhibitors, protein tyrosine phosphatase-2C inhibitors, proto-oncogene Mas agonists, purine receptor antagonists, Raf protein kinase inhibitors, RANTES ligands, Ras gene inhibitors, retinoic acid receptor responsive protein 2 stimulators, Rev protein modulators, ribonuclease stimulators, RIP-1 kinase inhibitors, RNA helicase inhibitors, and RNA polymerase inhibitors. Polymerase modulators, S-phase kinase-associated protein 2 inhibitors, SARS coronavirus 3C-like protease inhibitors, serine protease inhibitors, serine threonine protein kinase ATR inhibitors, serine threonine protein kinase TBK1 inhibitors, serum amyloid A modulators, CD24 signal transduction protein stimulators, silencing regulatory protein inhibitors, sodium channel stimulators, sodium glucose transporter-2 inhibitors, sphingosine kinase 1 inhibitors, sphingosine kinase 2 inhibitors, sphingosine kinase inhibitors, sphingosine-1-phosphate receptor-1 agonists, sphingosine-1-phosphate receptor-1 antagonists, sphingosine-1-phosphate receptor-1 modulators, sphingosine-1-phosphate receptor-5 agonists, sphingosine-1-phosphate receptor-5 modulators, spike glycoprotein inhibitors, Src tyrosine kinase inhibitors, STAT-1 modulators, STAT-3 inhibitors, STAT-5 inhibitors, STAT3 gene inhibitors, stem cell antigen-1 Inhibitors, interferon gene protein stimulators, sulfatase inhibitors, superoxide dismutase modulators, superoxide dismutase stimulators, Syk tyrosine kinase inhibitors, T cell immune receptor IgITIM protein inhibitors, T cell receptor agonists, T cell surface glycoprotein CD28 inhibitors, T cell differentiation antigen CD6 inhibitors, T cell surface glycoprotein CD8 stimulators, T cell transcription factor NFAT modulators, anchored polymerase-1 inhibitors, anchored polymerase-2 inhibitors, Tek tyrosine kinase receptor stimulators, telomerase modulators, tetanus toxin modulators, TGFβ receptor antagonists, TGFB2 gene inhibitors. Thymosin β4 ligand, thyroid hormone receptor β agonist, tissue factor inhibitor, tissue plasminogen activator modulator, tissue plasminogen activator stimulator, TLR agonist, TLR modulator, TLR-2 agonist, TLR-2 antagonist, TLR-3 agonist, TLR-4 agonist, TLR-4 antagonist, TLR-6 agonist, TLR-7 agonist, TLR-7 antagonist, TLR-8 antagonist.TLR-9 agonists, TMPRSS2 gene inhibitors, TNFα ligand inhibitors, TNFα ligand modulators, TNF binders, TNF gene inhibitors, topoisomerase inhibitors, transcription factor EB stimulators, transferrin modulators, transketolase inhibitors, translocation-related protein inhibitors, transmembrane serine protease 2 inhibitors, thyroxine transporter modulators, TREM receptor 1 antagonists, TRP cation channel C1 modulators, TRP cation channel C6 inhibitors, TRP cation channel V6 inhibitors, trypsin 1 inhibitors, trypsin 2 inhibitors, trypsin 3 inhibitors, trypsin inhibitors, tubulin α inhibitors, tubulin β inhibitors, tumor necrosis factor 14 ligand inhibitors, TYK2 gene inhibitors, type I IL-1 receptor antagonists, tyrosine protein kinase ABL1 inhibitors, and ubiquitin-cytochrome C reductase 14. kDa inhibitors, ubiquitin ligase modulators, unspecified GPCR agonists, unspecified cytokine receptor modulators, unspecified enzyme stimulators, unspecified gene inhibitors, unspecified receptor modulators, urokinase plasminogen activator inhibitors, vascular cell adhesion protein 1 agonists, vasodilators, VEGF ligand inhibitors, VEGF receptor antagonists, VEGF-1 receptor antagonists, VEGF-1 receptor modulators, VEGF-2 receptor antagonists, VEGF-3 receptor antagonists, vimentin inhibitors, vimentin modulators, VIP receptor agonists, viral envelope protein inhibitors, viral protease inhibitors, viral protease modulators, viral protein target modulators, viral ribonuclease inhibitors, viral structural protein modulators, vitamin D3 receptor agonists, X-linked inhibitors of apoptosis protein inhibitors, xanthine oxidase inhibitors or ligand inhibitors.
[0196] In some embodiments, the compounds and compositions of this disclosure may be administered in combination with Sars-Cov-2 treatments such as parenteral fluids (including glucose saline and Ringer's lactate), nutrients, antibiotics (including azithromycin, metronidazole, amphotericin B, amoxicillin / clavulanic acid, trimethoprim / sulfamethoxazole, R-327 and cephalosporin antibiotics such as ceftriaxone and cefuroxime), antifungal prophylaxis, antipyretics and analgesics, antiemetics (such as metoclopramide) and / or antidiarrheals, vitamin and mineral supplements (including vitamin K, vitamin D, cholecalciferol, vitamin C and zinc sulfate), anti-inflammatory agents (such as ibuprofen or steroids), corticosteroids (such as dexamethasone, methylprednisolone, prednisone, mometasone), immunomodulatory agents (e.g., interferon), vaccines and analgesics.
[0197] In some embodiments, the additional therapeutic agent is an Abl tyrosine kinase inhibitor, such as ladotinib or imatinib.
[0198] In some embodiments, the adjunctive therapeutic agent is an aldehyde dehydrogenase inhibitor, such as ADX-629.
[0199] In some embodiments, the adjunctive therapeutic agent is an adenosine A3 receptor agonist, such as piclidenoson.
[0200] In some embodiments, the adjunctive therapeutic agent is an adrenomedullin ligand, such as adrenomedullin.
[0201] In some embodiments, the adjunctive therapeutic agent is a p38 MAPK + PPARγ agonist / insulin sensitizer, such as KIN-001.
[0202] In some embodiments, the adjunctive therapeutic agent is a PPARα agonist, such as DWTC-5101 (fenofibratecholine).
[0203] In some embodiments, the adjunctive therapeutic agent is a cyclin inhibitor, such as rencofilstat.
[0204] In some embodiments, the adjunctive therapeutic agent is a p38 MAP kinase inhibitor, such as PRX-201 or Gen-1124.
[0205] In some embodiments, the adjunctive therapeutic agent is an aldose reductase inhibitor, such as cabifrestat.
[0206] In some embodiments, the adjunctive therapeutic agent is an AMPA receptor modulator, such as traneurocin.
[0207] In some embodiments, the adjunctive therapeutic agent is an annexin A5 stimulator, such as AP-01 or SY-005.
[0208] In some embodiments, the adjunctive therapeutic agent is an apralin receptor agonist, such as CB-5064MM.
[0209] In some embodiments, the adjunctive therapeutic agent is an anticoagulant, such as heparin (heparin and low molecular weight heparin), aspirin, apixaban, dabigatran, edoxaban, argatroban, enoxaparin, or fondaparin.
[0210] In some embodiments, the adjunctive therapeutic agent is an androgen receptor antagonist, such as bicalutamide, denlutamide, enzalutamide, or proxalutamide.
[0211] In some embodiments, the adjunctive therapeutic agent is an antihyperxia agent, such as disodium crocin.
[0212] In some embodiments, the adjunctive therapeutic agent is an antithrombotic agent, such as defibrinoside, rivaroxaban, alteplase, tirofiban, clopidogrel, prasugrel, bemiparin, bivalirudin, sulodexide, or tenecteplase.
[0213] In some embodiments, the adjunctive therapeutic agent is an antihistamine, such as clopidogrel or clomastine.
[0214] In some embodiments, the adjunctive therapeutic agent is an apolipoprotein A1 agonist, such as CER-001.
[0215] In some embodiments, the adjunctive therapeutic agent is a phospholipase A2 inhibitor, such as ethyl eicosapentaenoate (EEO). (Instructions for Use, Pages 34 / 58, 42 CN)121925423 A (icosapent ethyl).
[0216] In some embodiments, the adjunctive therapeutic agent is an axl tyrosine kinase receptor inhibitor, such as besentinib.
[0217] In some embodiments, the adjunctive therapeutic agent is a corticosteroid / β2-adrenergic receptor agonist, such as budesonide + formoterol fumarate.
[0218] In some embodiments, the adjunctive therapeutic agent is a BET bromide domain inhibitor / APOA1 gene stimulator, such as apabetalone.
[0219] In some embodiments, the adjunctive therapeutic agent is a blood coagulation modulator, such as lanaruzumab.
[0220] In some embodiments, the adjunctive therapeutic agent is a bradykinin B2 receptor antagonist, such as atebandon.
[0221] In some embodiments, the adjunctive therapeutic agent is an EGFR gene inhibitor / Btk tyrosine kinase inhibitor, such as abivertinib.
[0222] In some embodiments, the adjunctive therapeutic agent is a Btk tyrosine kinase inhibitor, such as ibrutinib or zanubrutinib.
[0223] In some embodiments, the adjunctive therapeutic agent is a calpain-I / II / IX inhibitor, such as BLD-2660.
[0224] In some embodiments, the adjunctive therapeutic agent is a cannabinoid CB2 receptor agonist, such as onternabez or PPP-003.
[0225] In some embodiments, the adjunctive therapeutic agent is a Ca2+ release-activating Ca2+ channel 1 inhibitor, such as zegocractin (CM-4620).
[0226] In some embodiments, the adjunctive therapeutic agent is an ATR inhibitor, such as berzosertib.
[0227] In some embodiments, the adjunctive therapeutic agent is a cadherin-5 modulator, such as FX-06.
[0228] In some embodiments, the adjunctive therapeutic agent is a casein kinase II inhibitor, such as silverasertib.
[0229] In some embodiments, the adjunctive therapeutic agent is a caspase inhibitor, such as emricasan.
[0230] In some embodiments, the adjunctive therapeutic agent is a catalase stimulator / superoxide dismutase stimulator, such as MP-1032.
[0231] In some embodiments, the adjunctive therapeutic agent is a CCR2 chemokine antagonist / CCR5 chemokine antagonist, such as sennavicilol.
[0232] In some embodiments, the adjunctive therapeutic agent is a CCR5 chemokine antagonist, such as maraviro or lelimumab.
[0233] In some embodiments, the adjunctive therapeutic agent is a CD122 agonist / IL-2 receptor agonist, such as bepeadine.
[0234] In some embodiments, the adjunctive therapeutic agent is a CD73 agonist / interferon β ligand, such as FP-1201.
[0235] In some embodiments, the adjunctive therapeutic agent is a cholesterol ester transporter inhibitor, such as dacetropeptide.
[0236] In some embodiments, the adjunctive therapeutic agent is a mannan-binding lectin serine protease / complement C1s subcomponent inhibitor / myeloperoxidase inhibitor, such as RLS-0071.
[0237] In some embodiments, the adjunctive therapeutic agent is a complement C5 factor inhibitor / leukotriene BLT receptor antagonist, such as nomacopan.
[0238] In some embodiments, the adjunctive therapeutic agent is a complement C5 factor inhibitor, such as eculizumab, STSA-1002, or zilucoplan.
[0239] In some embodiments, the adjunctive therapeutic agent is a CXCR4 chemokine antagonist, such as praxavir or motixafortide. Specification 35 / 58 pages 43 CN 121925423 A
[0240] In some embodiments, the adjunctive therapeutic agent is a cytochrome P450 3A4 inhibitor / peptidyl prolyl cis-trans isomerase A inhibitor, such as arapovir.
[0241] In some embodiments, the adjunctive therapeutic agent is a cysteine protease inhibitor, such as SLV-213.
[0242] In some embodiments, the adjunctive therapeutic agent is a dihydroorotate dehydrogenase inhibitor, such as Meds-433, buquina, RP-7214, farudostat, or emvododstat.
[0243] In some embodiments, the adjunctive therapeutic agent is a dehydropeptidase-1 regulator, such as Metablok.
[0244] In some embodiments, the adjunctive therapeutic agent is a dihydroorotate dehydrogenase inhibitor / IL-17 antagonist, such as vidofluradimo.
[0245] In some embodiments, the adjunctive therapeutic agent is a diuretic, such as an aldosterone antagonist, such as spironolactone.
[0246] In some embodiments, the adjunctive therapeutic agent is a deoxyribonuclease I stimulator, such as GNR-039 or dornase alfa.
[0247] In some embodiments, the adjunctive therapeutic agent is a NET inhibitor, such as NTR-441.
[0248] In some embodiments, the adjunctive therapeutic agent is a dihydroceramide δ4 desaturase inhibitor / sphingosine kinase 2 inhibitor, such as opaganib.
[0249] In some embodiments, the adjunctive therapeutic agent is a DNA methyltransferase inhibitor, such as azacytidine.
[0250] In some embodiments, the adjunctive therapeutic agent is an LXR antagonist, such as larsucosterol.
[0251] In some embodiments, the adjunctive therapeutic agent is a dipeptidyl peptidase I inhibitor, such as brensocatib.
[0252] In some embodiments, the adjunctive therapeutic agent is a protein arginine deiminase IV inhibitor, such as JBI-1044.
[0253] In some embodiments, the adjunctive therapeutic agent is an elongation factor 1 α2 regulator, such as privitin.
[0254] In some embodiments, the adjunctive therapeutic agent is a eukaryotic initiation factor 4A-I inhibitor, such as zotatifin.
[0255] In some embodiments, the adjunctive therapeutic agent is an exocytogenetic α-sialidase regulator, such as DAS-181.
[0256] In some embodiments, the adjunctive therapeutic agent is an export protein 1 inhibitor, such as selinexor.
[0257] In some embodiments, the adjunctive therapeutic agent is a fractalkine ligand inhibitor, such as KAND-567.
[0258] In some embodiments, the adjunctive therapeutic agent is an FYVE finger phosphoinositol kinase inhibitor / IL-12 receptor antagonist / IL-23 antagonist, such as apimod dimethylsulfonate.
[0259] In some embodiments, the adjunctive therapeutic agent is a GABA A receptor modulator, such as brinolone.
[0260] In some embodiments, the adjunctive therapeutic agent is a glucocorticoid receptor agonist, such as cistanosine, hydrocortisone, dexamethasone, dexamethasone phosphate, or 101-PGC-005.
[0261] In some embodiments, the adjunctive therapeutic agent is a GM-CSF receptor agonist, such as saxaglastine.
[0262] In some embodiments, the adjunctive therapeutic agent is a GPCR agonist, such as esuberaprost sodium.
[0263] In some embodiments, the adjunctive therapeutic agent is a Griffithsin modulator, such as Q-Griffithsin.
[0264] In some embodiments, the adjunctive therapeutic agent is a leukotriene D4 antagonist, such as montelukast.
[0265] In some embodiments, the adjunctive therapeutic agent is a histamine H1 receptor antagonist, such as ebastine, tranilast, or levocetirizine hydrochloride.
[0266] In some embodiments, the adjunctive therapeutic agent is a histamine H2 receptor antagonist, such as famotidine. Specification 36 / 58 pages 44 CN 121925423 A
[0267] In some embodiments, the adjunctive therapeutic agent is a heat shock protein stimulator / insulin sensitizer / PARP inhibitor, such as BGP-15.
[0268] In some embodiments, the adjunctive therapeutic agent is a histone inhibitor, such as STC-3141.
[0269] In some embodiments, the adjunctive therapeutic agent is a histone deacetylase-6 inhibitor, such as CKD-506.
[0270] In some embodiments, the adjunctive therapeutic agent is a HIF prolyl hydroxylase-2 inhibitor, such as dedustat.
[0271] In some embodiments, the adjunctive therapeutic agent is a HIF prolyl hydroxylase inhibitor, such as valdustat.
[0272] In some embodiments, the adjunctive therapeutic agent is an IL-8 receptor antagonist, such as reparixin.
[0273] In some embodiments, the adjunctive therapeutic agent is an IL-7 receptor agonist, such as CYT-107.
[0274] In some embodiments, the adjunctive therapeutic agent is an IL-7 receptor agonist / interleukin-7 ligand, such as efineptakin alfa.
[0275] In some embodiments, the adjunctive therapeutic agent is an IL-2 agonist, such as efmarodocokin alfa.
[0276] In some embodiments, the adjunctive therapeutic agent is an IL-22 agonist / interleukin 22 ligand, such as F-652.
[0277] In some embodiments, the adjunctive therapeutic agent targets IL-33, such as toretzimab.
[0278] In some embodiments, the adjunctive therapeutic agent is an IL-15 agonist, such as nogapendekin alfa.
[0279] In some embodiments, the adjunctive therapeutic agent is an integrin α-V / β-1 antagonist / integrin α-V / β-6 antagonist, such as bexotegrast.
[0280] In some embodiments, the adjunctive therapeutic agent is an interferon α2 ligand, such as interferon α-2b or Virafin.
[0281] In some embodiments, the adjunctive therapeutic agent is an interferon β ligand, such as a follow-up biologic to interferon β-1a, interferon β-1b, or SNG-001.
[0282] In some embodiments, the adjunctive therapeutic agent is an interferon receptor modulator, such as peginterferon lambda-1a.
[0283] In some embodiments, the adjunctive therapeutic agent is an interleukin-2 ligand, such as adeleukin.
[0284] In some embodiments, the adjunctive therapeutic agent is an IRAK-4 protein kinase inhibitor, such as zimlovisertib.
[0285] In some embodiments, the adjunctive therapeutic agent is a JAK inhibitor, for example, baricitinib, filgortinib, jaktinib, tofacitinib, or nezulcitinib (TD-0903).
[0286] In some embodiments, the adjunctive therapeutic agent is a neutral leukocyte elastase inhibitor, such as avelestat.
[0287] In some embodiments, the adjunctive therapeutic agent is a lung surfactant-associated protein D modulator, such as AT-100.
[0288] In some embodiments, the adjunctive therapeutic agent is a plasma kallikrein inhibitor, such as donidalorsen.
[0289] In some embodiments, the adjunctive therapeutic agent is a lysine-specific histone demethylase 1 / MAO B inhibitor, such as varifidestat.
[0290] In some embodiments, the adjunctive therapeutic agent is a mannan-binding lectin serine protease inhibitor, such as conestat alfa.
[0291] In some embodiments, the adjunctive therapeutic agent is a maxi K potassium channel inhibitor, such as ENA-001.
[0292] In some embodiments, the adjunctive therapeutic agent is a MEK protein kinase inhibitor, such as zapnometinib (Zapnometinib) as described in the product manual, pages 37 / 58, 45 CN 121925423 A.
[0293] In some embodiments, the adjunctive therapeutic agent is a MEK-1 protein kinase inhibitor / Ras gene inhibitor, such as androidquinolone.
[0294] In some embodiments, the adjunctive therapeutic agent is a melanocortin MC1 receptor agonist, such as PL-8177.
[0295] In some embodiments, the adjunctive therapeutic agent is a melanocortin MC1 / MC3 receptor agonist, such as resomelega acetate.
[0296] In some embodiments, the adjunctive therapeutic agent is a matrix metalloproteinase-12 inhibitor, such as FP-025.
[0297] In some embodiments, the adjunctive therapeutic agent is a NACHT LRR PYD domain protein 3 inhibitor, such as dapansutrile, DFV-890, or ZYIL-1.
[0298] In some embodiments, the adjunctive therapeutic agent is an NADPH oxidase inhibitor, such as isuzinaxib.
[0299] In some embodiments, the adjunctive therapeutic agent is a neurociliacin 2 modulator, such as efzofitimod.
[0300] In some embodiments, the adjunctive therapeutic agent is an NK1 receptor antagonist, such as aprepitant or tripipitant.
[0301] In some embodiments, the adjunctive therapeutic agent is an NMDA receptor antagonist, such as crocin or efendil.
[0302] In some embodiments, the adjunctive therapeutic agent is a nuclear factor κB inhibitor / p38 MAP kinase inhibitor, such as zenuzolac.
[0303] In some embodiments, the adjunctive therapeutic agent is an ornithine decarboxylase inhibitor, such as efornithine.
[0304] In some embodiments, the adjunctive therapeutic agent is an opioid receptor σ antagonist, such as MR-309.
[0305] In some embodiments, the adjunctive therapeutic agent is a PGD2 antagonist, such as asapiprant.
[0306] In some embodiments, the adjunctive therapeutic agent is a PDGF receptor antagonist / TGFβ receptor antagonist / p38 MAP kinase inhibitor, such as deupirfenidone.
[0307] In some embodiments, the adjunctive therapeutic agent is a phospholipase A2 inhibitor, such as methylvareniladine.
[0308] In some embodiments, the adjunctive therapeutic agent is a phosphoinositol 3-kinase inhibitor / mTOR complex inhibitor, such as dactolisib.
[0309] In some embodiments, the adjunctive therapeutic agent is an mTOR inhibitor, such as sirolimus.
[0310] In some embodiments, the adjunctive therapeutic agent is a phosphatidylinositol-3 kinase δ / γ inhibitor, such as duveliximab.
[0311] In some embodiments, the adjunctive therapeutic agent is a PIKfyve inhibitor, such as VRG-101.
[0312] In some embodiments, the adjunctive therapeutic agent is a plasminogen activator inhibitor 1 inhibitor, such as TM-5614.
[0313] In some embodiments, the adjunctive therapeutic agent is a protein tyrosine phosphatase β inhibitor, such as ralotafine.
[0314] In some embodiments, the adjunctive therapeutic agent is a RIP-1 kinase inhibitor, such as eclitasertib (DNL-758) or SIR-0365.
[0315] In some embodiments, the adjunctive therapeutic agent is a Rev protein modulator, such as obefazimod.
[0316] In some embodiments, the adjunctive therapeutic agent is an S-phase kinase-associated protein 2 inhibitor, such as niclosamide, CP-COV3, SCAI-502, or DWRX-2003.
[0317] In some embodiments, the adjunctive therapeutic agent is a signal transduction protein CD24 stimulator, such as EXO-CD24.
[0318] In some embodiments, the adjunctive therapeutic agent is a sodium glucose transporter-2 inhibitor, such as dapagliflozin (prescription page 38 / 58, 46 CN 121925423 A diol).
[0319] In some embodiments, the adjunctive therapeutic agent is a sodium channel inhibitor, such as solnatide.
[0320] In some embodiments, the adjunctive therapeutic agent is a sphingosine-1-phosphate-1 agonist / sphingosine-1-phosphate-5 agonist, such as ozamod.
[0321] In some embodiments, the adjunctive therapeutic agent is a nonsteroidal anti-inflammatory drug, such as Ampion.
[0322] In some embodiments, the adjunctive therapeutic agent is a superoxide dismutase agonist, such as avasopasem manganese.
[0323] In some embodiments, the adjunctive therapeutic agent is a Syk tyrosine kinase inhibitor, such as flotinib disodium salt.
[0324] In some embodiments, the adjunctive therapeutic agent is a Tie2 tyrosine kinase receptor agonist, such as AV-001.
[0325] In some embodiments, the adjunctive therapeutic agent is a TGFB2 gene inhibitor, such as trabedsen.
[0326] In some embodiments, the adjunctive therapeutic agent is a tissue factor inhibitor, such as AB-201.
[0327] In some embodiments, the adjunctive therapeutic agent is a TLR-3 agonist, such as lentamod.
[0328] In some embodiments, the adjunctive therapeutic agent is a TLR-4 antagonist, such as ApTLR-4FT, EB-05, or iritolen.
[0329] In some embodiments, the adjunctive therapeutic agent is a TLR-7 / 8 antagonist, such as enpatoran.
[0330] In some embodiments, the adjunctive therapeutic agent is a TLR-2 / 6 agonist, such as INNA-051.
[0331] In some embodiments, the adjunctive therapeutic agent is a TLR-7 agonist, such as PRTX-007 or APR-002.
[0332] In some embodiments, the adjunctive therapeutic agent is a TLR agonist, such as PUL-042.
[0333] In some embodiments, the adjunctive therapeutic agent is a TLR-4 agonist, such as REVTx-99.
[0334] In some embodiments, the adjunctive therapeutic agent is a TLR-2 / 4 antagonist, such as VB-201.
[0335] In some embodiments, the adjunctive therapeutic agent is a TNF α ligand inhibitor, such as pegipanermin.
[0336] In some embodiments, the adjunctive therapeutic agent is a type I IL-1 receptor antagonist, such as anakinin.
[0337] In some embodiments, the adjunctive therapeutic agent is a TREM receptor 1 antagonist, such as nangibotide.
[0338] In some embodiments, the adjunctive therapeutic agent is a trypsin inhibitor, such as ulinastatin.
[0339] In some embodiments, the adjunctive therapeutic agent is a microtubule inhibitor, such as sabizabulin, CCI-001, PCNT-13, CR-42-24, albendazole, entabulin, SAR-132885, or ON-24160.
[0340] In some embodiments, the adjunctive therapeutic agent is a VIP receptor agonist, such as aviptadil.
[0341] In some embodiments, the adjunctive therapeutic agent is a xanthine oxidase inhibitor, such as hydroxypurine.
[0342] In some embodiments, the adjunctive therapeutic agent is a vasodilator, such as iloprost, veprost, vazegepant, TXA-127, USB-002, ambesentan, nitric oxide nasal spray (NORS), pentoxifylline, propranolol, RESP301, sodium nitrite, or dipyridamole.
[0343] In some embodiments, the adjunctive therapeutic agent is a vitamin D3 receptor agonist, such as cholecalciferol.
[0344] In some embodiments, the adjunctive therapeutic agent is a zonulin inhibitor, such as larazotide acetate.
[0345] In some embodiments, the additional therapeutic agent is a synthetic retinoid derivative, such as fenivel-Amin.
[0346] In some embodiments, the additional therapeutic agent is a glucose metabolism inhibitor, such as WP-1122 or WP-1096. Instructions for Use, pages 39 / 58, 47 CN 121925423 A
[0347] In some embodiments, the additional therapeutic agents are adalimumab, AT-H201, 2-deoxy-D-glucose, AD-17002, AIC-649, AMTX-100, astodrimer, AZD-1656, belapectin, spiramycin, bucilamine, budesonide, CNM-AgZn-17, codivir, CT-38, danicopan, methotrexate, DW-2008S (DW-2008), EDP-1815, EG-009A, Fabencov, Gamunex, Gentianone, GLS-1200, hzVSF-v13, Imidazolylacetamide glutaric acid, IMM-101, MAS-825, MRG-001, Nasitrol, Nylexa, olverembatinib, OP-101, OPN-019, Orynotide, rhesus monkey theta defense-1, phenazine + artesunate, dapsone, RPH-104, sodium pyruvate, Sulforadex, tafenoxanone, TB-006, telacebec, Tempol, TL-895, thimesoral, trimodulin(trimodulin), XC-221, XC-7, zunsemetinib, glycine metformin, lucinactant, EOM-613, mosedipimod, ivermectin, leflunomide, isotetrast, RBT-9, raloxifene, prothione, zicarbene, or etoricoxib.
[0348] In some embodiments, the adjunctive therapeutic agent is a CD73 antagonist, such as AK-119.
[0349] In some embodiments, the adjunctive therapeutic agent is a CD95 protein fusion, such as asunercept.
[0350] In some embodiments, the adjunctive therapeutic agent is a complement factor C2 modulator, such as ARGX-117.
[0351] In some embodiments, the adjunctive therapeutic agent is a complement C3 inhibitor, such as AMY-101 or NGM-621.
[0352] In some embodiments, the adjunctive therapeutic agent is a CXC10 chemokine ligand inhibitor, such as EB-06.
[0353] In some embodiments, the adjunctive therapeutic agent is a cytotoxic T-lymphocyte protein-4 fusion protein, such as abatacept.
[0354] In some embodiments, the adjunctive therapeutic agent is an anti-Staphylococcus aureus antibody, such as tosatoxumab.
[0355] In some embodiments, the adjunctive therapeutic agent is an anti-LPS antibody, such as IMM-124-E.
[0356] In some embodiments, the adjunctive therapeutic agent is an adrenomedullin ligand inhibitor, such as embarreximab.
[0357] In some embodiments, the adjunctive therapeutic agent is a basigin inhibitor, such as meperizumab.
[0358] In some embodiments, the adjunctive therapeutic agent is a CD3 antagonist, such as francirumab.
[0359] In some embodiments, the adjunctive therapeutic agent is a connective tissue growth factor ligand inhibitor, such as PRS-220 or perrirumab.
[0360] In some embodiments, the adjunctive therapeutic agent is a complement C5a factor inhibitor, such as BDB-1 or velolimumab.
[0361] In some embodiments, the adjunctive therapeutic agent is a complement C5 factor inhibitor, such as eculizumab.
[0362] In some embodiments, the adjunctive therapeutic agent is a mannan-binding lectin serine protease-2 inhibitor, such as nasolimumab.
[0363] In some embodiments, the adjunctive therapeutic agent is a GM-CSF modulator, such as STSA-1005, lincomycin, nametrozine, punalimumab, otelilimumab, or lenzruzumab.
[0364] In some embodiments, the adjunctive therapeutic agent is a heat shock protein inhibitor / IL-6 receptor antagonist, such as storax.
[0365] In some embodiments, the adjunctive therapeutic agent is an IL-6 receptor antagonist, such as clazazumab, levilimab, olokizumab, tocilizumab, or sirukumab.
[0366] In some embodiments, the adjunctive therapeutic agent is an IL-8 receptor antagonist, such as BMS-986253. Specification 40 / 58 pages 48 CN 121925423 A
[0367] In some embodiments, the adjunctive therapeutic agent is an interleukin-1β ligand inhibitor, such as canakinumab.
[0368] In some embodiments, the adjunctive therapeutic agent is an interferon-γ ligand inhibitor, such as epavavamab.
[0369] In some embodiments, the adjunctive therapeutic agent is an anti-ILT7 antibody, such as daxdilimab.
[0370] In some embodiments, the adjunctive therapeutic agent is a monocyte differentiation antigen CD14 inhibitor, such as atibuclimab.
[0371] In some embodiments, the adjunctive therapeutic agent is a plasma kallikrein inhibitor, such as lanarumab.
[0372] In some embodiments, the adjunctive therapeutic agent is a platelet glycoprotein VI inhibitor, such as glenzocimab.
[0373] In some embodiments, the adjunctive therapeutic agent is a T-cell differentiation antigen CD6 inhibitor, such as itolizumab.
[0374] In some embodiments, the adjunctive therapeutic agent is a TNF α ligand inhibitor / TNF binder, such as infliximab.
[0375] In some embodiments, the adjunctive therapeutic agent is an anti-LIGHT antibody, such as AVTX-002.
[0376] In some embodiments, the adjunctive therapeutic agent is IMC-2 (valacyclovir + celecoxib) or AXA-1125.
[0377] In some embodiments, the additional therapeutic agent is COVID-19.
[0378] In some embodiments, the compounds of this disclosure or pharmaceutically acceptable salts thereof are co-administered with one or more agents that can be used to treat and / or prevent COVID-19.
[0379] Non-limiting examples of such agents include corticosteroids such as dexamethasone, hydrocortisone, methylprednisolone, or prednisone; interleukin-6 (IL-6) receptor blockers such as tocilizumab or thalidomab; Janus kinase (JAK) inhibitors such as baricitinib, ruxolitinib, or tofacitinib; and antiviral agents such as monoupivir, sotromab, or remdesivir.
[0380] In further embodiments, the compounds of this disclosure or pharmaceutically acceptable salts thereof are co-administered with two or more agents that can be used to treat and / or prevent COVID-19.Co-administration with agents for treating COVID-19. Agents that can be used to treat and / or prevent COVID-19 include, but are not limited to, the compounds of this disclosure and two additional therapeutic agents, such as nematvir and ritonavir, camrelizumab and edevimab, or ruxotinib and tofacitinib.
[0381] In some embodiments, the additional therapeutic agent is an antiviral agent. In some embodiments, the antiviral agent is an entry inhibitor. In some embodiments, the antiviral agent is a protease inhibitor. In some embodiments, the antiviral agent is an RNA polymerase inhibitor. In some embodiments, the additional therapeutic agent is an RNA-dependent RNA polymerase (RdRp) inhibitor.
[0382] In some embodiments, the antiviral agent is selected from angiotensin-converting enzyme 2 inhibitors, angiotensin-converting enzyme 2 modulators, angiotensin-converting enzyme 2 stimulators, angiotensin II AT-2 receptor agonists, angiotensin II AT-2 receptor antagonists, angiotensin II receptor modulators, coronavirus nucleoprotein modulators, coronavirus small envelope protein modulators, coronavirus spike glycoprotein inhibitors, coronavirus spike glycoprotein modulators, SARS-CoV-2 envelope small membrane protein inhibitors, SARS-CoV-2 envelope small membrane protein modulators, SARS-CoV-2 MPro inhibitors, SARS-CoV-2 nonstructural protein 8 modulators, SARS-CoV-2 nucleoprotein inhibitors, SARS-CoV-2 nucleoprotein modulators, SARS-CoV-2 protein 3a inhibitors, SARS-CoV-2 replicase polyprotein 1a inhibitors, SARS-CoV-2 replicase polyprotein 1a modulators, SARS-CoV-2 replicase polyprotein 1ab inhibitors, SARS-CoV-2 replicase polyprotein 1ab modulators, and SARS-CoV-2 spike glycoprotein inhibitors. SARS-CoV-2 spike glycoprotein modulator, SARS-CoV-2 structural glycoprotein modulator, papain inhibitor, protease inhibitor, protease modulator, RNA polymerase inhibitor, RNA polymerase modulator, RNA-dependent RNA polymerase (RdRp) specification 41 / 58 pages 49 CN 121925423 A inhibitor, SARS coronavirus 3C-like protease inhibitor, SARS-CoV-2 nsp14 methyltransferase inhibitor, 3CLpro / Mpro inhibitor, serine protease inhibitor, transmembrane serine protease 2 inhibitor, transmembrane serine protease 2 modulator, viral envelope protein inhibitor, viral protease inhibitor, viral protease modulator, viral protein target modulator, viral ribonuclease inhibitor, and viral structural protein modulator.
[0383] In some embodiments, the additional therapeutic agent is an entry inhibitor. For example, in some embodiments, the additional therapeutic agent is an entry inhibitor.The additional therapeutic agent is an ACE2 inhibitor, fusion inhibitor, or protease inhibitor.
[0384] In some embodiments, the additional therapeutic agent is an angiotensin-converting enzyme 2 inhibitor, such as SBK-001.
[0385] In some embodiments, the additional therapeutic agent is an angiotensin-converting enzyme 2 modulator, such as neumifil or JN-2019.
[0386] In some embodiments, the additional therapeutic agent is an entry inhibitor, such as MU-UNMC-1 or SAI-4.
[0387] In some embodiments, the additional therapeutic agent is an angiotensin-converting enzyme 2 stimulator, such as alunase alfa.
[0388] In some embodiments, the additional therapeutic agent is an angiotensin II AT-2 receptor agonist, such as VP-01.
[0389] In some embodiments, the additional therapeutic agent is an ACE II receptor antagonist, such as DX-600.
[0390] In some embodiments, the additional therapeutic agent is an angiotensin II receptor modulator, such as TXA-127.
[0391] In some embodiments, the adjunctive therapeutic agent is a transmembrane serine protease 2 modulator, such as BC-201 or N-0385.
[0392] In some embodiments, the adjunctive therapeutic agent is a viral envelope protein inhibitor, such as MXB-9 or MXB-004.
[0393] In some embodiments, the adjunctive therapeutic agent is an RNAi agent, such as ARO-COV or SNS-812.
[0394] In some embodiments, the adjunctive therapeutic agent is a vaccine. For example, in some embodiments, the adjunctive therapeutic agent is a DNA vaccine, an RNA vaccine, a live attenuated vaccine, an inactivated vaccine (i.e., an inactivated SARS-CoV-2 vaccine), a therapeutic vaccine, a prophylactic vaccine, a protein-based vaccine, a viral vector vaccine, a cell vaccine, or a dendritic cell vaccine.
[0395] In some embodiments, the adjunctive therapeutic agent is a vaccine, such as tozinameran, NVX-CoV2373, elasomeran, KD-414, Ad26.COV2-S, Vaxzevria, SCB-2019, AKS-452, VLA-2001, HDT-301, S-268019, MVC-COV1901, mRNA-1273.214, mRNA-1273.213, mRNA-1273.222, NVX-CoV2515, Covaxin, BBIBP-CorV, GBP-510, mRNA-1273.351+mRNA-1273.617 (SARS-CoV-2 multivalent mRNA vaccine, COVID-19), Ad5-nCoV, Omicron-based COVID-19 vaccine (mRNA vaccine)Vaccines for COVID-19, including mRNA-1073, mRNA-1273.214, mRNA-1230, mRNA-1283, Omicron-based COVID-19 vaccines, SARS-CoV-2 protein subunit recombinant vaccines, Sputnik M, ZyCoV-D, COVID-19 XWG-03, mRNA-1273.529, mRNA-1010, CoronaVac, AZD-2816, Sputnik V, inactivated SARS-CoV-2 vaccines (Vero cells, COVID-19), DS-5670, PHH-1V, INO-4800, UB-612, coronavirus vaccines (whole virus particles, inactivated / purified), ReCOV, MT-2766, ARCT-154, SP-0253, CORBEVAX, mRNA-1273.211, ZF-2001, and Sputnik. Light, recombinant protein vaccines (COVID-19 / SARS-CoV-2 infection), VSV vector-based vaccines targeting spike glycoprotein (COVID-19), VLA-2101, GRT-R912, GRAd-COV2, VPM-1002, COViran Barekat, Ad5-nCoV-IH, ARCoV, Covax-19, recombinant SARS-CoV-2 vaccine (protein subunit / CHO cells, COVID-19), BBV-154, RAZI Cov Pars, COVID-19 vaccine (inactivated / Vero cells / intramuscular, SARS-CoV-2 infection), COVID-19 vaccine (inactivated, Vero cells / intramuscular), BNT-162b2s01, BNT-162b4, BNT-162b5, BNT-162b2 Omi, BNT-162b2 bivalent, CIGB-66, mRNA-1273.617, Mycobacterium w strain, ERUCOV-VAC, AG-0301-COVID19, fakhravac, AV-COVID-19, peptide vaccine (COVID-19), Nanocovax, SARS-CoV-2 vaccine package insert 42 / 58 pages 50 CN 121925423 A (inactivated / Vero cells / intramuscular, COVID-19), QAZCOVID-IN, S-875670 nasal vaccine, VTP-500 or BNT162b5.
[0396] In some embodiments, the additional therapeutic agent is a protease inhibitor. For example, in some embodiments, the additional...The therapeutic agents are 3C-like cysteine protease inhibitors (3CLpro, also known as main protease, Mpro), papain-like protease inhibitors (PLpro), serine protease inhibitors, or transmembrane serine protease 2 inhibitors (TMPRSS2).
[0397] In some embodiments, the additional therapeutic agent is a 3CLpro / Mpro inhibitor, such as ABBV-903, AB-343, CDI-873, GC-373, GC-376, pomotrelvir (PBI-0451), UCI-1, bofutrelvir (FB-2001, DC-402234), DC-402267, GDI-4405, HS-10517, RAY-1216, MPI-8, SH-879, SH-580, EDP-235, VV-993, CDI-988, MI-30, nirmatrelvir, ensetrelvir, ASC-11, ASC-11+ritonavir, EDDC-2214, SIM-0417, PF-07817883, simnotrelvir, simnotrelvir+ritonavir, SYH-2055, ISM-3312, CDI-45205, LHP-803 (COR-803), ALG-097111, TJC-642, CVD-0013943, olgotrelvir (STI-1558), eracycline, cynarine, WPV-01 or prexasertib.
[0398] In some embodiments, the adjunctive therapeutic agent is a papain-like protease inhibitor (PLpro), such as SBFM-PL4 or GRL-0617.
[0399] In some embodiments, the adjunctive therapeutic agent is a SARS-CoV-2 helicase Nsp13 inhibitor, such as EIS-4363.
[0400] In some embodiments, the adjunctive therapeutic agent is a SARS-CoV-2 helicase Nsp14 inhibitor, such as TO-507.
[0401] In some embodiments, the adjunctive therapeutic agent is a SARS-CoV-2 spike protein (S) and protease modulator, such as ENU-200.
[0402] In some embodiments, the adjunctive therapeutic agent is a protease inhibitor, such as ALG-097558 or MRX-18.
[0403] In some embodiments, the adjunctive therapeutic agent is a serine protease inhibitor, such as upparstat, naphthostat, carmostat mesylate, naphthostat mesylate, or carmostat.
[0404] In some embodiments, the additional therapeutic agent is a 3CLpro / transmembrane serine protease 2 inhibitor, such as SNB-01 (pentarlandir) or SNB-02.
[0405] In some embodiments, the additional therapeutic agent is a viral protease inhibitor such as Pan-Corona, Cov-X, or benpredil.
[0406] In some embodiments, the additional therapeutic agent is an RNA polymerase inhibitor. For example, in some embodiments, the additional therapeutic agent is an RNA polymerase inhibitor, or an RNA-dependent RNA polymerase (RdRp) inhibitor.
[0407] In some embodiments, the additional therapeutic agent is an RNA-dependent RNA polymerase (RdRp) inhibitor, such as remdesivir, NV-CoV-2, NV-CoV-2-R, NV-CoV-1-encapsulated remdesivir, CMX-8521, GS-621763, GS-5245, GS-441524, DEP remdesivir, ATV-006, deuterated remdesivir (VV-116), LGN-20, CMX-521, SHEN-26, MB-905 and compounds disclosed in WO2022142477, WO2021213288, WO2022047065.
[0408] In some embodiments, the adjunctive therapeutic agent is an RNA polymerase inhibitor, such as monoupivir (EIDD-2801), favipiravir, bemnifosbuvir, sofosbuvir, ASC-10, or galidivir.
[0409] In some embodiments, the adjunctive therapeutic agent is a viral entry inhibitor, such as brilacidin.
[0410] In some embodiments, the adjunctive therapeutic agent is an antibody that binds to a coronavirus, such as an antibody that binds to SARS or MERS.
[0411] In some embodiments, the adjunctive therapeutic agent is an antibody, such as a monoclonal antibody. For example, the adjunctive therapeutic agent is an antibody against SARS-CoV-2, a neutralizing nanobody, an antibody targeting the SARS-CoV-2 spike protein, a fusion protein, a multispecific antibody, and an antibody capable of neutralizing SARS-CoV-2 (SARS-CoV-2 neutralizing antibody), as described on pages 43 / 58 of the specification (CN 121925423 A).
[0412] In some embodiments, the adjunctive therapeutic agent is an antibody targeting a specific site on ACE2. In some embodiments, the adjunctive therapeutic agent is a polypeptide targeting the SARS-CoV-2 spike protein (S-protein).
[0413] In some embodiments, the adjunctive therapeutic agent is a SARS-CoV-2 viral antibody.
[0414] In some embodiments, the antibody is ABBV-47D11, COVI-GUARD (STI-1499), C144-LS+C135-LS, DIOS-202, DIOS-203, DIOS-301, DXP-604, JMB-2002, LY-CovMab, bamlanivimab (LY-CoV555), GIGA-2050, IBI-314, S309, SAB-185, etesevimab (CB6), COR-101, JS016, VNAR, VIR-7832 and / or sotramab (VIR-7831), camrevimab + edevimab (REGN-COV2 or REGN10933+REGN10987), BAT2020, BAT2019, 47D11, YBSW-015 or PA-001.
[0415] In some embodiments, the additional therapeutic agent is STI-9199 (COVI-SHIELD), STI-9167 or AR-701 (AR-703 and AR-720).
[0416] In some embodiments, the adjunctive therapeutic agents are BRII-196, BRII-198, ADG-10, adintrevimab (ADG-20), ABP-300, BA-7208, BI-767551, BHV-1200, CT-P63, JS-026, sotraza (GSK-4182136), tixagevimab + cilgavimab (AZD-7442), regdanvimab, SAB-301, AOD-01, plutavimab (COVI-AMG), 9MW-3311 (MW-33), DXP-593, BSVEQAb, and anti-SARS-CoV-2. IgY, COVID-EIG, CSL-760, F-61, REGN-3048-3051, SARS-CoV-2 monoclonal antibody (COVID-19, ADM-03820), enuzovimab (HFB-30132A), INM-005, SCTA01, TY-027, XAV-19, ambavimab + romlusevimab, SCTA-01, betelovimab, beludavimab, IBI-O123, IGM-6268, FYB-207, FS-2101, RBT-0813, REGN-14256, REGN-14284, SPKM-001, XVR-011, TB202-3, TB181-36, TB339-031, LMN-301, LQ-050, COVAB-36, MAD-0004J08, STI-2099, TATX-03, TZLS-501, ZCB-11, AZD-3152, VYD-222, XVR-012, or ACV-200-17.
[0417] In some embodiments, the additional therapeutic agent is an engineered ACE-2-IgG1-Fc fusion protein targeting the SARS-CoV-2 RBD, such as EU-129, a bivalent ACE2-IgG Fc zero fusion protein (SI-F019).
[0418] In some embodiments, the additional therapeutic agent is an ACE2-Fc receptor fusion protein, such as HLX-71.
[0419] In some embodiments, the adjunctive therapeutic agent is ensovibep.
[0420] In some embodiments, the adjunctive therapeutic agent is SYZJ-001.
[0421] In some embodiments, the adjunctive therapeutic agent is an HIV-1 protease inhibitor, such as ASC-09F (ASC-09 + ritonavir) or lopinavir + ritonavir.
[0422] In some embodiments, the adjunctive therapeutic agent is a non-nucleoside reverse transcriptase inhibitor, such as favirine.
[0423] In some embodiments, the adjunctive therapeutic agent is a nucleoside reverse transcriptase inhibitor, such as azvudine.
[0424] In some embodiments, the additional therapeutic agents are AbbV-990, ABBV-903, 2b-11, 5-aminolevulinic acid phosphate, AGP-600, AGM-380, AIP-502, ALG-150150, BAT-2022, NED-260, burfiralimab, ALG-097431, bardoxolone, BW-PS-119, clofocaffeine, CR-405, delcetravir, D4-102-01, D4-102-02, ESFAM-289, ENOB-CV-01, and ENOB-CV-11. EIS-10700, EV-300, β-521, GEA-001, SIM-0417, Monupivir, Pan-Corona, Tollovir (instructions 44 / 58, page 52, CN 121925423 A), Nirmatrelvir + Ritonavir (Paxlovid®), JTBC-00201, Favipiravir, Favipiravir + cathepsin inhibitor (TNX-3900), GC-376, Upamostat, LeSoleil-01LeSoleil-02+, benfovir, VV-116, VV-993, SNB-01, EDP-235, Cov-X, ensetrelvir, MPI-8, masatitinib, ALG-097558, ASC-11, PBI-0451, nafamostat, nafamostat mesylate, CDI-45205, LHP-803 (COR-803), ALG-097111, BC-201, SH-879, CDI-873, CDI-988, remdesivir, NV-CoV-2-R, NV-CoV-1 encapsulated remdesivir, NA-831+ remdesivir, DEP remdesivir, GS-621763. GS-5245, GLS-5310, Benifosbuvir, QLS-1128, ASC-10, SBFM-PL4, Carmosta Mesylate, UCI-1, FB-2001 (DC-402234), Ebuselenol, SH-580, LeSoleil-01, LeSoleil-02+, MRX-18, MXB-9, MI-09, MI-30, SNB-02, SJP-002C, TJC-642, ENU-200, CVD-0013943, GS-441524, Bempidil, MXB-004, Elacycline, GRL-0617, GST-HG171, GST-HG171+Ritonavir, Carmosta, GC-373, KD-1, Nizoral, Sinnarin, Precetinib, PL-M, RAY-1216, SACT-COVID-19, MP-18, EIDD-1931, EDDC-2214, Nitric Oxide, Apabexinone, AnQlar, SBK-001, LQ-050, CG-SpikeDown, Barnivirumab, JTBC-00101, HLX-71, HT-002, HY-209, HY-3000, HSC-1553, FYB-207, Ensovibep, SYZJ-001, EU-129, Numifil, JN-2019 (KG-2019), LCB-99, AR-701, Vostesyl, PLM-402, PJS-539 CTB-ACE2, TB181-36, TB202-3, ABP-300, XVR-011, MSP-008-22, MU-UNMC-1, MU-UNMC-2, MIC-1930, MLT-103, Mpro inhibitor (Anixa Biosciences), PBF-4554, alunasiylase αα), VP-01, TRV-027, DX-600, TXA-127, NVX-CoV2515, raphamin, RCYM-002, RCYM-003, riamilovir, SARS-CoV-2 PL pro inhibitor (Enanta), SBP-502, SM-4, STB-R040, THY-01, tosinamelan, ellasemran, Ad5-nCoV, BBIBP-CorV, CoronaVac, MVC-COV1901, NVX-CoV2373, sotramab, Sputnik V, TEE-001, Tyme-19, Vaxzevria, XW-001, ZF-2001, or ZyCoV-D.
[0425] In some embodiments, the additional therapeutic or prophylactic agent is a SARS-CoV-2 MPro inhibitor. In some embodiments, the SARS-CoV-2 MPro inhibitor is nematamide. In some embodiments, the SARS-CoV-2 MPro inhibitor is ritonavir.
[0426] Any compound of the present invention may also be combined with one or more additional active therapeutic agents in a single dosage form for simultaneous or sequential administration to a patient. Combination therapy may be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more doses.
[0427] Co-administration of the compound of the present invention with one or more other active therapeutic agents generally refers to the simultaneous or sequential administration of the compound of the present invention and one or more other active therapeutic agents such that therapeutically effective amounts of the compound of the present invention and one or more other active therapeutic agents are present in the patient.
[0428] Co-administration includes administering a unit dose of the compound described herein before or after administering a unit dose of one or more other active therapeutic agents, for example, administering the compound described herein within seconds, minutes, or hours after administering one or more other active therapeutic agents. For example, a unit dose of the compound of the present invention may be administered first, followed by a unit dose of one or more other active therapeutic agents within seconds or minutes. Alternatively, a unit dose of one or more other therapeutic agents may be administered first, followed by a unit dose of the compound of the present invention over seconds or minutes. In some cases, it may be necessary to administer a unit dose of the compound of the present invention first, followed by a unit dose of one or more other active therapeutic agents several hours later (e.g., 1-12 hours). In other cases, it may be necessary to administer a unit dose of one or more other active therapeutic agents first, followed by a unit dose of the compound of the present invention several hours later (e.g., 1-12 hours). Specification 45 / 58 pages 53 CN 121925423 A
[0429] Combination therapy can provide “synergistic” and “synergistic” effects, meaning that the combined effect of using the active ingredients together is greater than the sum of the effects of using the compounds alone. Synergistic effects are achieved when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combination formulation; (2) delivered alternately or in parallel as individual formulations; or (3) by some other means. When delivered in alternating therapy, synergistic effects are achieved when the compounds are administered or delivered, for example, in separate tablets, pills, or capsules or by different injection sequences in separate syringes. Generally, in alternating therapy, each active ingredient is administered in an effective dose sequentially (i.e., consecutively), while in combination therapy, two or more active ingredients are administered together in an effective dose. Synergistic antiviral effects mean that the antiviral effect is greater than the predicted pure additive effect of the individual compounds in the combination.
[0430] The compounds described herein are also used in combination with other active therapeutic agents. For the treatment of pulmonary viral infections, preferably, the other active therapeutic agents have activity against pulmonary viral infections, particularly respiratory syncytial virus infection and / or metapneumovirus infection. Non-limiting examples of other active therapeutic agents with anti-RSV activity include ribavirin, palilizumab, mavitizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444 (also known as RSV604), MDT-637, BMS-433771, ALN-RSV0, ALX-0171, and mixtures thereof. Other non-limiting examples of other active therapeutic agents with anti-respiratory syncytial virus (RSV) infection activity include RSV protein F inhibitors such as AK-0529; RV-521, ALX-0171, JNJ-53718678, BTA-585, and prosatovir; RNA polymerase inhibitors such as luteimab and ALS-8112; anti-RSV G protein antibodies such as anti-G protein mAbs; and viral replication inhibitors such as nitrozonide.
[0431] In some embodiments, other active therapeutic agents may be vaccines for the treatment or prevention of RSV, including but not limited to MVA-BN RSV, RSV-F, MEDI-8897, JNJ-64400141, DPX-RSV, SynGEM, GSK-3389245A, GSK-300389-1A, RSV-MEDI deltaM2-2 vaccine, VRC-RSVRGP084-00VP, Ad35-RSV-FA2, Ad26-RSV-FA2, and RSV fusion glycoprotein subunit vaccines.
[0432] Non-limiting examples of other active therapeutic agents having activity against metapneumovirus infection include sialidase modulators, such as DAS-181; RNA polymerase inhibitors, such as ALS-8112; and antibodies for the treatment of metapneumovirus infection, etc.For example, EV-046113.
[0433] In some embodiments, other active therapeutic agents may be vaccines for the treatment or prevention of metapneumovirus infection, including but not limited to mRNA-1653 and rHMPV-Pa vaccines.
[0434] The compounds described herein are also used in combination with other active therapeutic agents. For the treatment of microviral infections, preferably, the other active therapeutic agents have activity against microviral infections, particularly enterovirus infections. Non-limiting examples of these other active therapeutic agents are capsid binding inhibitors, such as plencolamide, BTA-798 (vapendavir), and other compounds disclosed by Wu et al. (US 7,078,403) and Watson (US 7,166,604); fusion sialidase proteins, such as DAS-181; capsid protein VP1 inhibitors, such as VVX-003 and AZN-001; viral protease inhibitors, such as CW-33; phosphatidylinositol 4-kinase β inhibitors, such as GSK-480 and GSK-533; and anti-EV71 antibodies.
[0435] In some embodiments, other active therapeutic agents may be vaccines for the treatment or prevention of infection with picornaviridae viruses, including but not limited to EV71 vaccines, TAK-021, and vaccines based on EV-D68 adenovirus vectors.
[0436] Infections with many pulmonaviridae, picornaviridae, and coronavirusidae viruses are respiratory infections. Therefore, adjunctive active therapeutic agents for the treatment of respiratory symptoms and post-infectious sequelae may be used in combination with the compounds described herein. The adjunctive therapeutic agents are preferably administered orally or by direct inhalation. Other preferred adjunctive therapeutic agents for the treatment of viral respiratory infections, for example, include, but are not limited to, bronchodilators and corticosteroids, in combination with the compounds described herein.
[0437] Glucocorticoids, first introduced as a treatment for asthma in 1950 (Carryer, Journal of Allergy, instruction manual 46 / 58 pages 54 CN 121925423 A 21, 282-287, 1950), remain the most effective and sustained treatment for this disease, but their mechanisms of action are not fully understood (Morris, J. Allergy Clin. Immunol., 75 (1 Pt) 1-13, 1985). Unfortunately, oral glucocorticoid therapy is associated with serious adverse side effects, such as truncal obesity, hypertension, glaucoma, impaired glucose tolerance, accelerated cataract formation, bone mineral loss, and psychological effects, all of which limit its use as a long-term treatment (Goodman and Gilman, 10th ed., 2001). The solution to systemic side effects is direct administration of steroid drugs...Delivered to the site of inflammation. Inhaled corticosteroids (ICS) have been developed to alleviate the serious side effects of oral steroids. Non-limiting examples of corticosteroids that may be used in combination with the compounds described herein are dexamethasone, dexamethasone sodium phosphate, flumethonone, flumethonone acetate, clotipreno, clotipreno ecaprate, hydrocortisone, prednisolone, fludrocortisone, triamcinolone, triamcinolone, betamethasone, beclomethasone dipropionate, methylprednisolone, fluocinolone acetonide, flunisolone, fluocinolone acetonide, fluocinolone acetonide, fluocinolone acetonide, fluocinolone acetonide, fluocinolone acetonide, fluocinolone acetonide, fluocinolone acetonide, budesonide, halobetasol propionate, mometasone furoate, fludison, AZD-7594, cistanodine; or pharmaceutically acceptable salts thereof.
[0438] Other anti-inflammatory agents that act through an anti-inflammatory cascade mechanism may also be used as adjunctive therapeutic agents in combination with the compounds described herein for the treatment of viral respiratory infections. Applying “anti-inflammatory signal transduction modulators” (referred to as AISTMs in this text), such as phosphodiesterase inhibitors (e.g., PDE-4, PDE-5, or PDE-7 specific), transcription factor inhibitors (e.g., blocking NFκB via IKK inhibition), or kinase inhibitors (e.g., blocking P38 MAP, JNK, PI3K, EGFR, or Syk), is a logical approach to cutting off inflammation because these small molecules target a limited number of common intracellular pathways—those signal transduction pathways that are key points of intervention for anti-inflammatory therapies (see the review by PJ Barnes, 2006). These non-restricted adjunctive therapeutic agents include: 5-(2,4-difluoro-phenoxy)-1-isobutyl-1H-indazole-6-carboxylic acid (2-dimethylamino-ethyl)-amide (P38 Map kinase inhibitor ARRY-797); 3-cyclopropylmethoxy-N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-benzamide (PDE-4 inhibitor roflumilast); 4-[2-(3-cyclopentoxy-4-methoxyphenyl)-2-phenyl-ethyl]-pyridine (PDE-4 inhibitor CDP-840); N-(3,5-dichloro-4-pyridinyl)-4-difluoromethoxy-8-[(methanesulfonyl)amino]-1- Dibenzofuran carboxamide (PDE-4 inhibitor Oglemilast); N-(3,5-dichloro-pyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indole-3-yl]-2-oxo-acetamide (PDE-4 inhibitor AWD 12-281); 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide (PDE-4 inhibitor Sch 351591); 4-[5-(4-fluorophenyl)-2-(4-methanesulfinyl-phenyl)-1H-imidazol-4-yl]-pyridine (P38 inhibitor SB-203850); 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-but-3-yn-1-ol (P38 inhibitor RWJ-67657); 2-diethylamino-ethyl ester of 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexanecarboxylic acid (2-diethyl-ethyl ester prodrug of silost, PDE-4 inhibitor); (3-chloro-4-fluorophenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (gefitinib, EGFR inhibitor); and 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (imatinib, EGFR inhibitor).
[0439] Combinations of inhaled β2-adrenergic receptor agonist bronchodilators such as formoterol, salbutamol, or salmeterol with the compounds described herein are also suitable, but not limiting, combinations for the treatment of respiratory viral infections.
[0440] Combinations of inhaled β2-adrenergic receptor agonist bronchodilators such as formoterol or salmeterol with ICS are also used to treat bronchoconstriction and inflammation (Symbicort® and Advair®, respectively). Combinations of these ICS and β2-adrenergic receptor agonist combinations with the compounds described herein are also suitable, but not limiting, combinations for the treatment of respiratory viral infections.
[0441] Other examples of β2-adrenergic receptor agonists are bedorajun, vilanterol, indacaterol, olodaterol, tuloterrol, formoterol, abidilol, salbutamol, aforterol, levosalbutamol, fenoterol, and TD-5471. Instructions for use, pages 47 / 58, 55 CN 121925423 A
[0442] Anticholinergic agents have potential use for the treatment or prevention of pulmonary bronchoconstriction and can therefore be used as adjunctive therapeutic agents in combination with the compounds described herein for the treatment of viral respiratory infections. These anticholinergic agents include, but are not limited to, antagonists of muscarinic receptors (especially the M3 subtype), which have been shown to be effective in controlling cholinergic tension in humans for COPD (Witek, 1999); 1-{4-hydroxy-1-[3,3,3-tris-(4-fluorophenyl)propionyl]pyrrolidine-2-carbonyl}-pyrrolidine-2-carboxylic acid (1-methyl-piperidin-4-ylmethyl)-amide; 3-[3-(2-diethylamino-acetoxy)-2-phenyl-propionyloxy]-8-isopropyl-8-methyl-8-aza-bicyclo[3.2.1]octane (ipratropium-N,N-diethylglycine ester); 1-cyclohexyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester (sofenadrine)(New); 2-hydroxymethyl-4-methanesulfinyl-2-phenyl-butyric acid 1-aza-bicyclo[2.2.2]oct-3-yl ester (Revatropyl ester); 2-{1-[2-(2,3-dihydro-benzofuran-5-yl)-ethyl]-pyrrolidine-3-yl}-2,2-diphenyl-acetamide (Dapoxetine); 4-azacycloheptane-1-yl-2,2-diphenyl-butyramide (Buzepide); 7-[3-(2-diethylamino-acetoxy)-2-phenyl-propionyloxy]-9-ethyl-9-methyl-3-oxa-9-aza-tricyclo[3.3.1.02,4]nonane (Oxytropin-N,N-diethylglycine ester); 7-[2-(2-diethylamino-acetoxy)-2,2-di-thiophene-2-yl-acetoxy]- 9,9-Dimethyl-3-oxa-9-aza-tricyclo[3.3.1.02,4]nonane (tiotropium-N,N-diethylglycine ester); dimethylaminoacetic acid 2-(3-diisopropylamino-1-phenyl-propyl)-4-methyl-phenyl ester (tolterodine-N,N-dimethylglycine ester); 3-[4,4-bis-(4-fluorophenyl)-2-oxo-imidazolidine-1-yl]-1-methyl-1-(2-oxo-2-pyridin-2-yl- Ethyl)-pyrrolidine-onium; 1-[1-(3-fluorobenzyl)-piperidin-4-yl]-4,4-bis-(4-fluorophenyl)-imidazolidine-2-one; 1-cyclooctyl-3-(3-methoxy-1-aza-bicyclo[2.2.2]octyl-3-yl)-1-phenyl-prop-2-yn-1-ol; 3-[2-(2-diethylamino-acetoxy)-2,2-dithiophene-2-yl-acetoxy]-1-(3-phenoxy-propyl)-1-aza-onium-bicyclo[2.2.2]octane (aldeionium bromide-N,N-diethylglycine ester); or (2-diethylamino-acetoxy)-dithiophene-2- 1-Methyl-1-(2-phenoxy-ethyl)-piperidin-4-yl ester of methyl-acetic acid; refenapyridine, ganrobromium bromide, urodimethyl bromide, tiotropium bromide, adecyl bromide, benzylquinalium bromide.
[0443] The compounds described herein can also be combined with mucolytics to treat symptoms of infection and respiratory tract infection. A non-limiting example of a mucolytic is ambroxol. Similarly, these compounds can be combined with expectorants to treat symptoms of infection and respiratory tract infection. A non-limiting example of an expectorant is guaifenesin.
[0444] Nebulized hypertonic saline is used to improve the immediate and long-term clearance of small airways in patients with lung disease (Kuzik, J. Pediatrics 2007, 266). Therefore, the compounds described herein can also be combined with nebulized hypertonic saline, particularly when viral infection is complicated by bronchiolitis. The combination of the compounds described herein with hypertonic saline can also include any additional agents discussed above. In one embodiment, about 3% hypertonic saline is used.
[0445] The compounds and compositions provided herein may also be used in combination with other active therapeutic agents. For the treatment of Flaviviridae virus infections, preferably, the other active therapeutic agents have activity against Flaviviridae virus infections.
[0446] For the treatment of dengue virus infection, non-limiting examples of other active therapeutic agents are host cytokine modulators, such as GBV-006; fenivel-Amin ABX-220, BRM-211; α-glucosidase 1 inhibitors, such as sigosvir; platelet-activating factor receptor (PAFR) antagonists, such as modepapan; cadherin-5 / factor Ia modulators, such as FX-06; NS4B inhibitors, such as JNJ-8359; viral RNA splicing modulators, such as ABX-202; NS5 polymerase inhibitors; NS3 protease inhibitors; and TLR modulators.
[0447] In some embodiments, other active therapeutic agents may be vaccines for the treatment or prevention of dengue fever, including but not limited to TetraVax-DV, Dengvaxia®, DPIV-001, TAK-003, live attenuated dengue vaccine, quadrivalent dengue vaccine, quadrivalent DNA vaccine, rDEN2delta30-7169; and DENV-1 PIV.
[0448] The compounds described herein are also used in combination with other active therapeutic agents. For the treatment of filoviridae virus infections, preferably, the other active therapeutic agents have activity against filoviridae virus infections, particularly Marburg virus, Ebola virus, and Cueva virus infections. Non-limiting examples of these other active therapeutic agents are: ribavirin, amiodarone, dronedarone, verapamil, Ebola convalescent plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), TKM-Ebola, T-705 monophosphate, T-705 diphosphate, T-705 triphosphate, FGI-106 (1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinolone-1,7-diamine), rNAPc2, OS-2966, brincedofovir, remdesivir; RNA Polymerase inhibitors, such as glimepiride, favipiravir (also known as T-705 or Avigan), JK-05; host cytokine modulators, such as GMV-006; cadherin-5 / factor Ia modulators, such as FX-06; and antibodies used to treat Ebola, such as REGN-3470-3471-3479 and ZMapp.
[0449] Other non-limiting active therapeutic agents with anti-Ebola activity include α-glucosidase 1 inhibitors, tissue inhibitors, etc.Proteinase B inhibitors, CD29 antagonists, dendritic ICAM-3 grasping integrin 1 inhibitors, estrogen receptor antagonists, factor VII antagonists, HLA class II antigen modulators, host cytokine modulators, interferon α ligands, neutral α-glucosidase AB inhibitors, Niemann-Pick C1 protein inhibitors, nucleoprotein inhibitors, polymerase cofactor VP35 inhibitors, serine protease inhibitors, tissue factor inhibitors, TLR-3 agonists, viral envelope glycoprotein inhibitors, and Ebola virus entry inhibitors (NPC1 inhibitors).
[0450] In some embodiments, other active therapeutic agents may be vaccines for the treatment or prevention of Ebola, including but not limited to VRC-EBOADC076-00-VP, adenovirus-based Ebola vaccines, rVSV-EBOV, rVSVN4CT1-EBOVGP, MVA-BN Filo + Ad26-ZEBOV regimen, INO-4212, VRC-EBODNA023-00-VP, VRC-EBOADC069-00-VP, GamEvac-combi vaccine, SRC VB vector, HPIV3 / EboGP vaccine, MVA-EBOZ, recombinant Ebola glycoprotein vaccine, Ebola vaccine based on Vaxart adenovirus vector 5, FiloVax vaccine, GOVX-E301, and GOVX-E302.
[0451] The compounds described herein can also be used in combination with aminophosphate morpholino oligomers (PMOs), which are synthetic antisense oligonucleotide analogs designed to interfere with translation by forming base-pair duplexes with specific RNA sequences. Examples of PMOs include, but are not limited to, AVI-7287, AVI-7288, AVI-7537, AVI-7539, AVI-6002, and AVI-6003.
[0452] The compounds described herein are also intended for use with general care provided to patients with filoviridae virus infections, which include parenteral fluids (including glucose saline and Ringer's lactate) and nutrients, antibiotics (including metronidazole and cephalosporin antibiotics such as ceftriaxone and cefuroxime) and / or antifungal prophylaxis, fever and pain medications, antiemetics (such as metoclopramide) and / or antidiarrheals, vitamin and mineral supplements (including vitamin K and zinc sulfate), anti-inflammatory agents (such as ibuprofen), pain medications, and medications for other common illnesses in the patient population, such as antimalarial agents (including artemether and artemisinin-benfluridine combination therapy), typhoid vaccines (including quinolone antibiotics such as ciprofloxacin, macrolide antibiotics such as azithromycin, cephalosporin antibiotics such as ceftriaxone, or aminopenicillins such as ampicillin) or Shigella vaccines.
[0453] The invention will be described in more detail by way of specific examples. The following examples are provided for illustrative purposes and are not intended to be construed as...This invention is not intended to limit the invention in any way. Those skilled in the art will readily recognize that various non-critical parameters can be changed or modified to produce substantially the same results.
[0454] IX. Examples Example 1: Synthesis of (2R,3R,4S,5R)-2-(4-aminothieno[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carboxynitrile (C1) Specification 49 / 58 pages 57 CN 121925423 A Intermediate 1b-7-bromothieno[3,2-d]pyrimidin-4-amine Ammonium hydroxide (6 mL, 17.9 mmol) was added to a suspension of commercially available intermediate 1a (4.1 g, 16.4 mmol) in MeCN (6 mL), and the resulting mixture was heated to 50 °C. After 22 hours, the reaction mixture was cooled to rt (room temperature). The resulting solid was collected by vacuum filtration, washed with water, and dried under reduced pressure to give intermediate 1b. 1H NMR (400MHz, DMSO-d6) δ 8.48 (s, 1H), 8.35 (s, 1H), 7.71 (s, 3H).
[0455] Intermediate 1d-(3R,4R,5R)-2-(4-aminothiopheno[3,2-d]pyrimidin-7-yl)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-ol was rapidly added at -78°C to a solution of intermediate 1b (1.9 g, 8.3 mmol) and 1,2-bis(chlorodimethylsilyl)ethane (1.6 g, 7.5 mmol) in THF (100 mL) with 2.5 M n-butyllithium in hexane (12 mL, 30 mmol). After 5 minutes, a commercially available solution of 1c (3.15 g, 7.52 mmol) pre-cooled to -78°C in 20 mL of THF was added. After 1 hour, acetic acid (3 mL) was added, and the resulting mixture was allowed to warm to room temperature. The mixture was diluted with ethyl acetate (200 mL) and washed with 5% citric acid solution (2 × 100 mL) and saturated sodium bicarbonate solution (100 mL). The resulting organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (0%–100% ethyl acetate in hexane) to give intermediate 1d.
[0456] MS m / z = 567.2 [M+1]. Intermediate 1e-(2R,3R,4R,5R)-2-(4-aminothiopheno[3,2-d]pyrimidin-7-yl)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-carboxynitrile, specification 50 / 58 pages, CN 121925423 AAt -78°C, TMSOTf (6.5 mL, 36 mmol) was added dropwise to a solution of intermediate 1d (2.1 g, 3.6 mmol) in dichloromethane (36 mL). After 5 minutes, TMSCN (2.4 mL, 18 mmol) was added. After 5 minutes, the resulting mixture was allowed to warm to room temperature. After an additional 1.5 hours, the resulting mixture was cooled to 0°C, and triethylamine (11 mL) and solid NaHCO3 (5 g) were added. The resulting mixture was diluted with water (20 mL) and stirred for 2.5 hours. Then ethyl acetate (200 mL) and water (150 mL) were added. The organic layer was separated, washed with brine (150 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (0%–100% ethyl acetate in hexane) to give intermediate 1e. 1H NMR (400MHz, chloroform‑d) δ 8.16 (s, 1H) , 7.44 – 7.14 (m, 16H) , 5.01 (s, 2H) , 4.80 (br s, 1H) , 4.59 – 4.53 (m, 2H) , 4.48 (d , J = 11.6Hz, 1H), 4.38 (d, J = 12.2Hz, 1H), 4.20 (d, J = 12.0Hz, 1H), 4.01 (dd, J = 7.5, 4.8Hz, 1H), 3.94 (dd, J = 11.1, 3.2Hz, 1H), 3.66 (dd, J = 11.0, 3.2 Hz, 1H).
[0457] (2R,3R,4S,5R)-2-(4-aminothiopheno[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carboxynitrile (C1) At -78°C, BCl3 (2.3 mL, 2.3 mmol) was added to a solution of intermediate 1e (330 mg, 0.57 mmol) in dichloromethane (10 mL). After 30 minutes, additional BCl3 (1 mL, 1 mmol) was added. After another 30 minutes, additional BCl3 (1 mL, 1 mmol) was added, and the reaction was heated to -40°C. After 2 hours, the reaction mixture was cooled to -78°C, and methanol (10 mL) was added sequentially, followed by a solution of Et3N (10 mL) in methanol (10 mL). The resulting mixture was allowed to warm to room temperature and concentrated under reduced pressure. The resulting mixture was ground with hexane to remove BnCl, and the resulting solid was dissolved in a 3:2 mixture of DMF and water (approximately 2 mL) and purified by reversed-phase HPLC (0%–35% MeCN in water) to obtain Example 1. ¹H NMR (400 MHz,DMSO‑d6) δ 8.37 (s, 1H) , 8.32 (s, 1H) , 7.74 (s, 2H) , 6.24 (d , J = 5.8Hz, 1H) , 5.82 (dd , J = 8.6, 3.6Hz, 1H) , 5.17 (d , J = 4.3Hz, 1H), 4.63 (t, J = 5.4Hz, 1H), 4.16 (d, J = 3.4Hz, 1H), 4.05 (q, J = 4.4Hz, 1H), 3.74 – 3.66 (m, 1H), 3.62 – 3.51 (m, 1H). MS m / z = 309.5 [M+1] Example 2: Synthesis of ((2R,3S,4R,5R)-5-(4-aminothiopheno[3,2-d]pyrimidin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrotriphosphate (C2) At 0 °C, POCl3 (50 mg, 0.32 mmol) was added to a solution of C1 (Example 1 (19 mg, 0.020 mmol)) in PO(OMe)3 (0.6 mL). The reaction mixture was stirred at 0 °C for 6 hours, at which point ion-exchange HPLC showed a conversion of approximately 90%. A solution of tributylamine pyrophosphate (250 mg) in ACN (0.6 mL) was added, followed by the addition of tributylamine (110 mg, 0.59 mmol). The reaction mixture was stirred at 0 °C for 1 hour. The reaction was quenched with triethylamine bicarbonate buffer (1 M, 5 mL). The reaction mixture was stirred at room temperature for 0.5 hours, then concentrated and co-evaporated twice with water. The residue was dissolved in H2O (5 mL) and loaded onto an ion exchange column, eluted with H2O, and then eluted with 5% to 35% triethylamine bicarbonate buffer (1 M)-H2O. The product fractions were combined, concentrated, and co-evaporated with H2O. The solid residue was dissolved in 3 mL of H2O and 100 µL of NaOH (1 N) was added. The resulting mixture was purified by a C-18 column, eluted with H2O, and the fractions containing the product were combined and concentrated under reduced pressure to give C2 as a tetrasodium salt. Specification 51 / 58 pages 59 CN 121925423 A
[0458] MSm / z = 547.0 [M-1] Example 3: – Synthesis of ((((2R,3S,4R,5R)-5-(4-aminothiopheno[3,2-d]pyrimidin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine 2-ethylbutyl ester (C3) at room temperature under an argon atmosphere, to C1 (Example 1, 8.5 mg, 27tert-butyl magnesium chloride (1.0 M solution in THF, 0.041 mL, 41 µmol) was added to a solution of 3a (WO2015069939, 18.6 mg, 41.4 µmol) in DMF (0.4 mL). After 45 minutes, additional solutions of 3a (18.6 mg, 41.4 µmol) in DMF (0.1 mL) and tert-butyl magnesium chloride (1.0 M solution in THF, 0.041 mL, 41 µmol) were added sequentially at room temperature. Nineteen hours later, the resulting mixture was directly purified by preparative HPLC (Phenominex Synergi 4u Hydro-RR 80Å 150 x 30 mm column, 40%–100% acetonitrile / water gradient) to obtain C3 of a 2:1 diastereomer mixture. ¹H NMR (400 MHz, chloroform-d) δ 8.62–8.58 (m, 1H), 8.03–7.98 (m, 1H), 7.19–7.12 (m, 2H), 7.07–6.87 (m, 3H), 5.57–5.47 (m, 2H), 4.73–4.64 (m, 1H), 4.41–3.87 (m, 6H). 3.62–3.44 (m, 1H), 3.18–3.05 (m, 1H), 1.80–1.23 (m, 7H), 0.94–0.82 (m, 6H). 31P NMR (162MHz, chloroform-d) δ 2.38, 2.14. MS m / z = 620.29 [M+1]. Example 4: Synthesis of C4 C1 (Example 1, 67.5 mg, 0.024 mmol) was dissolved in NMP (0.3 mL) and THF (0.15 mL) was added. Then, tert-butylmagnesium chloride (1.0 M solution in THF, 0.031 mL, 0.031 mmol) was added at room temperature under an argon atmosphere. After 10 minutes, a solution of intermediate 4a (WO2015069939, 18.5 mg, 0.037 mmol) in THF (0.15 mL) was added, and the resulting mixture was warmed to 50 °C. After 3.5 hours, the resulting mixture was cooled to room temperature and purified directly by preparative HPLC (Phenominex Synergi 4u Hydro-RR 80 Å 150 x 30 mm column, 40%–100% acetonitrile / water gradient) to give C4. ¹H NMR(400MHz, chloroform‑d) δ 8.60 (s, 1H) , 8.23 (s, 1H) , 4.67 (s, 1H) , 4.48 – 4.25 (m, 4H) , 4.13 – 3.95 (m, 4H) , 3.14 – 2.98 (m, 4H) , 1.22 (s, 9H), 1.21 (s, 9H). 31P NMR (162MHz, chloroform-d) δ -1.66.MS m / z = 677.30 [M+1]. Example 5: Synthesis of ((S)-(((2R,3S,4R,5R)-5-(4-aminothiopheno[3,2-d]pyrimidin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine 2-ethyl butyl ester (C5) At room temperature, THF (1.0 mL) was added to a solution of C1 (50 mg, 0.163 mmol, 1.0 equivalent) in NMP (2.0 mL), followed by the addition of tert-butylmagnesium chloride (2 M, in diethyl ether, 0.12 mL, 1.5 equivalent). A solution of 5a (US20160122374, 147 mg, 0.325 mmol, 2.0 equivalent) in THF (1.0 mL) was then added. The reaction mixture was stirred for 1 hour, and then additional tert-butylmagnesium chloride (2 M, in diethyl ether, 0.30 mL) was added. The reaction mixture was stirred overnight, then quenched with saturated NH4Cl (50 mL), followed by quenching with saturated sodium bicarbonate (50 mL), and extracted with EtOAc (3 × 50 mL). The organic fractions were combined, dried over sodium sulfate, filtered, and purified by neutral preparative HPLC (10%–90% ACN / water) to obtain C5. ¹H NMR (400MHz, DMSO–d6) δ 8.43 (s, 1H), 8.21 (s, 1H), 7.66 (s, 2H), 7.38–7.28 (m, 2H), 7.22–7.11 (m, 3H), 6.68 (d, J = 5.0Hz, 1H), 6.08 (dd, J = 12.8, 10.1Hz, 1H), 5.30 (d, J = 5.8Hz, 1H), 4.61–4.53 (m, 1H), 4.36– 4.23 (m, 2H) , 4.18 – 4.08 (m, 1H) , 3.99 – 3.77 (m, 4H) , 1.45 – 1.36 (m, 1H) , 1.31 – 1.17 (m, 7H) , 0.79 (t, J = 7.4Hz,6H). 31P NMR (162MHz, DMSO-d6) δ 3.99 (s). MS m / z = 619.9 [M+1] Antiviral Activity Assay Protocol Example 6: RSV EC50HEp-2 Antiviral activity against RSV was determined in HEp-2 cells using an infectious cytopathic cytopathic cytoprotective assay. In this assay, compounds that inhibit viral infection and / or replication produce cytoprotective effects against virus-induced cell killing, which can be quantified using a cell viability reagent. HEp-2 cells were obtained from ATCC (Manassas, VI) and maintained in MEM medium supplemented with 10% fetal bovine serum and penicillin / streptomycin. Cells were passaged twice weekly and maintained in the hybridization phase. (See page 53 / 58 of the product manual, 61 CN 121925423 A) A commercial stock solution of RSV strain A2 (Advanced Biotechnologies, Columbia, MD) was titrated prior to compound testing to determine the appropriate dilution of the viral stock solution to produce the desired cytopathic effect in HEp-2 cells. For the antiviral assay, HEp-2 cells were grown in large cell culture flasks to near-confluence, but not complete confluence. The compounds to be tested were pre-diluted in DMSO in 384-well compound dilution plates in a standardized dose-response format of 8 or 40 samples / plate. Serial dilution increments of 3-fold were prepared for each test compound in the plate, and test samples were transferred to the 384-well cell culture assay plate at 100 nL / well via an acoustic transfer device (Echo, Labcyte). Each compound dilution was transferred to a dry assay plate, either individually or in quadruplicate, and stored until ready for assay. Positive and negative controls were arranged in vertical blocks (one column) at opposite ends of the plate.
[0459] Subsequently, an infectious mixture was prepared by titrating a predetermined appropriate dilution of the viral stock solution with cells at a density of 50,000 cells / ml, and added to the test plates containing the compound at 20 µL / well via automation (uFlow, Biotek). Each plate included a negative control and a positive control (16 replicates each) to generate 0% and 100% viral inhibition standards, respectively. After RSV infection, the test plates were incubated in a 37°C cell culture incubator for 4 days. After incubation, the cell viability reagent Cell TiterGlo (Promega, Madison, WI) was added to the test plates, briefly incubated, and luminescence readings (Envision, Perkin Elmer) were measured in all test plates. The RSV-induced cytopathic effect (inhibition percentage) was determined by the level of residual cell viability. These values were calculated for each test concentration relative to the 0% and 100% inhibition controls, and for each compound...The EC50 value of the compound was determined by nonlinear regression to be the concentration that inhibited RSV-induced cytopathic effects by 50%. Various potent anti-RSV tool compounds were used as positive controls for antiviral activity.
[0460] Example 7: MERS CoV EC50 The compound was serially diluted to eight half-log dilutions in MEM medium containing 50 µg / mL gentamicin, ultimately producing an initial maximum concentration of 47 µM. Each dilution was added to five wells of a 96-well plate containing 80%–100% confluence of Vero 76 cells, and then three wells of each dilution were infected with MERS-CoV at a multiplicity of infection (MOI) of 0.003. Two wells were left uninfected as a toxicity control. A known active compound (Infergen) was run in parallel as a control. After observing cytopathic effect (CPE) under a microscope (day 3), the plate was stained with neutral red dye for approximately 2 hours, then the dye in the supernatant was removed, and the incorporated dye was extracted in 50:50 Sorensen citrate buffer / ethanol and read on a spectrophotometer. The optical density of the test wells was converted into the percentage of cells and virus controls, and then the concentration of the test compound required to inhibit 50% CPE (EC50) was calculated by regression analysis. Similarly, the concentration of the compound that would cause 50% CPE in the absence of virus (CC50) was calculated. The selectivity index (SI) was CC50 divided by EC50.
[0461] Example 8: DENV EC50Huh7 Huh7 (human hepatocellular carcinoma 7) cells were maintained in DMEM complete medium containing 10% FCS. On the day of assay, cells were trypsinized (0.1% trypsin-EDTA), washed, and infected with dengue serotype 2 New Guinea C (NGC) strain at MOI=0.1 in serum-free DMEM for 2 hours with gentle agitation at 37°C. After 2 hours, cells were washed with serum-free medium and resuspended in DMEM (Gibco, supplemented with sodium pyruvate, NEAA, and penicillin-streptomycin) containing 10% FCS. 10⁵ cells were triple-platened in 96-well plates, with compounds dispensed in fractionated doses (Hewlett-Packard D300 digital dispenser). All wells were normalized to 0.25% DMSO. After 48 hours, cells were washed with 1×PBS and all supernatant was removed. Total RNA was extracted using an RNEasy 96-plate (Qiagen), and the total RNA was used to generate first-strand cDNA using XLT cDNA 5× Supermix (QuantaBio). cDNA was used as a template in a Taqman qPCR doublet reaction specific to DENV2 virus and GAPDH gene expression. EC50 values were determined using Prism Graphpad software and normalized to positive.Control and negative control wells without composite.
[0462] Example 9: Zika EC50 Huh7 Instruction manual 54 / 58 pages 62 CN 121925423 A Test material was determined in DMSO at 10 mM or 20 mM and stored at -20°C. The test material was evaluated using an upper limit test concentration of 20 µM and five consecutive 4-fold dilutions. Ribavirin was purchased from Sigma-Aldrich and used as a control compound in the antiviral assay.
[0463] Prior to use in the antiviral assay, Huh7 cells (human hepatocellular carcinoma, licensed from Ralf Bartenschlager) were passaged in T-75 flasks in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U / mL penicillin, 100 µg / mL streptomycin, 1 mM sodium pyruvate and 0.1 mM NEAA. The cells were passaged 1:2 the day before the assay to ensure they were in the exponential growth phase at the time of infection. Total cell count and viability were quantified using a hemocytometer and trypan blue exclusion method. Cell viability was greater than 95% for cells to be used in the assay. Cells were resuspended in tissue culture medium at 1 × 10⁴ cells / well and added to flat-bottomed microtiter plates in 100 µL. The plates were incubated overnight at 37°C / 5% CO₂ to allow cell adhesion. Approximately 70% confluence of monolayers was observed.
[0464] Zika virus strain MR766 was obtained from ATCC (catalog number VR-84) and a stockpile of virus was generated in LLCMK2 cells. Pre-titrated aliquots of virus were removed from the freezer (-80°C) and allowed to thaw in a biosafety cabinet. The virus was diluted in assay medium (DMEM supplemented with 2% heat-inactivated FBS, 2 mM L-glutamine, 100 U / mL penicillin, and 100 µg / mL streptomycin) such that the amount of virus added to each well at a volume of 100 µL was the amount determined to produce 85% to 95% cell killing 4 days post-infection.
[0465] Each plate contained cell control wells (cells only), virus control wells (cells plus virus), three copies of drug toxicity wells for each compound (cells plus drug only), and three copies of experimental wells (drug plus cells plus virus).
[0466] After incubation at 37°C in a 5% CO2 incubator, the test plates were stained with tetrazolium dye XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide). XTT-tetraazonium is metabolized by mitochondrial enzymes in metabolically active cells to a soluble formazan product, allowing for rapid quantitative analysis of the inhibitory effect of antiviral assays on virus-induced cell killing. XTT solutions are prepared daily as a stock solution of 1 mg / mL in RPMI 1640. In PBS...A 0.15 mg / mL phenazine sulfate (PMS) solution was prepared and stored in the dark at -20°C. An XTT / PMS stock solution was prepared just before use by adding 40 µL of PMS to each mL of XTT solution. Fifty µL of XTT / PMS was added to each well, and the plate was incubated at 37°C for another 4 hours. The plate was sealed with an adhesive plate sealer, and gently shaken or inverted several times to mix the soluble formazan product. The plate was then read spectrophotometrically at 450 / 650 nm using a Molecular Devices Vmax plate reader.
[0467] Example 10: Evaluation of the antiviral activity of compounds against SARS-CoV-2 using SARS-CoV2 EC50A549-hACE2, as described by Xue, Xi et al., 2020 (Xie, X et al., (2020). "A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19", Nature Communications Biology Preprint (Nat. Comm. bioRxiv), 2020.06.22.165712; doi: https: / / doi.org / 10.1101 / 2020.06.22.165712). A549-hACE2 cells stably expressing human angiotensin-converting enzyme 2 (hACE2) were grown in high-glucose DMEM supplemented with 10% fetal bovine serum, 1% P / S, 1% HEPES (Thermo Fisher Scientific), and 10 µg / mL cyprodinil S (Mossel, EC et al., (2005). "Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication," *Journal of Virology*, 79, 3846-3850, doi:10.1128 / JVI.79.6.3846-3850.2005). Cells were grown at 37°C and 5% CO2. (Instructions for use, pages 55 / 58, 63 CN 121925423 A)Long duration. All culture media and antibiotics were purchased from ThermoFisher Scientific (Waltham, MA). Mycoplasma testing was negative for all cell lines. A549-hACE2 cells (12,000 cells per well in phenol red-free medium containing 2% FBS) were seeded into white opaque 96-well plates (Corning). The next day, a 3-fold serial dilution of the compound was prepared in DMSO. The compound was further diluted 100-fold in phenol red-free medium containing 2% FBS. The cell culture was removed and incubated with 50 µL of the diluted compound solution and 50 µL of SARS-CoV2-Nluc virus (MOI 0.025). 48 hours post-infection, 50 µL of nano-luciferase substrate (Promega) was added to each well. Luciferase signal was measured using a Synergy™ Neo2 microplate reader. The relative luciferase signal was calculated by normalizing the luciferase signal of the compound treatment group to the luciferase signal of the DMSO treatment group (set to 100%). The relative luciferase signal (Y-axis) was plotted against the log10 value (X-axis) of the compound concentration in Prism 8 software. The EC50 (the compound concentration at which the luciferase signal decreased by 50%) was calculated using a nonlinear regression model (four parameters).
[0468] Example 11: HEp-2 CC50 and MT4 CC50 HEp-2 cells (1.5 × 10³ cells / well) or MT4 cells (2 × 10³ cells / well) were seeded in 384-well plates and incubated with appropriate medium containing 3-fold serially diluted compounds (ranging from 15 nM to 100,000 nM). Cells were cultured at 37°C for 4 to 5 days. After incubation, cells were allowed to equilibrate to 25°C, and cell viability was determined by adding CellTiter Glo viability reagent. The mixture was incubated for 10 minutes, and the luminescent signal was quantified using an Envision microplate reader. As part of routine use in cytotoxicity assays, the cell line was not identified and mycoplasma was not tested.
[0469] Example 12: Huh7 CC50 Human hepatocellular carcinoma 7 (Huh7) cells were maintained in complete DMEM containing 10% FCS. On the day of assay, cells were trypsinized with 0.1% trypsin-EDTA, washed, and cultured in triplicate at 1×10⁴–2×10⁴ cells / well in 96-well plates, with the compound dispensed in fractionated doses (Hewlett-Packard D300 digital dispenser). All wells were normalized to 0.25% DMSO. After 48 hours, CellTiter-Gio (Promega) was added, and the cells were incubated at room temperature for 10 minutes, then read on a spectrophotometer. Viability % curves were calculated relative to the compound-free and cell-free control wells. Prism was used.The CC50 value (the concentration of the compound that reduces the luminescence signal by 50%, as a measure of cell viability) was determined using Graphpad software.
[0470] Example 13: A549-hACE2 CC50 The cytotoxicity of the compound was determined in A549-hACE2 cells as follows. The compound (200 nL) was spotted onto a 384-well Grenier plate, and 5000 A549-hACE2 cells / well were seeded in 40 µL of culture medium. The plate was incubated at 37°C for 48 hours in 5% CO2. On day 2, 40 µL of CellTiter-Glo (Promega) was added and mixed 5 times. The luminescence of the plate was read on an Envision (PerkinElmer) and the CC50 value was calculated using a nonlinear regression model (four parameters).
[0471] Example 14: RSV RNP polymerase IC50 transcription reaction contained 25 µg of crude RSV RNP complex in 30 µL of reaction buffer (50 mM TRIS-acetate [pH 8.0], 120 mM potassium acetate, 5% glycerol, 4.5 mM MgCl2, 3 mM DTT, 2 mM EGTA, 50 µg / mL BSA, 2.5 U RNasin, 20 µM ATP, 100 µM GTP, 100 µM UTP, 100 µM CTP and 1.5 µCi [α-32P]ATP [3,000 Ci / mmol]). Radiolabeled nucleotides used in the transcription assay were selected to match nucleotide analogs for evaluating their inhibition of RSV RNP transcription. To determine whether the nucleotide analogs inhibited RSV RNP transcription, compounds were added in 5-fold increments using a 6-step serial dilution. After incubation at 30°C for 90 minutes, the RNP reaction was terminated with 350 µL Qiagen RLT lysis buffer, and the RNA was purified using the Qiagen RNeasy 96 kit. The purified RNA was denatured at 65°C in RNA loading buffer for 10 minutes and run on a 1.2% agarose / MOPS gel containing 2M formaldehyde. The agarose gel was dried, exposed to a Storm phosphorescence imaging screen, and developed using a Storm phosphorescence imaging system. (Instructions for use, pages 56 / 58, 64 CN 121925423 A
[0472] ) Example 15: Dengue sshRNA polymerase IC50 In the DENV2-NS5 polymerase assay, a 244-nucleotide secondary unstructured heteropolymer RNA (sshRNA) with the sequence 5'-(UCAG)20(UCCAAG)14(UCAG)20-3' (SEQ ID NO: 1) was used as a template with a 5'-CUG-3' primer. Six 2-fold dilutions of the compound starting at 200 nM and a no-inhibitor control were plated in 96-well plates.100 nM DENV2 NS5 was pre-incubated at room temperature for 5 minutes in a reaction mixture containing 40 mM Tris-HCl (pH 7.5), 10 mM NaCl, 3 mM DTT, 0.2 units / µL RNasin Plus RNase inhibitor, 200 ng / µL sshRNA, 20 µM CUG, and 2 mM MgCl2. The enzyme mixture was added to the compound dilution, and the reaction was initiated by adding a mixture containing 20 µM of the three natural NTPs plus 2 µM of an analogue containing 1:100 α-33P-NTP:base matching competing natural NTPs. After 90 minutes at 30 °C, 5 µL of the reaction mixture was spotted onto DE81 anion exchange paper. The filter paper was washed three times with Na2HPO4 (125 mM, pH 9) for 5 minutes each time, rinsed with water and ethanol, then air-dried and exposed to a phosphorescent imager. Synthesized RNA was quantified using a Typhoon Trio imager and Image Quant TL software, and the reaction rate was calculated using linear regression with GraphPad Prism 5.0. The IC50 value was calculated in Prism using the following dose-response (variable slope) equation (four-parameter logistic equation) via nonlinear regression analysis: Y = bottom + (top - bottom) / (1 + 10^((LogIC50 - X) HillSlope)).
[0473] Example 16: MTNAP SNI A mixture of MTCN buffer (50 mM MES, 25 mM Tris-HCl, 25 mM CAPS and 50 mM NaCl, pH 7.5), 200 nM 5′-32P-R12 / D18, 10 mM MgCl2, 1 mM DTT and 376 nM POLRMT) was preheated at 30°C for 1 minute. The reaction was initiated by adding 500 µM of (final) natural NTP or NTP analogue. At selected time points, the reaction mixture was removed and quenched with a gel loading buffer containing 100 mM EDTA, 80% formamide, and bromophenol blue, and heated at 65°C for 5 minutes. Samples were run on 20% polyacrylamide gels (8M urea), and product formation was quantified using a Typhoon Trio imager and Image Quant TL software (GE Healthcare, Piscataway, NJ). The single nucleotide incorporation rate of mitochondrial RNA polymerase (mtRNApol) was calculated by fitting the product formation using the following single-exponential equation: [R13] = A(1 - e-kt), where [R13] represents the amount of elongated product formed (in nM), t represents the reaction time, k represents the observed rate, and A represents the amplitude of the exponent.
[0474] Table A: Antiviral ActivityTable B: CC50 Data; Table C: NTP Data. All references, including publications, patents, and patent documents, are incorporated herein by reference as separately as CN 121925423 A, pp. 57 / 58 / 65. This disclosure provides reference to various embodiments and techniques. However, it should be understood that many changes and modifications can be made while maintaining the spirit and scope of this disclosure. In making this description, it should be understood that it is intended to be illustrative of the claimed subject matter and is not intended to limit the appended claims to the specific embodiments described. CN 121925423 A, pp. 58 / 58 / 66.
Claims
1. A compound or a pharmaceutically acceptable salt thereof, wherein said compound has the following formula: ; Where R is H, , , , or ; R 1 It is a C1-C8 alkyl group; R 2 It is a C1-C6 alkyl group; and R 3 It is a C1-C6 alkyl group.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R is H, , or .
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is H.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is... .
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is... .
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is .
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is... or .
8. The compound according to any one of claims 1 or 7, or a pharmaceutically acceptable salt thereof, wherein R is... .
9. The compound according to any one of claims 1, 7, and 8, or a pharmaceutically acceptable salt thereof, wherein R is... .
10. The compound according to any one of claims 1 and 7 to 9, or a pharmaceutically acceptable salt thereof, R 1 It is methyl, ethyl, propyl, butyl, pentyl, or hexyl.
11. The compound according to any one of claims 1 and 7 to 10, or a pharmaceutically acceptable salt thereof, R 1 It is a C3-C6 alkyl group.
12. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1, 7 to 11, R 1 yes .
13. The compound according to claim 1 or 7, or a pharmaceutically acceptable salt thereof, wherein R is... .
14. The compound according to any one of claims 1, 7, and 13, or a pharmaceutically acceptable salt thereof, wherein R 2 It is methyl, ethyl, propyl, or butyl.
15. The compound according to any one of claims 1, 7, 13 and 14, or a pharmaceutically acceptable salt thereof, wherein R 3 It is methyl, ethyl, propyl, or butyl.
16. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1, 7, and 13 to 15, wherein R 2 It is methyl, ethyl, propyl, or butyl, and R 3 It is methyl, ethyl, propyl, or butyl.
17. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1, 7, and 13 to 16, wherein R 2 It is butyl, and R 3 It is butyl.
18. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 、 、 , and .
19. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 。 20. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 。 21. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 。 22. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 。 23. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 。 24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
25. The pharmaceutical composition of claim 23, further comprising an additional therapeutic agent.
26. The pharmaceutical composition according to claim 23 or 24, wherein the pharmaceutical preparation is for subcutaneous, intramuscular, intravenous, oral, or inhalation administration.
27. The pharmaceutical composition according to any one of claims 23 to 25, wherein the pharmaceutical formulation is for oral administration.
28. A method of treating or preventing viral infection in a person in need, wherein the method comprises administering to the person a compound according to any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 23 to 26.
29. The method of claim 27, wherein the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition, is administered to the person via oral, intramuscular, intravenous, subcutaneous, or inhalation administration.
30. The method of claim 27 or 28, wherein the method comprises administering at least one additional therapeutic or preventative agent to the person.
31. The method of claim 29, wherein the additional therapeutic agent or the prophylactic agent is monopivir, oseltamivir, nematvir, or ritonavir.
32. The method according to any one of claims 27 to 30, wherein the viral infection is a coronavirus infection.
33. The method according to any one of claims 27 to 31, wherein the viral infection is a zoonotic coronavirus infection.
34. The method according to any one of claims 27 to 32, wherein the viral infection is caused by a virus having at least 70% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase and SARS-CoV-2.
35. The method according to any one of claims 27 to 33, wherein the viral infection is caused by a virus having at least 80% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase and SARS-CoV-2.
36. The method according to any one of claims 27 to 34, wherein the viral infection is caused by a virus having at least 90% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase and SARS-CoV-2.
37. The method according to any one of claims 27 to 35, wherein the viral infection is caused by a virus having at least 95% sequence homology with a viral polymerase selected from the group consisting of SARS-CoV polymerase, MERS-CoV polymerase and SARS-CoV-2.
38. The method according to any one of claims 27 to 32, wherein the viral infection is selected from the group consisting of: 229E virus infection, NL63 virus infection, OC43 virus infection and HKU1 virus infection.
39. The method according to any one of claims 27 to 32, wherein the viral infection is SARS-CoV-2 infection (COVID-19).
40. The method according to any one of claims 27 to 32, wherein the viral infection is a SARS-CoV virus infection.
41. The method according to any one of claims 27 to 32, wherein the viral infection is a MERS-CoV virus infection.
42. The method according to any one of claims 27 to 29, wherein the viral infection is a pulmonary virus infection.
43. The method according to any one of claims 27 to 29 and 41, wherein the pulmonary viral infection is a respiratory syncytial virus infection.
44. The method according to any one of claims 27 to 29 and 41, wherein the pulmonaryviridae virus infection is human metapneumovirus infection.
45. The method according to any one of claims 27 to 29, wherein the viral infection is a piconerivirus infection.
46. The method according to any one of claims 27 to 29, wherein the viral infection is an enterovirus infection.
47. The method according to any one of claims 27 to 29 and 45, wherein the viral infection is selected from the group consisting of: Coxsackie A virus infection, Coxsackie A virus infection, enterovirus D68 infection, enterovirus B69 infection, enterovirus D70 infection, enterovirus A71 infection, and poliovirus infection.
48. The method according to any one of claims 27 to 29 and 44, wherein the microribonucleoviridae virus infection is a human rhinovirus infection (HRV).
49. The method according to any one of claims 27 to 29 and 44, wherein the microribonucleovir infection is HRV-A infection, HRV-B infection or HRV-C infection.
50. The method according to any one of claims 27 to 29, wherein the viral infection is a flaviviridae virus infection.
51. The method according to any one of claims 27 to 29 and 49, wherein the Flaviviridae virus infection is dengue virus infection, yellow fever virus infection, West Nile virus infection, tick-borne encephalitis, Kunzin Japanese encephalitis, St. Louis encephalitis, Murray Valley encephalitis, Omsk hemorrhagic fever, bovine viral diarrhea, Zika virus infection, Alkulma hemorrhagic fever (AHF) virus, or HCV infection.
52. The method according to any one of claims 27 to 29, wherein the viral infection is a filoviridae virus infection.
53. The method according to any one of claims 27 to 29 and 51, wherein the viral infection is an Ebola virus infection or a Marburg virus infection.
54. The method according to any one of claims 27 to 29, wherein the viral infection is an orthomyxovirus infection.
55. The method according to any one of claims 27 to 29 and 53, wherein the viral infection is an influenza virus infection.
56. The method according to any one of claims 27 to 29, 53 and 54, wherein the viral infection is an influenza A virus infection or an influenza B virus infection.
57. The method according to any one of claims 27 to 29, wherein the viral infection is a virus infection of the Arenaviridae family.
58. The method according to any one of claims 27 to 29 and 57, wherein the viral infection is Lassa virus infection or Junin virus infection.
59. The method according to any one of claims 28 to 30, wherein the viral infection is a paramyxoviridae virus infection.
60. The method according to any one of claims 28 to 30 and 59, wherein the viral infection is a Langya virus infection.
61. The method according to any one of claims 28 to 30 and 59, wherein the viral infection is a Hennipa virus infection.
62. The method according to any one of claims 28 to 30, 57 and 58, wherein the viral infection is human parainfluenza virus infection, Nipah virus infection, Hendra virus infection, measles infection or mumps infection.
63. The method according to any one of claims 27 to 29, wherein the viral infection is a Bunyavirales infection.
64. The method according to any one of claims 27 to 29 and 63, wherein the viral infection is a virus infection of the Leukoviridae family, the Nairoviridae family, the Arenaviridae family, or the Hantaviridae family.
65. The method according to any one of claims 27 to 29, 63 and 64, wherein the viral infection is Crimean-Congo hemorrhagic fever virus infection, Rift Valley fever virus infection or Hantavirus infection.
66. The method according to any one of claims 27 to 30, wherein the viral infection is a poxvirus infection.
67. The method according to any one of claims 28 to 30 and 66, wherein the viral infection is monkeypox virus infection.
68. The method according to any one of claims 28 to 30, wherein the viral infection is a phenotypic virus infection.
69. The method according to any one of claims 28 to 30 and 68, wherein the viral infection is Eastern Equine Encephalitis Virus (EEV), Western Equine Encephalitis Virus (FEV), Venezuelan Equine Encephalitis Virus (VEEV), or Chikungunya Virus (Chikungunya) infection.
70. A method for preparing a medicament for treating or preventing viral infections in people in need, characterized in that... The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 23.
71. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 23 in the preparation of a medicament for treating or preventing viral infections in persons in need.
72. The use according to claim 61, wherein the drug is used in conjunction with at least one additional therapeutic or preventative agent.
73. The use according to claim 63, wherein the additional therapeutic agent or the prophylactic agent is monopivir, oseltamivir, nematvir, or ritonavir.
74. A composition comprising any one of the compounds according to claims 1 to 22 or a pharmaceutically acceptable salt thereof, said composition for treating or preventing viral infections in persons in need.
75. The composition of claim 64, wherein the composition comprises at least one additional therapeutic or preventative agent.
76. The composition of claim 65, wherein the additional therapeutic agent or the prophylactic agent is monopivir, oseltamivir, nematvir, or ritonavir.
